Immunomodulatory, anti-inflammatory and wound healing properties of Echinacea species by Zhai, Zili
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2008
Immunomodulatory, anti-inflammatory and
wound healing properties of Echinacea species
Zili Zhai
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Agriculture Commons, Allergy and Immunology Commons, Food Science
Commons, and the Medical Immunology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Zhai, Zili, "Immunomodulatory, anti-inflammatory and wound healing properties of Echinacea species" (2008). Retrospective Theses
and Dissertations. 15689.
https://lib.dr.iastate.edu/rtd/15689
 Immunomodulatory, anti-inflammatory and wound healing properties of Echinacea 
species 
 
 
by 
 
 
Zili Zhai 
 
 
 
 
A dissertation submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
Major:  Neuroscience  
 
Program of Study Committee: 
Joan E. Cunnick, Major Professor 
Tim A. Day 
Walter H. Hsu 
Marian L. Kohut 
Patricia A. Murphy 
 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2008 
 
Copyright © Zili Zhai, 2008.  All rights reserved. 
 
3316206 
 
3316206 
 2008
ii 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES ................................................................................................................. iv 
LIST OF TABLES................................................................................................................... vi 
LIST OF ABBREVIATIONS................................................................................................. vii 
ABSTRACT............................................................................................................................. ix 
CHAPTER 1. GENERAL INTRODUCTION ......................................................................... 1 
Introduction................................................................................................................... 1 
Dissertation Organization ............................................................................................. 3 
Literature Review.......................................................................................................... 4 
References................................................................................................................... 20 
CHAPTER 2. ENHANCEMENT OF INNATE AND ADAPTIVE IMMUNE  
FUNCTIONS BY MULTIPLE ECHINACEA SPECIES ................................................. 31 
Abstract ....................................................................................................................... 31 
Introduction................................................................................................................. 32 
Materials and Methods................................................................................................ 34 
Results......................................................................................................................... 41 
Discussion ................................................................................................................... 46 
Acknowledgements..................................................................................................... 52 
References................................................................................................................... 52 
CHAPTER 3. ALCOHOL EXTRACTS OF ECHINACEA INHIBIT PRODUCTION 
OF NITRIC OXIDE AND TUMOUR NECROSIS FACTOR-ALPHA BY 
MACROPHAGES IN VITRO ........................................................................................... 66 
Abstract ....................................................................................................................... 66 
Introduction................................................................................................................. 67 
Materials and Methods................................................................................................ 69 
Results......................................................................................................................... 73 
Discussion ................................................................................................................... 76 
Acknowledgements..................................................................................................... 80 
References................................................................................................................... 81 
CHAPTER 4. ECHINACEA INCREASES ARGINASE ACTIVITY AND HAS 
ANTI-INFLAMMATORY PROPERTIES IN RAW 264.7 MACROPHAGE 
CELLS INDICATIVE OF ALTERNATIVE MACROPHAGE ACTIVATION............. 92 
Abstract ....................................................................................................................... 92 
Introduction................................................................................................................. 93 
Materials and Methods................................................................................................ 96 
Results....................................................................................................................... 102 
Discussion ................................................................................................................. 106 
Acknowledgements................................................................................................... 111 
References................................................................................................................. 111 
iii 
 
CHAPTER 5. ALCOHOL EXTRACT OF ECHINACEA PALLIDA REVERSES 
STRESS-DELAYED WOUND HEALING IN MICE .................................................. 126 
Abstract ..................................................................................................................... 126 
Introduction............................................................................................................... 127 
Materials and Methods.............................................................................................. 130 
Results....................................................................................................................... 134 
Discussion ................................................................................................................. 137 
Acknowledgements................................................................................................... 142 
References................................................................................................................. 143 
CHAPTER 6.  GENERAL CONCLUSIONS ...................................................................... 154 
General Discussion ................................................................................................... 154 
Recommendations for Future Research .................................................................... 156 
References................................................................................................................. 158 
ACKNOWLEDGEMENTS.................................................................................................. 160 
iv 
 
LIST OF FIGURES 
 
Figure 2.1. HPLC chromatograms of the lipophilic amides and hydrophilic caffeic acid 
derivatives in Echinacea preparations .................................................................. 57 
Figure 2.2. Effect of Echinacea preparations on the percentages of (A) splenic CD49+ 
subset and (B) CD19+ subset.................................................................................59 
Figure 2.3. Effect of Echinacea preparations on NK cytotoxity after covarying for the 
percentage of CD49+ splenocytes in each animal. ............................................... 60 
Figure 2.4. Effect of Echinacea preparations on splenic plaque forming cell (PFC) 
response after covariance for the percentage of CD19+ splenocytes in each 
animal.....................................................................................................................61 
Figure 2.5. Effect of Echinacea preparations on (A) splenic lymphocyte proliferation 
and (B) blood lymphocyte proliferation ................................................................62 
Figure 2.6. Effect of Echinacea preparations on TH2 cytokine production by mouse 
splenocytes stimulated in vitro without or with mitogen...................................... 63 
Figure 2.7. Effect of Echinacea preparations on TH1 cytokine production by mouse 
splenocytes stimulated in vitro without or with mitogen...................................... 64 
Figure 2.8. Effect of Echinacea preparations on macrophage cytokine production in 
vitro without or with mitogen ............................................................................... 65 
Figure 3.1. Viability of RAW 264.7 cells exposed to Echinacea alcohol extracts................. 86 
Figure 3.2. Effect of Echinacea alcohol extracts on NO production and TNF-α secretion 
in LPS-activated RAW 264.7 cells. ...................................................................... 87 
Figure 3.3. Survival of Salmonella within RAW 264.7 cells pretreated with indicated 
concentrations of Echinacea alcohol extracts....................................................... 88 
Figure 3.4. NO production by RAW 264.7 cells infected with Salmonella at an MOI of 
100:1 for 2h............................................................................................................89 
Figure 3.5. Effect of Echinacea alcohol extracts in vivo on cell viability of PECs as well 
as NO and cytokine release by PECs.....................................................................90 
Figure 3.6. Survival of Salmonella within PECs (A) and NO production by PECs (B) 
harvested from mice treated with Echinacea alcohol extracts.............................. 91 
Figure 4.1. Alcohol extracts of Echinacea inhibit production of TNF-α by LPS-
stimulated macrophages...................................................................................... 119 
Figure 4.2. Alcohol extracts of Echinacea inhibit production of NO by LPS-stimulated 
macrophages. ...................................................................................................... 120 
Figure 4.3. Scavenging of NO derived from SNP by alcohol extracts of Echinacea........... 121 
v 
 
Figure 4.4. Time course of inhibition of NO production by alcohol extracts of 
Echinacea............................................................................................................ 122 
Figure 4.5. Regulation of NO production and arginase activity of activated RAW 
264.7 cells by alcohol extracts of Echinacea.......................................................123 
Figure 4.6. Regulation of NO production and arginase activity of activated RAW 
264.7 cells by fractions of alcohol extracts of Echinacea. ..................................124 
Figure 4.7. Regulation of iNOS expession by alcohol extracts and fractions of 
Echinacea............................................................................................................ 125 
Figure 5.1. HPLC chromatograms of alcohol extract of EPA. ............................................. 148 
Figure 5.2. Effects of RST and EPA on body weight loss.................................................... 150 
Figure 5.3. Effects of RST and EPA on wound closure of (A) the non-restraint stressed 
groups and (B) the stressed groups with the non-stressed FWD group.............. 151 
Figure 5.4. Effects of RST and EPA on healing time........................................................... 152 
Figure 5.5. Effects of RST and EPA on (A) spleen/body weight ratio, (B) viability of 
splenocytes treated with LPS (1 µg/ml) and corticosterone, and plasma 
concentrations of (C) corticosterone and (D) IL-6 ............................................. 153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
LIST OF TABLES 
 
Table 1.1. Bioactive metabolites of Echinacea and their properties ...................................... 19 
Table 2.1. Concentration and percentage of known amides and caffeic acid 
derivatives in Echinacea preparations. ..................................................................58 
Table 3.1. The levels of amides and caffeic acid derivatives in Echinacea alcohol 
extracts. ..................................................................................................................85 
Table 4.1. Concentration of known metabolites in alcohol extracts......................................117 
Table 4.2. Echinacea fractions and their chemical constituents. ...........................................118 
Table 5.1. The amounts of alkamides, ketones and caffeic acid derivatives in 
EPA preparation as determined using HPLC.......................................................149 
 
 
 
 
 
 
vii 
 
LIST OF ABBREVIATIONS 
 
cAMP 3'-5'-cyclic adenosine monophosphate 
CB2 cannabinoid receptor 2 
CFU colony forming unit 
Con A concanavalin A 
COX-2 cyclooxygenase-2 
Cr Chromium 
EA Echinacea angustifolia 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EP Echinacea purpurea 
EPA Echinacea pallida 
EtOH Ethanol 
FBS fetal bovine serum 
FWD food and water deprived 
GC Glucocorticoids 
GM-CSF granulocyte monocyte colony stimulating factor 
HBSS hank’s balanced salt solution 
HPA axis hypothalamic-pituitary-adrenal axis 
HPLC high performance liquid chromatography 
ICAM-1 intercellular adhesion molecule 1 (CD54) 
IFN-γ interferon-γ 
Ig Immunoglobulin 
IκB-α NF-κB inhibitor alpha 
IL Interleukin 
viii 
 
iNOS inducible nitric oxide synthase   
ip intraperitoneal(ly) 
iv intravenous(ly) 
LB Luria-Bertani 
LPS Lipopolysaccharide 
MIP-1α macrophage inflammatory protein-1α 
MOI multiplicity of infection 
NF-κB nuclear factor kappa B 
NK cell natural killer cell 
NO nitric oxide 
PBS phosphate buffed saline 
PBST PBS/0.1% Tween-20 
PE Phycoerythrin 
PECs peritoneal exudate cells 
PFC plaque forming cell 
PGE2 prostaglandin E2 
RST Restraint 
SAM sympathetic-adrenal mendullary axis 
SNP sodium nitroprusside 
sRBC sheep red blood cells 
STATs signal transducers and activators of transcription 
TLR toll-like receptor 
TNF-α tumor necrosis factor-alpha 
UV Ultraviolet 
 
 
 
 
ix 
 
ABSTRACT 
        Herbal or botanical supplements have multiple health benefits. Public interest in these 
supplements has increased greatly in recent years aimed at modulation of the immune system 
to combat immune-related diseases. Historically, Echinacea has long been used as 
phytotherapy for wound healing, pain relief and treatment of the common cold. Although the 
non-specific immunostimulating properties of Echinacea species have been widely 
investigated, academic knowledge of the adaptive immune-modulating activity, the anti-
inflammatory activity and the mechanistic basis for these immunomodulatory properties 
remain elusive. In this dissertation, we focused our research interest in these less explored 
fields, with an emphasis on the herbal anti-inflammatory activity in both in vitro macrophage 
cell line and in vivo oral administration models. In vivo, alcohol extracts of Echinacea 
exhibited multiple immune-modulating effects. In addition to the non-specific, innate 
immunomodulation, they enhance B cell and T cell function (determined by increased 
production of antibodies and cytokines). These modulating effects of Echinacea were more 
robust when host immune functions were disturbed by mild stress. In vitro, alcohol extracts of 
Echinacea suppressed activated macrophages (RAW 264.7 cells) so they produced lower 
amounts of inflammatory mediators including nitric oxide (NO). The decreased NO production 
might be relative to decreased inducible nitric oxide synthase (iNOS) enzyme expression and 
increased arginase activity, suggesting that Echinacea could switch macrophage to alternate 
activation. In a cutaneous wound healing model, we demonstrated that alcohol extract of E. 
pallida helped improve restraint stress-delayed wound healing. These data provided novel 
evidence to support the multiple immunomodulatory properties of Echinacea and will help 
define the mechanisms behind the success of traditional use of Echinacea for pathogenic 
infections and inflammatory diseases.              
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CHAPTER 1.  GENERAL INTRODUCTION 
Introduction 
        Plants are a rich source of natural chemicals whose importance to human beings is self-
evident. Plants provide us not only food and building materials, but also medicines. Plants 
harbor great treasures of chemicals with medicinal value. The plants with medicinal purposes 
are regarded as medicinal herbs. Human use of herbal medicine has a long history, whose 
record can date back to about 60,000 years ago (Solecki, 1975). Today science and technology 
diversify medical services and medicines, however, it is estimated that as many as 80% of the 
world population still depend on herbal medicines to meet their primary healthcare (van Wijk, 
2000). In the far East, Chinese medicines enjoy an important place in health care, more than  
80 % of them originate from plants (Lee, 2000). In the Western world, the birthplace of 
“modern” medicine, although the importance of herbal medicine has been replaced by 
synthesized pure drugs, herbal medicine is still playing an essential role in the health care 
system and scientific community. Moreover, medicinal herbs are an important source for new 
drug development. About 40% of all current medical drugs derive their chemistry from 
medicinal herbs. In contrast to modern pure single drugs, herbal medicine has multiple health 
benefits. In the US, herbal medicine is classified as dietary supplements, which are consumed 
without prescription. Surveys indicate that over 30% of Americans are using herbal products 
for health purposes, spending about $4 billion annually (O'Hara et al., 1998; Bent and Ko, 
2004). Notable examples of the botanical dietary supplements used widely in the US today 
include Echinacea, garlic, ginkgo biloba, ginseng, and St. John’s wort.   
        Echinacea is a purple coneflower native to North America. Plains Indians first used it to 
relieve pain and to treat various conditions such as snakebites and wounds (Borchers et al., 
2000). Early European settlers learned of its medicinal effects, and expanded its uses in 
treatment of infectious diseases. Since then, Echinacea has become one of the popular herbal 
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medicines in North America and Europe. Today, Echinacea products are mainly used for 
reducing the duration and/or the symptoms associated with the common cold and other upper 
respiratory infections. It is estimated that Americans spend about $300 million per year on 
Echinacea products and their sales make up 10% of the total US herbal market (Islam and 
Carter, 2005). There are nine known species of Echinacea, three of them, E. angustifolia (EA), 
E. palllida (EPA) and E. purpurea (EP) are considered useful medicinal plants and, therefore, 
widely used in phytotherapy. They have similar, but differential, chemical profiles and 
biological properties. Active principles may include hydrophobic alkamides, water-soluble 
caffeic acid derivatives and high molecular weight polysaccharides. Pharmacokinetics studies 
indicate that at least alkamides are readily bioavailable (Matthias et al., 2005a; Woelkart et al., 
2005a). The biological activities of Echinacea are largely relative to its modulation of the 
immune system. In addition to the three commonly used species, other Echinacea species may 
have biological activities (Senchina et al., 2006; McCann et al., 2007).  
        Echinacea is closely linked to human use and health care. Its huge herbal market evokes 
the need to understand the plant itself and its biological nature. In recent years, hundreds of 
papers that pertain to Echinacea have been published, however, this is only the first step to 
understand the biochemical utility of the herb. Fortunately, comprehensive and 
interdisciplinary studies of Echinacea are underway to define the genetics, phytophysiology, 
phytochemistry and immunopharmacology of this herb. This dissertation is an inseparable part 
of a larger effort on Echinacea. We explored its immunomodulation and anti-inflammatory 
activity. It can be asserted that the data derived from these studies will enrich our 
understanding of the herbal biological properties, and help develop novel therapeutic strategies 
and plant-based drugs. The significance of studying Echinacea and other medicinal herbs can 
be illustrated by a successful example. After all, facts speak louder than words. Artemisia 
annua or Qinhao was long used as a Chinese medicinal herb in the treatment of fevers. 
Laboratory study of Qinhao led to isolation and purification of the active principle artemisinin 
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or qinghaosu (essence of Qinghao) in the 1970s. The work on modification of artemisinin 
structure resulted in emergence of potent classes of novel semi-synthesized derivative, such as 
artemether and artesunate. Artemisinin and its derivatives are not only currently widely used to 
treat multidrug-resistant malaria and cerebral malaria, but also found to have new uses such as 
antitumor, antiangiogenesis, antiviral and immunomodulation. Today, synthesis of artemisinin 
derivatives and analogs and study of their biological properties are a hot topic and represent a 
promising field in drug discovery (Li and Wu, 2003; Lee, 2007). 
Dissertation Organization 
        This dissertation is organized in six chapters in order of general introduction, original 
research papers and general conclusion. Original research papers are arranged in chapter 2-5 
which have been published by or will be submitted to their respective journals. Each paper was 
designed to address a specific and self-explanatory research interest. Four papers as a whole 
reflect continuity of our laboratory experiments under this dissertation topic.   
        Chapter 1 is a general introduction to the dissertation. It provides background information 
on the (non-specific) immunomodulatory properties of three medicinally used Echinacea 
species, mainly identified by laboratory work so far. In this review, we provide some necessary 
information related to our research in alternative macrophage activation and wound healing.   
        In chapter 2, we determined the immunoenhancing properties of Echinacea species in an 
in vivo gavage model, with an emphasis of their positive effects on adaptive immunity. We 
reported an “unexpected” finding that Echinacea exhibited an anti-inflammatory potential. 
This formed the basis for our subsequent research in alternative macrophage activation 
        In Chapter 3, we preliminarily determined the nitric oxide (NO) inhibiting activity of 
Echinacea alcohol extracts in both in vitro macrophage cell line and in vivo gavage models. 
Since NO is a key mediator involved in both host defense and inflammation, the potentially 
compromised macrophage function (phagocytosis and bacterial killing) was evaluated in the 
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parallel experiments.  
        Chapter 4 is an extension of chapter 3. We determined the mechanistic basis for the NO 
inhibiting activity of Echinacea species in macrophage cell line. We investigated the effect of 
Echinacea alcohol extracts on macrophage activation switching (between inflammatory 
activation and alternative activation), and explored the respective role of five fractions of 
alcohol extracts in macrophage activation.  
        In chapter 5, we applied our research to an in vivo model and determined the activity of 
EPA in a skin wound healing model. Chronic restrain stress was introduced in this model to 
further understand the immunomodulatory (immune homeostasis regulation) properties of 
Echinacea.  
       This dissertation ends in chapter 6 with a general discussion on the four original 
experimental papers. Additionally, it suggests certain recommendations for future research.   
Literature Review 
        The genus Echinacea enjoys a long history as an herbal remedy.  It first attracted 
academic attention in the 1930s (Cundell et al., 2003). In the past two decades, a large number 
of papers pertaining to Echinacea have been published in German, English and other 
languages, and the number of the papers is still rising rapidly. As we carried out experiments 
for this dissertation, several papers closely related to our research were already published. 
Since clinical data provided little information about the possible action of mechanism of the 
herb, in this review we discuss the biological activities and the immunomodulatory properties 
of Echinacea based on the collected data from in vitro assays and animal studies, and published 
in English.   
        Bearing in mind that most of the Echinacea preparations used in laboratory studies are a 
mixture of many naturally occurring compounds. The biological activities of a given 
preparation are determined by its specific chemical properties, which are subject to both 
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internal and external factors, such as species, parts of the plant selected, phase of plant 
development at harvest, soil type in which the plant is grown, preparation method, preparation 
form, experimental model, and administration route and dose (Percival, 2000; Hermann et al., 
2003; Islam and Carter, 2005). These factors are interdependent and largely determine the 
diversities of Echinacea preparations. Precisely because of this, several aspects should be 
addressed at the beginning of this review. First, although it is more accurate to cite each 
Echinacea study with its preparation methods or active principles, in most cases we still used 
Echinacea as a general term instead of a “specific” preparation for the sake of a simplified 
review. Note that this is true for inductive reasoning (from a specific preparation to Echinacea) 
but not vice versa (it may be wrong to draw a conclusion from Echinacea to a specific 
preparation). Secondly, some study results, particularly those using crude preparations, might 
be difficult to compare and reproduce in the laboratory because of a lack of chemical analysis. 
Lastly, unlike single pure drugs which usually target certain tissues or molecules, Echinacea 
preparations may target many tissues or cell components and then elicit a wider range of 
biological activities because they contain indefinite bioactive metabolites. 
Echinacea has multiple biological activities, most of them determined from in vitro and 
animal studies    
        Historically, Echinacea was used as a cure by Native Americans for various conditions 
and ailments. From current viewpoints, we believe most of the early uses of Echinacea lacked 
sufficient scientific support. However, Echinacea has stood the test of time. Today, Echinacea 
is most widely used as a preventive and treatment for upper respiratory infections including 
colds and influenza. In order to evaluate its effectiveness for these conditions, a number of 
human studies have been conducted. Unfortunately, the results are rather inconsistent. While 
some have validated its antiviral effects, others have refuted it. Nevertheless, the most 
consistent results indicate that Echinacea possesses an ability to inhibit the development and 
alleviate the symptoms of colds (Barrett, 2003; Barnes et al., 2005; Woelkart et al., 2008).  
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        In contrast to a conflicting clinical standpoint, a majority of laboratory investigations 
suggested that Echinacea plays a positive role in the context of its medicinal uses including 
infection-fighting capacity. Note that some laboratory studies only provided indirect evidence 
due to the use of a blend of Echinacea and other herbs. Until now, Echinacea has been found 
to have multiple antimicrobial activities, such as antiviral (Thompson, 1998; Binns et al., 2002; 
Kapadia et al., 2002), antibacterial (Roesler et al., 1991b; Steinmuller et al., 1993), antifungal 
(Roesler et al., 1991b; Steinmuller et al., 1993; Binns et al., 2000; Morazzoni et al., 2005), 
insecticidal (Clifford et al., 2002), and anti-parasitic activity (Steinmuller et al., 1993; Parnham, 
1996). Echinacea harbors the anti-infective activities mainly through the enhancement of host 
immune system, rather than direct killing of pathogens (Awang, 1999). A subsequent section 
will address the immunoenhancing properties of Echinacea. 
        Echinacea has antioxidant and anti-inflammatory activities. These activities clearly reflect 
another nature of Echinacea, that is, it may possess an opposite modulation of host 
physiological and immune responses. Use of in vitro free radical generation systems shows 
Echinacea has strong antioxidant activities which can be attributed to its chemical constituents 
- caffeic acid derivatives (Hu and Kitts, 2000; Sloley et al., 2001; Mishima et al., 2004; Pellati 
et al., 2004). Caffeic acid and its derivative echinacoside protect hydroxyl radical-induced 
degradation of type III collagen in skin photodamage (Facino et al., 1995). Of the three 
medicinally used Echinacea species, EPA exhibits the highest reducing power and greatest 
antioxidant activity, consistent with the highest echinacoside concentration in this plant 
(Cervellati et al., 2002; Zaporozhets et al., 2004). Alkamides, another class of bioactive 
phytochemicals in Echinacea are now recognized as largely responsible for the anti-
inflammatory properties that will be discussed later.  
        The dual capacities of Echinacea as both immunostimulant and anti-inflammatory agent 
guarantee its wide range of biological activities. Other miscellaneous activities of Echinacea 
include antitumor (Currier and Miller, 2002; Kapadia et al., 2002), modulation of apoptosis (Di 
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Carlo et al., 2003; Chicca et al., 2007; Smalinskiene et al., 2007), and anti-ageing (Brousseau 
and Miller 2005; Miller, 2005).  
        Note that most of the biological activities of Echinacea have been demonstrated only by 
in vitro and/or animal studies, but not through use in humans. As one of the dietary 
supplements, safety from potential side-effects and interactions with other therapies should be a 
first concern when consuming Echinacea for treatment of some immune-mediated diseases, i.e. 
cancer, allergy, multiple sclerosis and AIDS (Bielory, 2004; Quimby, 2007). For example, as 
an immunostimulant, Echinacea is supposed to help people with HIV/AIDS develop a stronger 
immune system, however, it may further weaken their immune system to control HIV (Hosein,  
1999). 
Echinacea enhances overall immune function though it acts more strongly on innate 
immunity 
        A growing body of evidence supports that most of Echinacea’s biological effects are 
relevant to its immunomodulatory properties. Of the two main immune branches, Echinacea 
primarily targets the non-specific innate immunity. The effects of Echinacea on innate 
immunity appear to be contradictory. In some studies Echinacea can stimulate an immune 
response, but other studies indicate it can also suppress the same response. Whether the effect 
of Echinacea is immunoenhancing or immunosuppressive (anti-inflammatory) might be 
dependent on both the chemical profiles in a given herbal preparation and the host and/or 
immune cell functional state. In this section, we focus on the immunoenhancing properties. In 
the next section, the anti-inflammatory activities will be discussed.  
        Animal studies demonstrate Echinacea increases the number of circulating leukocytes, 
stimulates the proliferation of phagocytes in the spleen and bone marrow, and alters the 
percentage of white blood cells and splenocytes (Roesler et al., 1991a; Sun et al., 1999; O'Neill 
et al., 2002; Cundell et al., 2003; Brousseau and Miller, 2005). Cundell et al. (2003) observed a 
sustained increase in the percentage of circulating lymphocytes and monocytes associated with 
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a remarkable decrease in the percentage of circulating neutrophils in aging rats fed with aerial 
parts of Echinacea (without indicating species). The decreased percentage of neutrophils might 
be due to increases in granulocyte migration into the tissues (Roesler et al., 1991b; O'Neill et 
al., 2002). Echinacea-induced increase in total white blood cell count usually occurs 
synchronously with the activation in the function of these immune cells. 
        Macrophages and neutrophils are the main cell components that are influenced by 
Echinacea. Purified polysaccharides from Echinacea stimulated the phagocytosis and 
production of inflammatory mediators by macrophages and neutrophils in both in vitro assays 
and animal models (Stimpel et al., 1984; Luettig et al., 1989; Steinmuller et al., 1993). In vitro, 
human macrophages were activated by commercial preparations of EP (fresh pressed juice) to 
produce oxygen radicals and proinflammatory cytokines (Burger et al., 1997). Oral 
administration of Echinacea preparations including alkamides, polysaccharides and cichoric 
acid, to normal rats stimulated production of many cytokines, i.e. tumor necrosis factor-alpha 
(TNF-α), interleukin (IL)-1β, interferon (IFN)-β and IL-10 by alveolar macrophages and/ 
spleen cells (Goel et al., 2002a, 2002b). Hwang et al. (2004) found water soluble EP extracts 
able to stimulate IL-6, IL-10, macrophage inflammatory protein (MIP)-1α and TNF-α from 
non-adherent murine splenocytes. In vitro alkamides of Echinacea has also been found to 
mediate cytokine gene expression within human peripheral leukocytes. It induces de novo 
synthesis of TNF-α mRNA in human macrophages, T and B cells, but no measurable increase 
in TNF-α protein (Gertsch et al., 2004).  
        Natural killer (NK) cells play a critical role in clearing viral infections through the 
processes of cytotoxicity, and production of cytokines such as IFN-γ and granulocyte 
monocyte colony stimulating factor (GM-CSF) (Gan et al., 2003). Studies with Echinacea have 
demonstrated its enhancing effect on NK cell activity in vitro and in vivo (Miller, 2005). Dried, 
ground preparation of fresh EP increased NK cytotoxic function in vitro in human peripheral 
blood lymphocytes of both healthy individual and patients with chronic fatigue syndrome or 
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acquired immunodeficiency syndrome (See et al., 1997). Currier and Miller (2000 and 2001) 
observed that aging mice, fed with a diet containing Echinacea ingredients, had a significant 
enhancement of NK cell cytotoxic activity and an increase in NK cell numbers. Gan et al. 
(2003) further found that Echinacea extracts could modulate NK cells at multiple levels 
including the maturation and increased cytotoxic potential of NK cells. Miller (2005) suggested 
that increased NK activity is partially associated with macrophage activation by Echinacea.  
        While many studies have emphasized the innate immune stimulation of Echinacea, its 
effects on adaptive immune functions are less known. Freier et al. (2003) observed an increase 
in immunoglobulin (Ig) M response against sheep red blood cells (sRBC) in mice orally treated 
with glycerine extracts of aerial parts of EP plant following sRBC immunization. Several other 
studies observed an increase of humoral immunity (antibodies against sRBC) in vivo but only 
provided indirect information because of the use of a blend of Echinacea with other herbs 
(Rehman et al., 1999; Bodinet et al., 2002a; Bodinet et al., 2004).  
         In addition, Echinacea products may possess the ability to modulate T cell function. A 
recent investigation with EP dried powder administrated intraperitoneally (ip) found an 
increase in CD4+ T-cells in mouse peripheral blood but implied it is a secondary effect in 
association with macrophage activation (Mishima et al., 2004). Another study reported that an 
EA root extract with a high content of polysaccharides and echinacoside enhances T-cell 
function in vitro by stimulating IFN-γ production (Morazzoni et al., 2005). However, in Jurkat 
cells, a human T-cell line, alkamides inhibit IL-2 production (Sasagawa, 2006) and have a 
mixed effect on the transcriptional factor nuclear factor kappa B (NFκB) expression (Matthias 
et al., 2008). 
        Echinacea is well known as a non-specific immunostimulant. This concept may partly 
come from its positive effects on the nonadaptive cell immunity, but more importantly 
originate from its ability to boost the whole immune system. As time goes on, there is some 
evidence to support the herbal capacity for modulation of adaptive immune branch. On the 
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other hand, the concept of Echinacea as a nonspecific immunostimulant is based on a 
sufficiently large number of empirical observations on crude preparations of Echinacea or a 
mixture of many natural chemicals, which combinationally exert either direct or indirect 
modulating effect on different immune components. 
Echinacea harbors anti-inflammatory properties that may represent an active research field 
in future Echinacea study        
        The collective evidence mentioned above supports the immunoenhancing properties of 
Echinacea. The up-regulation of immune responses is consistent with an immune activated 
antimicrobial effect (Stimpel et al., 1984; Steinmuller et al., 1993; Burger et al., 1997). 
However, Echinacea exhibits an opposite pharmacological activity, too. In this case, it acts as 
an anti-inflammatory agent that actually suppresses some immune function.  In recent years, 
the anti-inflammatory activity of Echinacea has attracted increasing attention not only 
because is has been used for centuries for wound healing benefits, but more importantly, 
there is an increasing concern about the possible negative effects caused by excessive 
inflammation. Robust immune function is beneficial for host defense in response to various 
infections and injuries, but can also lead to inflammation. Inflammation is a double-edged 
sword. It has important physiological significance, but excessive inflammation is detrimental 
in various health conditions including cancer, diabetes, asthma, Alzheimer's disease, 
rheumatoid arthritis and the normal aging (Caruso et al., 2004; Ware, 2005). At present, 
Echinacea is commonly termed as an immunomodulant instead of the previous nomenclature 
of immunostimulant.     
        Experiments with mice demonstrated that topical application of a polysaccharide 
fraction from EA roots or oral administration of EP root dry powder significantly inhibited 
carrageenan-induced paw edema formation (Tubaro et al., 1987; Raso et al., 2002), and this 
effect was in part related to the down-regulation of cyclooxygenase (COX)-2 expression in 
peritoneal macrophages (Raso et al., 2002). Echinacoside was proposed to have 
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hyaluronidase inhibiting activity and thus increase the amount of hyaluronan available to the 
extracellar matrix required for scarless wound repair (Speroni et al., 2002; Rousseau et al., 
2006). When one dose of alcohol extracts of EP or EPA was applied topically to abraded skin 
or excised wounds on rats for 72 h, EPA extract exhibited more robust anti-inflammatory and 
enhanced wound healing effects than EP extract. The authors attributed the effects of EPA 
extract to its constituent echinacoside (Speroni et al., 2002). 
        More recent studies suggested that from both pharmacological and bioavailability 
standpoints, it is the lipophilic alkamides of Echinacea that play a more important role in the 
herbal anti-inflammatory activities (Woelkart and Bauer, 2007). In vitro, polyunsaturated 
alkamides from EA inhibited microsomal cyclooxygenase and leukocyte 5-lipoxygenase 
activity, two enzymes responsible for production of local proinflammatory hormones and 
regulation of fibroblast wound closure (Muller-Jakic et al., 1994; Clifford et al., 2002).  
        In the light of the role of macrophages in inflammatory response, studies with 
macrophage cell line RAW 264.7 cells demonstrated that Echinacea alcohol extracts and 
their alkamides inhibited activated macrophages to produce NO, prostaglandin E2 (PGE2) 
and TNF-α (Chen et al., 2005, Lalone et al., 2007; Zhai et al., 2007). Such decreased 
production of inflammatory mediators might be relative to downregulated NF-κB activity by 
certain individual alkamides (Matthias et al., 2007). However, a recent study showed certain 
alkamides from EA roots inhibited PGE2 formation by human neuroglioma cells through 
decreased cyclooxygenase-2 (COX-2) activity, but not COX-2 mRNA and protein expression. 
On the contrary, alkamides increased COX-2 mRNA and protein expression (Hinz et al., 
2007).  
        As matters stand now, research work on the anti-inflammatory activity of Echinacea 
may be of significance in both understanding of the biological activity of Echinacea and new 
drug discovery. Firstly, individual phytochemicals, i.e. alkamides, are receiving 
unprecedented attention. Unlike polysaccharides which occur in every plant, certain 
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alkamides and caffeic acid derivatives are unique to Echinacea species (Bone, 1997). They 
may represent important natural sources for new drug discovery. Second, an in-depth study of 
the anti-inflammatory activity of individual phytochemicals will facilitate finding potential 
molecular target candidates, especially those that play a key role in regulation of signal 
transduction pathways and inflammatory responses.  
Echinacea contains many bioactive metabolites that determine its wide spectrum of 
biological activities 
        Echinacea depends on its phytochemical profiles for specific pharmacological activities. 
The three medicinal Echinacea species have similar phytochemical profiles with slight 
variation in amounts of individual compounds. Several widely accepted active compounds can 
be divided into three classes: high molecular weight polysaccharides, lipophilic alkamides and 
polar caffeic acid derivative (Barnes et al., 2005). The typical biological activities, mechanistic 
basis and physical properties of these three classes of phytochemicals are listed in table 1.   
        Polysaccharide constituents. Polysaccharides are common natural compounds in the plant 
kingdom. There are two types, PS1 (a methylglucuronoarabinoxylan) and PS2 (an acidic 
arabinorhamnogalactan) that are relative to the biological activity of Echinacea (Bone, 1997; 
Barnes et al., 2005). Some studies on Echinacea polysaccharides used a purified component 
derived from tissue cultures of Echinacea. Other studies used polysaccharides-containing 
Echinacea materials such as water extracts or fresh pressed juice. Echinacea polysaccharides 
received early scientific attention because of their antimicrobial and immune stimulating 
properties. They were shown to stimulate macrophages and neutrophils to produce 
inflammatory cytokines and reactive oxygen species (ROS) (Stimpel et al., 1984; Luettig et al., 
1989; Burger et al., 1997; Rininger et al., 2000), and protect immunocompromised mice from 
lethal fungal and bacterial infection (Roesler et al., 1991; Steinmuller et al., 1993). 
Polysaccharides from EP stimulated both classical and alternative pathways of complement 
activation (Alban et al., 2002). 
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        The absorption of polysaccharides in gastrointestinal tract is uncertain. In animal models, 
polysaccharides were usually administered via ip or intravenous (iv) injection, thus, bypassing 
digestion and absorption (Luettig et al., 1989; Roesler et al., 1991). Topical application of 
polysaccharides was found to have anti-inflammatory effects in the carrageenan paw edema 
and the Croton oil ear test models (Tubaro et al., 1987; Tragni et al., 1988). For studies of 
water-soluble polysaccharides, especially with in vitro cell culture or injection into animals, 
special attention should be paid to endotoxin contamination, which may give rise to false-
positive results via activation of toll-like receptor (TLR)-4 expressed on the membranes of 
certain immune cell components, i.e. macrophages. The specific medicinal value of 
polysaccharides from Echinacea is doubtful because they are common components of plant 
cell wall and have an oral bioavailability problem (Bone, 1997).   
        Alkamide constituents. Lipophilic alkamides are predominantly present in the roots of 
EA and EP, but largely absent in EPA. They are composed of a highly unsaturated fatty acid 
and an amide. The unsaturated fatty acid may be reflective of the true active form (Bone, 
1997). Compared to the fading interest in polysaccharides, alkamides have received more 
attention recently as they may represent a group of natural compounds with 
immunomodulating and anti-inflammatory properties when administered in vivo and are 
recognized to be a prime choice of biological marker for activity of Echinacea preparations. 
        In vitro, alkamides inhibited metabolic enzymes involved in inflammatory response 
(Muller-Jakic et al., 1994; Clifford et al., 2002) and suppress macrophage production of 
inflammatory mediators (Chen et al., 2005, Lalone et al., 2007; Zhai et al., 2007). The 
inhibitory effect of alkamides on NF-κB has been preliminarily demonstrated (Matthias et al., 
2007).  
        Alkamides have a structural similarity with anandamide, an endogenous cannabinoid 
(CB) receptor ligand. Thus, they may modulate immune responses through their interaction 
with CB2 receptors (Gertsch et al., 2004; Woelkart et al., 2005b). Alkamides have been 
14 
 
demonstrated to significantly inhibit LPS-induced inflammation in human whole blood via 
both CB2-dependent and -independent pathways (Raduner et al., 2006). CB2 receptors 
belong to the family of G protein-coupled receptors, which are mainly expressed on immune 
cells and in the spleen (Raduner et al., 2006). CB2 receptors are thought of as an important 
molecular target in drug discovery since they take part in various pathophysiological 
processes. The finding of the interaction of Echinacea-derived alkamides with CB2 receptors 
may be one of the biggest achievements in Echinacea studies so far since this group of 
natural occurring compounds may provide parental structures for the design and development 
of novel drugs that target CB2 receptors (Gertsch et al., 2006; Matovic et al., 2007).  
        In addition to the anti-inflammatory activity, alkamides may enhance macrophage 
function similarly to Echinacea-derived polysaccharides. In a healthy rat model, oral 
administration of a mixture of alkamides, polysaccharides and cichoric acid significantly 
increased the phagocytosis and production of NO and cytokines by LPS-stimulated alveolar 
macrophages and/or spleen macrophages (Geol et al., 2002a, 2002b). Such a macrophage 
enhancing effect may be attributable to alkamides from the viewpoint of bioavailability. 
        Intestinal absorption studies using Caco-2 monolayers, a model for the intestinal 
epithelial barrier, found alkamides diffused rapidly through the Caco-2 monolayers, 
suggesting that alkamides can easily reach the bloodstream without being modified by the 
digestive process (Jager et al., 2002; Matthias et al., 2004; Matthias et al., 2005b). The results 
from the Caco-2 model have been confirmed in human pharmacokinetic studies (Matthias et 
al., 2005a, 2005b; Woelkart et al., 2005a).  
        Caffeic acid derivatives. Polar caffeic acid derivatives include a wide range of 
phytochemicals such as echinacoside, cichoric acid, caftaric acid, chlorogenic acid and cynarin. 
Echinacoside occurs in EA and EPA. EP contains high levels of cichoric acid, but lacks 
echinacoside. Cynarin is a characteristic compound of EA. Caffeic acid and its derivatives 
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received attention in recent years for their antioxidant, anti-inflammatory, and cicatrizing 
(forming scar tissue) activities (Speroni et al., 2002).  
        Laboratory investigations show that caffeic acid and its derivatives have strong 
antioxidant activities and free radical scavenging abilities in cell-free free radical generation 
systems (Facino et al., 1995; Hu et al., 2000; Sloley et al., 2001; Mishima et al., 2004; Pellati et 
al., 2004), and the antioxidant potential could be enhanced by alkamides and polysaccharides 
(Dalby-Brown et al., 2005). In vitro, caffeic acid derivatives have antihyaluronidase activity 
(Facino et al., 1993). This biochemical nature of echinacoside has been functionally linked to 
the anti-inflammatory and wound healing properties of Echinacea (Speroni et al., 2002; 
Rousseau et al., 2006). The immunomodulating effects of the above-mentioned individual 
caffeic acid derivatives are unknown, but they may elicit a wide range of biological responses 
(Verma and Hansch, 2004; Jiang et al., 2005).  
        Pharmacokinetic studies of naturally occurring or synthetic caffeic acid derivatives (e.g. 
caftaric acid, chlorogenic acid and echinacoside) showed that they are quickly absorbed in the 
rat stomach, but eliminated rapidly from the blood circulation (Jia et al., 2006; Lafay et al., 
2006; Vanzo et al., 2007). Matthias et al. (2004) suggested a low bioavailability for caffeic acid 
derivatives of Echinacea based on the observations that they permeate poorly through the 
Caco-2 monolayer model. Human studies indicated undetectable parent caffeic acid derivatives 
or their metabolites in plasma samples of healthy volunteers after Echinacea tablet ingestion 
(Matthias et al., 2005a, 2005b). 
        Other bioactive constituents. In addition to the above-mentioned three mainly 
recognized classes of phytochemicals, there might be other plant metabolites that are 
responsible for the herbal biological activities. For examples, glycoproteins are purported to 
be active components (Classen et al., 2000; Thude and Classen, 2005). Ketones are lipophilic 
compounds that usually concomitantly appear in alkamide fractions of EPA. Like alkamides, 
ketones are easily absorbed by the intestine (Chicca et al., 2008). The interaction between 
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ketones and alkamides is unknown. Ketones have been suggested to have antifungal activity 
(Binns et al., 2000) and direct cytotoxicity on cancer cells (Pellati et al., 2006; Chicca et al., 
2008). In addition, melanin from Echinacea was suggested to be an effective mucosal 
immune modulator. It activates NF-κB in monocytes in vitro through a TLR-2-dependent 
process. In vivo melanin enhances production of IFN-γ by spleen cells and IgA and IL-6 
production by Peyer’s patch cells (Pugh et al., 2005). 
        It should be noted that different classes of chemicals may have some biological activities 
in common. For examples, polysaccharides show anti-inflammatory activities in addition to 
immunomodulation, and alkamides showed immunostimuating activities in addition to anti-
inflammation. This may indicate that each chemical class has pharmacological diversities. In 
addition, individual metabolites within each chemical class may also have distinct biological 
activities.  
        Natural bioactive chemicals of Echinacea may work not only individually, but also 
additively, synergistically or antagonistically, endowing the herb with multiple biological 
activities, and therefore could account for the diverse effects observed in studies using extracts 
of Echinacea. On the current herbal market, Echinacea products are mainly crude preparations 
and often blended with other herbs in various forms. Interestingly, it has been shown that 
isolated phytochemicals do not mimic the biological effects of whole plant extracts (Currier et 
al., 2003) and in animal experiments a combination of Echinacea extracts demonstrated a 
higher activity than extracts of a single plant (Bodinet et al., 2002a). It appears that the 
biological activity of a combination of its phytochemical components is more robust than one 
individual compound (Bodinet et al., 2002a; Currier et al., 2003; Randolph et al., 2003). 
Studies of the interactive effects of individual chemicals may have important clinical 
implications. 
Perspective and research interests related to this dissertation 
         Although Echinacea has a long history as an herbal medicine, its precise mechanism 
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has not been completely identified. Mechanistic understanding of Echinacea is of both 
potential medicinal significance and of important academic value. Almost all of the known 
biological activities of Echinacea are, to a large extent, linked to its immunomodulating 
nature. A typical example is that Echinacea modulates production of the endpoint products of 
inflammatory macrophages in vitro and ex vivo. Macrophages as one of the important 
immune components are usually used to screen and evaluate the efficacy of new Echinacea 
preparations including fractions and individual compounds. Although Echinacea preparations 
can modulate production of inflammatory cytokines and free radicals by activated 
macrophages, the mechanistic basis for these observed phenomena remains unclear. 
Fortunately, certain individual alkamides have been found to modulate NF-κB activities 
and/or bind CB2 receptor (Gertsch et al., 2004; Raduner et al., 2006; Matthias et al., 2007), 
providing a molecular basis for understanding of the herbal anti-inflammatory activities.  
        It is worthwhile to note that macrophages have dual immune functions and can be either 
classically activated (pro-inflammatory) or alternatively activated (anti-inflammatory). A 
given macrophage may switch from an activated state to another upon an external stimulus 
(Porcheray et al., 2005). Two types of activated macrophages are characterized by specific 
activation phenotypes and distinct biochemical pathways. It is interesting to determine 
Echinacea-mediated changes in the intracellular and extracellular molecular markers, and 
biochemical metabolic processes by using immunological, biochemical, cell and molecular 
biology techniques. For examples, L-arginine can be metabolized to produce either NO or L-
ornithine (Morris et al., 1998; Meurs et al., 2003). Macrophages undergo classical activation 
to activate inducible nitric oxide synthase (iNOS) and produce NO as well as other mediators 
that cause excessive inflammation. In addition macrophages undergo alternative activation to 
activate arginase leading to L-ornithine production as well as other mediators resulting in 
wound healing. Studies of the effects of Echinacea on these cross-regulated pathways may 
provide a new viewpoint for understanding of Echinacea.          
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        Compared to in vitro assays, animal experiments may be more appropriate to study the 
true efficacy of Echinacea. To that end wound healing may be used as model to evaluate the 
effectiveness of various Echinacea preparations and to understand its anti-inflammatory 
mechanism. Wound healing is a complex process (Park et al., 2004). Wounding initiates 
migration of neutrophils and macrophages to the wound site at the earliest stage of tissue 
repair. These two immune cell types play an integral role in wound healing through release of 
cytokines, growth factors and mediators. Inflammatory mediators i.e. TNF-α , NO and ROS are 
indispensable for excisional wound repair (Kondo and Ohshima, 1996). However, to 
accomplish successful wound repair, these inflammatory mediators are tightly regulated by a 
set of complex mechanisms through which the body makes full use of its positive regulation 
but controls its negative effect. In this case, Echinacea may be used to improve wound healing 
due to its immunomodulatory properties. Although Echinacea had been studied in several 
animal inflammatory models, they lacked a systemic determination of the dynamic pattern of 
wound healing as well as proinflammatory and anti-inflammatory mediators throughout wound 
healing process with exposure to Echinacea. 
        It should be noted that Echinacea has multiple functional influences on the immune 
system. The combined effect of several active compounds may be synergistic or antagonistic, 
and the type of action initiated largely relies on the host condition. If Echinacea is beneficial 
for wound healing, it would be interesting to know what effect of Echinacea could have if the 
wound healing process is perturbed by other factors, i.e. stress. Chronic psychological or 
physical stressors activate the hypothalamic-pituitary-adrenal (HPA) axis, leading to elevated 
plasma levels of glucocorticoids. The pharmacological level of glucocorticoids usually inhibit 
many components of inflammatory response, i.e. down-regulated production of 
proinflammatory cytokines and decreased phagocytosis of activated neutrophils and 
macrophages, which in turn delay cellular recruitment and proliferation at the wound site 
(Dhabhar, 2002; Sheridan et al., 2004; Paus et al., 2006). It has been well demonstrated in 
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murine model of cutaneous healing that chronic restraint stress can inhibit cellular infiltration, 
delay wound healing and increase the susceptibility to wound infection (Padgett et al., 1998;  
  Table 1.1. Bioactive metabolites of Echinacea and their properties  
 
Bioactive Metabolites1,2  
 
Properties Polysaccharides Alkamides Caffeic acid 
derivatives 
Chemical 
distribution 
Every plant Mainly in EA and EP 
(EPA has unique 
ketones) 
Echinacoside occurs in 
EA and EPA; 
EP has rich cichoric acid; 
Cynarin is unique to EA 
Chemical structure Polymers of simple 
sugars 
Condensation of an 
unsaturated fatty acid 
and an amine 
Caffeic acid monomer or 
polymer  
Physical nature Hydrophilic Lipophilic Water-soluble 
Oral bioavailability Low  High Low 
Common 
administration route 
in animal studies 
i,p, iv, or topically Orally Topically 
Biological activities Immunostimulatory  
i.e. increase phagocytosis 
and production of 
inflammation mediators 
Anti-inflammatory 
i.e. inhibition of 
production of 
inflammatory mediators; 
Bind CB2 receptor 
 
Anti-oxidant and free 
radical scavenging 
1. Structure-activity relationship is undefined  
2. The biological activity of a combination of multiple phytochemicals is more robust than single 
individual compound 
Rojas et al., 2002; Sheridan et al., 2004; Head et al., 2006). In this case, it is of interest to 
determine the effect if Echinacea on stress-induced inhibition of wound healing. It is highly 
likely that Echinacea exerts multiple immunomodulatory effects, i.e. enhancement of immune 
function in the earlier stages, and a switch to alternate macrophage activation in the later stages 
in order to allow wound tissue regeneration.  
Conclusion       
Echinacea is a laboratorily proven effective herbal medicine. It shows many pharmacological 
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activities mainly through modulation of the immune system in response to pathogenic 
challenge or mitogenic stimulation. One of the potential advantages with the use of 
Echinacea may be that many natural chemicals in a given herbal preparation act together, 
leading to ideal biological effects that are of  health benefit via a dynamic homeostasis of the 
host’s physiological and immune functions. Polysaccharides, alkamides and caffeic acid 
derivatives are three widely accepted classes of medicinal phytochemicals in Echinacea. 
They, however, unlike crude preparations with additional miscellaneous activities, exhibit 
strikingly distinct biological properties; they are immunostimulating, anti-inflammatory and 
antioxidant, respectively. Some of these identified chemicals and other potential yet 
unidentified chemicals may represent important chemical structures for novel drug discovery. 
Mechanistic study of Echinacea’s effects is underway and some biomacromolecules, i.e. CB2 
receptor, have been suggested to be therapeutic target candidates. Study of the structure-
activity relationship of individual effective natural chemicals may help to not only 
understand the biological nature of Echinacea, but also make new plant-based drugs possible.      
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CHAPTER 2.  ENHANCEMENT OF INNATE AND ADAPTIVE 
IMMUNE FUNCTIONS BY MULTIPLE ECHINACEA SPECIES 
 
Modified from a paper to be published in Journal of Medicinal Food 
 
Zili Zhai,2,3  Yi Liu,4 Lankun Wu,5 David S. Senchina,6,7 Eve S. Wurtele,5 Patricia A. Murphy,4 
Marian L. Kohut,6,7 and Joan E. Cunnick2,3,6 
 
Abstract 
        Echinacea preparations are commonly used as non-specific immunomodulatory agents. 
Alcohol extracts from three widely used Echinacea species, E. angustifolia, E. pallida and E. 
purpurea, were investigated for immunomodulating properties. The three Echinacea species 
demonstrated a broad difference in concentrations of individual lipophilic amides and water 
soluble caffeic acid derivatives. Mice were gavaged once/day (7 days) with one of the 
Echinacea extracts (130 mg/kg) or vehicle and immunized with sheep red blood cells (sRBC) 4 
days prior to collection of immune cells for multiple immunological assays. The three herb 
extracts induced similar, but differential changes in the percentage of immune cell populations 
and their biological functions, including increased percentages of CD49+ and CD19+ 
lymphocytes in spleen, and natural killer cell cytotoxicity. Antibody response to sRBC was 
significantly increased equally by extracts of all three Echinacea species. Concanavalin A 
stimulated splenocytes from E. angustifolia- and E. pallida-treated mice demonstrated 
significantly higher T cell proliferation. In addition, the Echinacea treatment significantly 
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altered the cytokine production by mitogen-stimulated splenic cells. The three herbal extracts 
significantly increased interferon-γ production, but inhibited the release of tumor necrosis 
factor-α and interleukin (IL)-1β. Only E. angustifolia- and E. pallida-treated mice 
demonstrated significantly higher production of IL-4 and increased IL-10 production. Taken 
together, these findings demonstrated that Echinacea is a wide-spectrum immunomodulator 
that modulates both innate and adaptive immune responses. In particular, E. angustifolia or E. 
pallida, may have more anti-inflammatory potential.     
Introduction 
        Echinacea is an herbaceous plant genus, consisting of nine species. Three species, E. 
angustifolia, E. pallida and E. purpurea, have been used medicinally in the US and Europe and 
are being introduced into other regions due to the increasing popularity in alternative herbal 
remedies. Echinacea has a wide range of pharmacological activities. Besides its common 
function as an supportive therapy in the treatment of the common cold and upper respiratory 
tract infections, in which it reduces  the duration and/or the severity of the symptoms, 1,2 it has 
been shown to possess palliative effects on wound damage,3 inflammation, 3,4 and tumor 
growth.5  
        As a widely used over-the-counter and self-prescribed herbal medicine, it is important to 
elucidate its mode of action in order to enhance clinical benefits and minimize toxicity. The 
most consistent result identified by the majority of studies so far indicates that Echinacea has 
non-specific immunomodulatory properties through the activation of innate immune cells.6,7 
For example, in animals Echinacea showed profound effects on immune cell number,8 
granulocyte migration,9,10 macrophage phagocytosis,10,11 natural killer (NK) cell 
cytotoxicity,12,13 and cytokine production.8,11 In addition, an arabinogalactan-protein isolated 
from E. purpurea stimulates both the classical and alternative pathways of complement 
activation.14 
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While the bulk of studies have emphasized the innate immune properties of Echinacea, 
few studies investigated its adaptive immune modulation. One study demonstrated an increase 
in immunoglobulin (Ig) M response against sheep red blood cells (sRBC) in the mice treated 
with a glycerine extract of E. purpurea.15 Other studies demonstrated an increase of humoral 
immunity in vivo but only provided indirect information due to the use of a blend of Echinacea 
and other herbs.16,17 Data regarding the effect of Echinacea on T cells are more limited. A 
previous study with E. purpurea found an increase in CD4+ T-lymphocytes in mouse 
peripheral blood but implied it is a secondary effect in association with macrophage 
activation.18 Morazzoni et al.19 recently reported that E. angustifolia extract enhances T cell 
function in vitro by stimulating interferon (IFN)-γ production in anti-CD3-treated murine T-
cell cultures. These experimental results suggest that Echinacea may modulate adaptive 
immune responses.    
 However, the evidence for Echinacea effects is confusing and inconsistent since most 
studies have used different Echinacea preparations, and these preparations are largely 
influenced by many factors, such as phytochemical variability due to growing conditions and 
lack of extraction standardization.2,7 Moreover, bacteria-derived endotoxin contamination 
during the extraction processes may give rise to false positive results by way of the stimulation 
of the immune system, especially with in vitro cell culture experiments or injection of the 
extracts into animals. Many previous reports have neglected this confounding factor of 
endotoxin, although some touched upon it.19-22   
Isolation and characterization of bioactive phytochemicals in Echinacea extracts used in 
studies is essential. A few widely accepted active compounds of Echinacea include lipophilic 
alkamides and polar caffeic acid derivatives (cichoric acid and echinacoside).23,24 The in-depth 
investigation of these active compounds seems to be helpful for the better understanding of the 
biological nature of Echinacea. However, a purified phytochemical does not mimic the 
immunological effects of whole plant extracts. It appears that the immunopharmacological 
34 
 
activities of Echinacea depend on a combination of several active compounds,25 but not any 
single individual constituent. In addition, extracts of Echinacea are commercially available and 
economical, but commercially available purified compounds are expensive and not approved 
for human consumption.  Thus, studies using the Echinacea extracts are still of great value. 
Animal experiments have show that a combination of Echinacea extracts demonstrated greater 
effects than extracts of single plants (reviewed in 17), but using a mixture of plants makes it 
difficult to distinguish the biological significance of each plant or identify redundancy in 
effects.   
Our preliminary studies using oral administration of Echinacea found that the dry powder 
or alcohol extract of E. purpurea root could stimulate splenic T cell proliferation and NK cell 
cytotoxicity. Based on the experimental data accessible to date on Echinacea, the purpose of 
the present study was (1) to provide a comparison of the immunomodulatory activity  of three 
species of Echinacea, (2) to clarify Echinacea’s activities on specific acquired immunity, and 
(3) identify differences in immune activation based on differences in high performance liquid 
chromatography (HPLC) profiles. Alcohol extracts of the three Echinacea species were 
prepared and administered in order to compare their effects on multiple immune parameters, 
i.e. NK cell activity, plaque forming cell (PFC) response against sRBC, B- lymphocyte and T- 
lymphocyte proliferation as well as T cell and macrophage cytokine production in healthy 
BALB/c mice. We found many functional immune assays were affected by Echinacea 
preparations, suggesting that Echinacea not only stimulates innate immunity, but also enhances 
adaptive immunity.        
Materials and Methods 
Echinacea preparation   
        E. angustifolia, E. pallida and E. purpurea were harvested in the USDA North Central 
Regional Plant Introduction Station (Ames, IA) in October 2003 with identification numbers PI 
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631285 (E. angustifolia), PI 631293 (E. pallida), and PI 631307 (E. purpurea). Extracts from 
the dried roots of these plants were prepared as follows: ground root powder was placed into 
Whatman 43 mm × 123 mm cellulose extraction thimble (Whatman International Ltd., 
Maidstone, England), covered with glass wool on the top, and refluxed with 250 ml different 
organic solvents, 100% ethanol, 95% ethanol, chloroform, and hexane, for 6 h using Soxhlet 
extraction device.  The extract was evaporated to dryness with a rotary evaporator (Büchner-
Brinkman, R-114, Switzerland) at < 30°C under reduced pressure, and the residue was stored 
in a red glass bottle to preserve it from photoxidation 3 at -20°C. The average efficiency of 
Soxhlet extraction of the three species is 23% (230 mg residue/gram starting material).  
Before animal treatment, the extracts were dissolved in 95% ethanol and then diluted in 
Nanopure water to a final suspension containing 14.7 mg/ml extracts in 5% ethanol. Ultrasonic 
treatment was used during the dilution process to improve solubility. After a homogenized 
suspension was obtained, aliquots were stored at -20°C and thawed for gavage or other 
analyses with each aliquot used once. The endotoxin level was evaluated in aliquots of the 
three Echinacea preparations using the Bio-Whitaker QCL 1000 kit (Cambridge, MA) and was 
below the limit of detection (0.1 EU/ml). 
Phytochemical analysis  
        The phytochemical analysis was performed to detect amides and caffeic acid derivatives 
in the Echinacea preparations with the use of high performance liquid chromatography 
(HPLC).26 Before analysis, dimethyl sulfoxide was added in order to obtain fully dissolved 
samples. Into 320 µl of Echinacea extracts, 40 µl (1 mg/ml) N-isobutylundeca-2-ene-8,10-
diynamide (C15H21O2) and 3,5-dimethoxy-4-hydroxy-cinnamic acid (C11H12O5) each were 
added as internal standards for quantification of lipophilic chemicals and hydrophilic 
chemicals, respectively. Fifteen microliters of each sample was injected into a Beckman 
Coulter HPLC with a 508 autosampler, 126 pump control and 168 UV-photodiode array 
detector controlled by 32 Karat TM software (Version 5.0), and a YMC-Pack ODS-AM RP C18 
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(250 × 4.6 mm, 5 µm) analytical column (Waters, MA). Solvent system for lipophilic 
constituents was acetonitrile/H2O at a flow rate of 1.0 ml/min following a linear gradient of 40-
80% acetonitrile over 45 min. Solvent system for hydrophilic constituents consisted of 
acetonitrile/H2O and 0.01% formic acid, at a flow rate of 1.0 ml/min following a linear gradient 
of 10-35% acetonitrile over 25 min. Online UV spectra were collected between 190-400 nm. 
The lipophilic chemicals were quantified based on the internal standard with the limit of HPLC 
detection at approximately 0.02 µg/ml.  
Animals 
        Animal care and experimental procedures were approved by the Iowa State University 
Committee on Animal Care. Male BALB/c mice at 8 weeks of age were obtained from Harlan 
Laboratories (Indianapolis, IN) and allowed to acclimate to new environment for 2 -3 weeks. 
The mice were housed three/cage and provided free access to food and water. The animal room 
was maintained on a reverse 12 h light /dark cycle (lights on at 8PM).  
Echinacea administration 
        This study consisted of two independent experiments with an identical study design. 
After acclimation, the mice were randomly assigned to five groups. Groups 1-3 were 
gavaged with one of the three Echinacea preparations. Group 4 was gavaged with an equal 
volume of 5% ethanol as vehicle control. Group 5 served as a no gavage control (no 
treatment group). The vehicle control and the no gavage control were established to control 
for the effects of vehicle as well as handling stress. The Echinacea preparations were orally 
administered to the animals at 130mg/kg body weight once daily for 7 consecutive days 
using an animal feeding needle. This dosage and regimen was chosen based on an 
extrapolation of the dose recommended for humans (4 g powder/day for an average 65 kg 
human ×1 week).27 We extrapolated the dose by using a 10-fold increase for mice according 
to skin to body ratio difference for mice and humans. We multiplied the dose by 23%, as this 
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was the average efficiency of Soxhlet extraction. The gavage dose volume was 0.18 ml 
extract suspension per 20 g mouse body weight. On the fourth day, all mice were injected 
intraperitoneally with 0.5 ml of 20% washed sRBC (Remel, Lenexa, KS) in Hank’s balanced 
salt solution (HBSS; GIBCO, Invitrogen Corporation) to induce an immune response. Our 
preliminary observation found that sRBC-injected mice did not display significantly 
immunological changes as measured in this study when compared to those animals receiving 
an injection of HBSS except that there were somewhat of changes in the percentage of 
leukocyte compositions in the spleen. Thus, in this study all mice were treated equally with 
sRBC injection to maintain the same experimental condition.    
Sample collection 
        The mice were weighed at the beginning and the end of the experimental treatments. 
Twelve to fifteen hours after the last gavage, the mice were euthanized by CO2 asphyxiation 
and immune samples collected immediately. Blood was collected by heart puncture using a 
heparin-containing syringe. An aliquot of blood was taken to perform hematological assay by 
using Hemavet 850 Hematology Analyzer (Drew Scientific, Inc., Oxford, CT). The remaining 
blood was diluted 1:10 with AIM-V media, supplemented with 2 mM glutamine, 25 mM 
Hepes buffer and 50 µg/ml gentamicin (AIM-V media), for use in a whole blood proliferation 
assay.  
        The spleens were aseptically removed from the mice and placed in AIM-V media. The 
spleen weight was recorded to assess spleen/body weight ratio. The spleen was then dissociated 
into a single cell suspension by gently grinding between the frosted ends of two sterile 
microscope slides. The splenocytes were enumerated and diluted to 5×106 cells/ml in RPMI 
1640 (GIBCO, Invitrogen Corporation) supplemented with 2 mM glutamine, 25 mM Hepes 
buffer, 50 µg/ml gentamicin and 10% heated-inactivated fetal bovine serum (FBS)  (complete 
media, CM) to use in immune function assays. A separate aliquot of splenocytes was diluted in 
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HBSS containing 25 mM Hepes buffer, 50 µg/ml gentamicin and 6% FBS (HBSS-6% FBS) 
for antibody staining for CD19+ and CD49+ subsets.  
Flow cytometric assay of lymphocyte subsets 
        Fluorescent-labeled monoclonal antibodies were used to identify lymphocyte subsets in 
the spleen. Freshly isolated splenocytes from mice were simultaneously stained with 
phycoerythrin (PE)-labeled anti-mouse CD49b mAb (pan NK cells) and biotin-labeled anti-
mouse CD19 mAb (B cells) (Pharmingen, San Diego, CA).  PE rat IgM kappa and biotinylated 
rat IgG2α kappa (Pharmingen) were used for the negative isotypic controls. Strepavidin-
cychrome (Pharmingen) was used as a fluorescent tag for biotinylated antibodies. Splenocytes 
(5×105 cells) in HBSS-6%FBS were diluted with 100 µl of ice-cold phosphate buffered 
saline/0.1% NaN3 (PBS/Azide). One microgram of anti-CD49b or 0.2 µg of anti-CD19 as well 
as 4 µl of normal mouse serum for blocking were added. An equal amount of isotypic 
antibodies and normal mouse serum were added to the corresponding control tubes. After 
incubation for 40 min in ice water bath, red blood cells were lysed using ice cold ammonium 
chloride solution. Cells were washed with PBS/Azide and Strepavidin-cychrome was then 
added to tubes containing biotinylated antibodies. The cells were incubated again in ice water 
bath. After one more wash the cells were fixed with PBS containing 1% formaldehyde. The 
cells were analyzed within 72 h using Beckman-Coulter Epics XL-MCL flow cytometer 
(Fullerton, CA).  
NK cell cytotoxicity 
        Splenic NK cell cytotoxicity was assessed by the chromium (51Cr) release assay as 
previously described,28 but with a small modification. Briefly, recombinant human-IL-2 (5 ng, 
Sigma) and splenocytes were plated to flat-bottom 96-well plate (Corning Incorporation, 
Corning, NY) and incubated at 37°C in 7% CO2 incubator overnight. YAC-1 cells (American 
Type Culture Collection, Manassas, VA) were used as targets and were labeled with 200 µCi 
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of 51Cr as sodium chromate (PerkinElmer, Boston, MA) at 37°C for 70 min. Washed target 
cells were plated at 104/well in all experimental, spontaneous and maximum wells and the 
plates incubated for additional 4.5 h at 37°C.  Three effector/target cell ratios, 25:1, 50:1 and 
100:1 were assessed in triplicate. Total incubation time including IL-2 activation and target 
killing was 24 h. Following addition of trichloroacetic acid (10%) to maximum release wells to 
lyse the targets, the plate was centrifuged at 500 rpm for 5 min. An aliquot of cell-free 
supernatant was removed and counted in a gamma Trac 1191 counter (TM Analytic, Inc., Elk 
Grove Village, IL). Percent cytotoxicity of experimental samples was calculated using the 
following formula: 
                                cpm experimental release – cpm spontaneous release   
    % cytotoxicity =                                                                                          ×100% 
                                cpm maximum release – cpm spontaneous release 
PFC  assay   
      B-cells making antigen specific antibodies to sRBC’s were quantitated using a PFC assay. 
Guinea pig complement (Cedarlane Laboratories Limited, Ontario, Canada) adsorbed against 
packed sRBC, 4% sRBC, and mouse splenocytes were mixed in equal volume. An aliquot (40 
µl) was immediately transferred into two sides of a Cunningham chamber.29  Slide chambers 
were sealed with melted paraffin and incubated for 1 h at 37°C in a humidified incubator. 
Plaques were counted under low power on a microscope. 
Cell proliferation assay   
      Mitogen-induced proliferation assay was performed using whole spleen cells and whole 
blood cells as described previously. Concanavalin A (Con A) and E. coli lipopolysaccharide 
(LPS) (Sigma, St. Louis, MO) were used as non-specific T-lymphocyte mitogen and B-
lymphocyte mitogen, respectively.  
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Splenocyte proliferation was performed using 5×105 cells/well in triplicate in a 96-well 
Costar plate and a final concentration of LPS at 10 µg/ml and Con A at 1 and 3 µg/ml. After 
co-incubation for 28 h, all wells were pulsed with [3H]-thymidine (1 µCi/well) (PerkinElmer, 
Boston, MA) and continued to incubate at 37°C, 7% CO2. Following 48 h of total incubation, 
the cultures were harvested using Skatron Cell Harvester (Sterling, VA), and the 3H-thymidine 
incorporation was determined by using a liquid scintillation analyzer (Mode Tri-carb 2100TR, 
Packard Instrument Company, Inc., Downers Grove, IL).   
The blood cell proliferation assay was conducted by using a similar protocol as described 
in the splenocyte proliferation assay. Diluted blood was incubated without or with LPS (10 
µg/ml) or Con A (20 µg/ml) for 52 h, all wells were then pulsed with 1 µCi/well of [3H]-
thymidine and incubated for 20 h. The cultures were harvested and the 3H-thymidine 
incorporation was determined. 
Enzyme-linked immunosorbent assay (ELISA) of cytokine production 
        The levels of cytokines were measured in the cultures of mitogen-stimulated mouse 
splenocytes ex vivo. Five hundred microliters of spleen cells were added to a 24- well flat-
bottom Costar plate containing 500 µl of media or mitogen (LPS or Con A, 20 µg/ml) and 
incubated for 24-72 h at 37°C, 7% CO2. Following incubation, the culture supernatants were 
harvested and frozen at -20°C for later analysis by enzyme-linked immunosorbent assay 
(OptEIA ELISA mouse kits, BD Biosciences, San Diego, CA). ELISA’s for IL-1β, IL-2, IL-4, 
IL-6, IL-10, IL-12 (p40), IFN-γ and TNF-α were conducted according to the manufacturer’s 
protocol with the exception that the plates were read at 655 nm in a plate reader (Bio-Rad, 
Hercules, CA) 30 min after the addition of substrate. The cytokine levels were determined by 
comparison to a standard curve generated from serial dilutions of purified recombinant mouse 
cytokines.    
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 Statistical analysis 
        Statistix software (version 8.0, Analytical Software, Tallahasee, FL) was used for the 
statistical analysis. Differences between Echinacea groups or the no gavage control and the 
vehicle control were tested by two-way analysis of variance (group × experiment) with 
subsequent a priori contrasts using to compare all three Echinacea treatments to the vehicle 
control. For analysis of NK data a factor for effector/target ratio was included in the model. For 
the PFC cell assay the model contained a factor for covariance based on the percentage of 
CD19+ cells and for the NK cell activity the model contained a factor for covariance based on 
the percentage of CD49+ cells. A value p<0.05 was considered statistically significant. 
Results 
HPLC analysis 
        The HPLC profiles of alcohol extracts of three Echinacea species are shown in Fig.2.1. 
The levels of phytochemical constituents quantified using HPLC are listed in Table 2.1. 
Amounts and types of identifiable amides and caffeic acid derivatives were quite distinct 
between the three species.  Total identifiable constituents in the preparations of E. angustofolia, 
E. pallida and E. purpurea were 107.7, 29.5 and 87.4 µg/ mg extract, respectively. Most 
phytochemicals detected were lipophilic amides, especially in E. angustifolia and E. purpurea 
preparations in which amides represents approximately 94.5% and 91.2% of all 
phytochemicals, respectively. A minor part of the phytochemicals was caffeic acid derivatives. 
Echinacoside was found to be the main caffeic acid derivative in both preparations of E. 
angustifolia and E. pallida, whereas no echinacoside was detected in the E. purpurea 
preparation. Cichoric acid was measurable in both E. pallida and E. purpurea preparations and 
was the main caffeic acid derivative of the E. purpurea preparation. Cynarin was detected in 
the E. angustofolia preparation, chlorogenic acid in the E. angustifolia and E. pallida 
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preparations and caftaric acid in the E. purpurea and E. pallida preparations. None of the 
phytochemical constituents was detectable in the vehicle. 
General animal observation 
        Adverse effects or obvious changes in behavior of the animals were not seen throughout 
the 7-day treatment course. No difference in body weight of the animals was found between the 
vehicle control and any of other groups before or after experimental treatment. The mean body 
weights of five groups before and after treatment were 25.8 ± 2.0 g and 25.6 ± 1.8 g, 
respectively. 
Peripheral blood and spleen cell subpopulations 
        Peripheral blood hematological parameters were measured following the 7-day Echinacea 
treatment. No significant changes to leukocyte number, red blood cell number, hemoglobin 
level or other hematological parameters were associated with oral administration of any of the 
three Echinacea preparations as compared to the vehicle control and the no gavage control 
(data not shown).  However, the three Echinacea preparations significantly increased the 
percentage of lymphocytes in peripheral blood over the vehicle control group and the no 
gavage control (62.7% vs 58.0%; p =0.001). For other leukocyte subpopulations (neutrophil, 
monocyte, eosinophil and basophil), no significant difference was observed between the 
Echinacea treatment groups and the two control groups. 
        There were no significant differences in spleen weight, spleen-to-body weight ratio, and 
total spleen cell number per mouse between the vehicle control and any of the other four 
groups. However, Echinacea treatment groups demonstrated a significant increase in the 
percentage of the lymphocyte subpopulation when compared to the vehicle control plus the no 
gavage control (83.3% vs 81.1%; p = 0.004). Meanwhile, the Echinacea treatment induced a 
marginal decrease in the percentage of splenic neutrophils as compared to the vehicle and no 
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gavage controls (10.1% vs 11.5%; p=0.084). There was no significant change in any of the 
other splenocyte subpopulations measured.  
        Noting an increase in the general percentage of splenic lymphocytes, specific lymphocyte 
subsets were further analyzed by flow cytometry for the expression of the CD49 and CD19 
markers (Fig 2.2). After 7 days of oral administration of vehicle (5% ethanol), there was a 
significant decrease in the percentages of both CD49+ and CD19+ splenocytes when compared 
with the no gavage control (p=0.002 and p=0.017, respectively). However, groups which 
received Echinacea preparations by gavage did not exhibit the decrease in these 
subpopulations, as the Echinacea treatments are not significantly different than the no gavage 
control. Individual comparisons of the Echinacea treatment groups demonstrated that E. 
purpurea treatment group was significantly increased in the percentage of both CD49+ and CD 
19+ cells over the vehicle control. E. angustifolia group was significantly increased in the 
percentage of CD49+ cells, but not CD19+ cells when compared with the vehicle control. No 
significant effect of E. pallida on splenic CD49+ and CD19+ subsets was seen.  
NK cell killing 
        The capacity of NK cells to lyse the target YAC-1 tumor cells in vitro was performed by 
51Cr- release assay. Since Echinacea treatment altered the CD49+ subset in spleen, NK cell 
cytotoxicity analysis was covaried for the percentage of CD49+ cells measured in each 
individual (Fig 2.3). No difference was seen between the three Echinacea treatment groups and 
the no gavage control. When compared to the vehicle control, both the Echinacea treatment 
and the no gavage control showed a higher NK cell killing (p < 0.03 and p < 0.035, 
respectively).  If the three Echinacea treatment groups were compared to the vehicle control 
separately, only the E. pallida group demonstrated significant increase in NK cell cytotoxicity 
(p < 0.035).  
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PFC response against sRBC         
        B-cells specific for sRBC were enumerated using a PFC assay. Since the Echinacea 
treatment groups displayed significant effects on the percentage of B cells as measured by 
CD19+ splenocytes, statistical analysis of PFC was adjusted by covariance with the percentage 
of CD19+ cells (Fig 2.4). No significant difference in antibody response against sRBC was 
found between the two control groups. Nor was there a significant difference among the three 
Echinacea treatment groups. However, the PFC counts of three Echinacea treatment groups 
were significantly higher than those of the two control groups (p = 0.003). Individual 
comparisons demonstrated that all three Echinacea species increased PFC response to sRBC (p 
values < 0.035).  
Mitogen-stimulated lymphocyte proliferation 
        Splenic lymphocyte and blood lymphocyte proliferation was performed by 3H-thymidine 
incorporation in the presence or in the absence of LPS or Con A. For splenic lymphocytes, the 
two mitogens produced a significant increase in cell proliferation (p values < 0.0001) (Fig 
2.5A). In the absence of mitogen, there was no significant difference among the five groups for 
splenic lymphocyte proliferation. In the presence of LPS, splenic lymphocyte proliferation was 
not affected by any of the three Echinacea treatments. With Con A at a low concentration of 1 
µg/ml, the three Echinacea treatments demonstrated a marginal enhancement of splenic 
lymphocyte proliferation (p = 0.065). Individual comparisons demonstrated that E. pallida had 
a significant enhancing effect on splenic lymphocyte proliferation when compared with the 
vehicle control (p = 0.046). When the Con A concentration was increased to 3 µg/ml in the 
cultures, the three Echinacea treatments were significantly increased over the vehicle control (p 
= 0.034), which was due to both E. angustifolia and E. pallida having significantly higher 
splenic lymphocyte proliferation than the vehicle control (p = 0.032 and p = 0.015, 
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respectively). Under all conditions, no difference in lymphocyte proliferation was observed 
between the vehicle control and the no gavage control.  
In blood cultures (Fig 2.5B), there was a significant stimulation of baseline blood 
lymphocyte proliferation by the Echinacea treatment in comparison to both controls (p = 
0.014).  E. angustifolia and E. pallida were both significantly different than controls (p values 
< 0.043), while E. purpurea was only marginally different (p = 0.091). However, in the 
presence of Con A and LPS, Echinacea did not enhance blood lymphocyte proliferation. For 
the blood cultures there was no difference in lymphocyte proliferation between the vehicle 
control and the no gavage control.  
Cytokine production 
        Cytokines are recognized as immune transmitters that regulate interactive effects among 
immune cells. A specialized cytokine can stimulate certain types of immune cells, but inhibits 
others.  Cytokine concentrations were assessed in cultures of unstimulated and mitogen-
stimulated splenocytes derived from the gavage and no gavage treatment groups.  
TH2 cells secrete a number of cytokines, such as IL-4, IL-6 and IL-10 that drive humoral 
immunity, but inhibit macrophages and are considered anti-inflammatory. E. angustifolia and 
E. pallida showed increased IL-4 and IL-10 production over the vehicle control in Con A-
stimulated spleen cells, however the enhancement reached significance only for the increased 
IL-4 production (p = 0.046) (Fig 2.6). The increase in IL-10 was only marginally significant for 
cultures from E. angustifolia and E. pallida when compared to the vehicle control group (p = 
0.057). For spleen cells without mitogen stimulation, E. angustifolia significantly increased IL-
4 production compared to the vehicle control group (p = 0.013). The three Echinacea 
preparations had no effect on IL-6 release. 
TH1 cells secrete IL-2 and IFN-γ that activate cell mediated immunity, including NK cells 
and macrophages. The Echinacea treatment significantly increased IL-2 and IFN-γ production 
in baseline cultures of splenocytes (p values < 0.035) and IFN-γ production by Con A-
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stimulated splenocytes (p = 0.005) (Fig 2.7). Individual comparison of Echinacea treatment 
groups showed that only E. angustifolia produced a significant increase in IL-2 production in 
Con A-stimulated splenocytes (p = 0.037). It is of interest to note that IFN- γ production in the 
vehicle control group was suppressed in comparison to the no gavage control group (p = 
0.054). 
Macrophages produce numerous inflammatory mediators, among them the cytokines 
TNF-α, IL-1β and IL-12.  In comparison to the vehicle control group, the three Echinacea 
preparations significantly decreased the production of IL-1β (p = 0.007) and TNF-α (p = 0.004) 
by LPS-stimulated splenocytes, but had no significant effect on IL-12 production (Fig 2.8). It is 
interesting to note that the vehicle control group demonstrated a significantly enhanced 
production of the inflammatory cytokine TNF-α compared to the no gavage group (p = 0.004), 
while IL-1β demonstrated a non-significant trend towards an increase. However, for baseline 
spleen cells without mitogen stimulation, E. purpurea induced a significant increase in IL-1β 
production compared to the vehicle control (p = 0.006).        
Discussion 
According to accumulated data, Echinacea exerts its pharmacological action via the 
modulation of non-specific innate immune parameters such as macrophage phagocytosis and 
pro-inflammatory cytokine production.6,7 Thus, Echinacea is thought of as a non-specific 
immunomodulator. “Non-specific” may also mean that the herb promotes overall immune 
system function. The results from the present study provide information supporting the later 
concept as oral administration of Echinacea resulted in multiple immunological changes, 
including the activation of NK cell activity, the enhancement of B-cell response to sRBC, 
increased T cell proliferation in response to mitogens, and increased production of some T cell 
cytokines. Also, this study demonstrates that the preparations from three common Echinacea 
species did not display opposing influences on immune system function.      
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For the experimental animals, the 7-day orogastric gavage and daily handling is 
doubtlessly a stressor that leads to stress induced changes of immunity.30,31 In addition, the 
vehicle of 5% ethanol could also contribute to some immune changes. It has been shown that a 
short term consumption of low dose dietary ethanol (4-7%) for 1-2 weeks could inhibit cell- 
mediated immune responses and sensitize the host to infection.32,33 In order to control these 
“stress” effects and highlight the effects of Echinacea on the immune system, both the vehicle 
control and the no gavage control were tested in this study. The observed differences in the 
vehicle control from the no gavage control reflect the immunological changes induced by stress 
and vehicle. Under the same stress condition, the difference between the Echinacea treatment 
groups and the vehicle control mirrors the immunological changes caused by Echinacea. We 
found that as compared with the no gavage control, Echinacea treatment groups did not differ 
in all of the immune parameters we measured, but it did differ significantly from the vehicle 
control. In comparison to the no gavage control, the vehicle control displayed a weakened 
immune capacity as evidenced by a decrease in splenic CD19+ cells and CD49+ cells, as well 
as, NK cell cytotoxicity. Conversely, the gavage with vehicle induced an increase in TNF-α 
and IL-1β production as compared to the no gavage control, suggesting that the 7-day handling 
and gavage with 5% ethanol altered host immune responsiveness. Interestingly, all these 
altered immune parameters could be returned to their normal levels by treatment with 
Echinacea. These results are of particular significance under clinical aspects, since the 
weakened immune system ranks high among the main indications for herbal 
immunomodulants.17 For this purpose, the immunostimulating effects of Echinacea have been 
investigated in several non-pathogenic, immunosuppressed animal models (i.e. old age or 
hydrocortisone-treated animals).8,12,13,17,34 In this respect, mild handling stress- and/or low dose 
ethanol- induced immunosuppression is likely another ideal model to observe the 
immunological potential of Echinacea with greater similarities to daily human stressful 
conditions.        
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Previous research demonstrated that Echinacea increases the numbers of circulating 
leukocytes, including total cell count and subpopulations (i.e. neutrophil, NK cell, and T 
lymphocyte).8,10,18 We found an increased percentage of lymphocytes not only in peripheral 
blood but also in the spleens of mice following 7-day oral treatment with our Echinacea 
preparations so that extends the previous findings. Cundell et al.8 observed a sustained, 
significant increase in the percentage of circulating mononuclear cells (lymphocytes and 
monocytes) associated with a significant decrease in the percentage of circulating neutrophils 
in aging rats fed with Echinacea for 8 weeks. In healthy horses Echinacea increases the 
number of peripheral lymphocytes, but decreases neutrophil count on day 35 during a 42- day 
feeding with E. angustifolia extract.10 The present study observed a significant increase in the 
percentage of total lymphocytes in animals gavaged with Echinacea compared to vehicle 
treated animals, suggesting that other leukocyte types must be decreased. Although the 
percentage of neutrophils in both blood and spleen was not significantly different among the 
animals from Echinacea and vehicle treated groups, this population exhibited a small, non-
significant, decrease in Echinacea treated animals. Other studies have suggested that the 
decrease in the percentage of neutrophils may be due to increases in granulocyte migration into 
the tissues.9,10 As lymphocytes consist of NK cells, T cells and B cells, Echinacea-induced 
changes in the percentage of lymphocyte subpopulations indicated Echinacea might modulate 
both innate and adaptive immune functions.  
NK cells play a critical role in clearing viral infections through the processes of 
cytotoxicity and production of cytokines, such as IFN-γ. It has been demonstrated that 
Echinacea increased NK cytotoxic function in vitro in human peripheral blood lymphocytes of 
both healthy individuals and patients with chronic fatigue syndrome or acquired 
immunodeficiency syndrome.34 Currier and Miller12,13 observed a significant activation of NK 
cells and an increase in NK cell numbers in aging mice fed with a diet containing commercially 
prepared root extract of E. purpurea. Our present study found the three Echinacea preparations 
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induced similar effects on NK cell activity. In comparison to the no gavage control, gavage 
with vehicle resulted in a decrease in the NK cell cytotoxicity, which is likely due to both stress 
effects of daily handling and 5% ethanol. It is interesting that Echinacea could attenuate the 
decreased NK cell activity. Moreover, analysis of data using covariance indicated that 
Echinacea increased NK cell activity over a simple increase in the cell count. 
Changes in B cell responses by a glycerine extract of E. purpurea have been noted.15 To 
discern an effect on B cells we measured PFC response against sRBC, the percentage CD19+ 
cells in spleen, and B cell proliferation in LPS-stimulated spleen cell. Gavage with Echinacea 
extracts led to a significant increase in PFC response against sRBC. Echinacea also affected 
the percentage of lymphocytes as well as the percentage of CD19+ cells in the spleen. As with 
the effects on NK cell activity, the vehicle control decreased the number of CD19+ cells in 
spleen cells when compared with the no gavage control. However, the vehicle-induced 
decrease in CD19+ cells was attenuated in animals receiving Echinacea, with a greater increase 
in animals gavaged with E. purpurea, suggesting that Echinacea may affect B lymphocyte 
development or migration in vivo.  
        It is well known that both subsets of TH cells are usually activated in immune response to 
complex antigens. In response to viral infection, antigen-specific T-helper and T-cytotoxic cells 
proliferate, secrete cytokines and the T-cytotoxic cells kill virally infected cells. Historical use 
of Echinacea in the treatment of viral infection has lead to the reasoning that Echinacea acts on 
T cells.22 Morazzoni et al.19 observed anti-CD3-treated murine T cell proliferation by LPS-free 
E. angustifolia root extract and suggested Echinacea activity on the immune system involves 
the interaction with T cells. Our results demonstrated that Con A induced splenic T cell 
proliferation could be enhanced by in vivo treatment with E. angustifolia or E. pallida. In 
addition, it was found that E. angustifolia administered in vivo stimulated lymphocyte 
proliferation in the absence of mitogens. The effects of Echinacea on T cell cytokine 
production were measured, including both TH1 cytokines, IFN-γ and IL-2 and TH2 cytokines, 
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IL-4, IL-6 and IL-10. Echinacea extracts were found to have enhancing effects on IFN-γ and 
IL-2 production and IL-4 and IL-10 levels showed 3-4-fold increase by spleen cells from 
animals gavaged with E. angustifolia and E. pallida. These results indicate that E. angustifolia 
and E. pallida modulate both the TH1- and TH2-cell immune function. E. purpurea, in contrast 
to other two Echinacea species, showed a relatively weaker effect on the TH1 cell cytokine 
productions. 
TH1 cell activation will in turn activate macrophages that protect against intracellular 
pathogens. The effects of Echinacea on phagocytosis and cytokine production by macrophages 
have been extensively investigated in vitro and in vivo, but the results were rather inconsistent 
(see review 6,7). Macrophages are important as a first line of defense against infections. Upon 
activation, they may secrete many pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-12 
and IL-6. However, inflammatory processes subsequently need to be downregulated to allow 
healing. These divergent and at times, seemingly contradictory effects reflect the dichotomy of 
macrophages as both pro- and anti-inflammatory effectors in response to host environmental 
changes. Recently one study25 reported opposing effects of Echinacea on cytokine gene 
expression when used in vitro vs oral administration in vivo.  The in vitro data found a short-
term (6 h) exposure of human monocytic cell line THP-1 cells to E. purpurea stimulates the 
expression of inflammation-related genes, such as IL-1β, TNF-α, IL-8, ICAM-1 and Cox-2. 
However, oral administration of Echinacea in vivo induced a reduction in the expression of 
inflammation-related genes, but increases the IFN-α expression in healthy individuals.25 The 
effects of Echinacea on cytokine production vary considerably, depending on the experimental 
conditions used (e.g. animal model, cell culture model, and the treatment scheme). Our animal 
model in this study demonstrated Echinacea exerted a strong inhibition on the TNF-α and IL-
1β production by macrophages in the presence of LPS, suggesting that Echinacea has anti-
inflammatory activity, as demonstrated previously.3,4 The down-regulation of these two 
important inflammatory mediators might be associated with increased production of IL-4. IL-4 
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supports the differentiation of CD4+ into TH2-typed cells and simultaneously suppresses the 
development of TH1-typed cells. On macrophages, IL-4 acts in an anti-inflammatory manner to 
inhibit the production of pro-inflammatory cytokines, i.e. IL-1β and TNF-α.35,36 
        Undoubtedly, the observed differential effects of three Echinacea species on certain 
immune parameters are associated with their variation in phytochemical composition. Among 
phytochemicals, amides, echinacoside and cichoric acid are thought of as the main active 
compounds responsible for the immunomodulatory action of alcohol extracts of 
Echinacea.24,37,38 E. purpurea has been reported to have a mix of constituents different from 
the other two species.24,38 Chromatographic analysis of our preparations showed that E. 
purpurea lacks echinacoside, but contains cichoric acid. Most, though not all, amides were 
present in the three Echinacea preparations and occupied a major part of all identifiable 
phytochemicals, especially for E. angustifolia and E. purpurea preparations. Among the three 
Echinacea species, E. purpurea is believed to have the strongest potency on the immune 
system.39 It is unexpected that E. purpurea displayed a weaker potential to stimulate TH2- and 
TH1-type cytokine production than E. angustifolia and E. pallida, especially since the HPLC 
results demonstrate that the E. purpurea extract contained high levels of amides and cichoric 
acid, the latter proven to have stronger immunostimulatory effects than echinacoside.38 So in 
this study, other phytochemicals, but not amides and cichoric acid in the E. angustifolia and E. 
pallida preparations, may be responsible for the strong immunomodulatory effects on T 
lymphocytes. Echinacoside and chlorogenic acid were the main caffeic acid derivatives in both 
E. angustifolia and E. pallida preparations we used. Echinacoside has been studied for its 
antioxidant, anti-inflammatory and cicatrizing activities.3,4,23,37  Data on the 
immunomodulatory effect of chlorogenic acid and cynarin, a characteristic component of E. 
angustifolia, are few. Given the use of the crude extracts in the present study and minor 
proportion of measurable constituents in total extracts (< 10.8%), we could not answer which 
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chemical makes the major contribution to the modulatory effect on immune function and if 
there are other undetected active phytochemicals in the extracts.  
        In conclusion, the present oro-gastric administration studies with three different 
Echinacea species have proven them to be effective immunomodulators. We found that three 
different species of Echinacea exhibit multiple modulating effects on immune function. They 
stimulate not only non-specific, innate immune response, but also specific, adaptive immune 
function, suggesting that Echinacea possesses an immunomodualting potential for the overall 
immune system. The effects of Echinacea were more robust in immune responses that were 
suppressed by the daily handling in the vehicle control group as compared to the no gavage 
group. To our knowledge, this is the first study that demonstrates the relevance of Echinacea’s 
immune enhancing effects in conjunction with a mild stress.  
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Fig. 2.1. HPLC chromatograms of the lipophilic amides and hydrophilic caffeic acid 
derivatives in Echinacea preparations. (A) E. angustifolia, (B) E. pallida, (C) E. purpurea, 
(D) vehicle. HPLC conditions see Materials and Methods.  UV absorbance at 210 nm (upper 
line) and 260 nm (lower line) for lipophilic chromatography. Peak 1-14 represent amides as 
shown in table 1. UV absorbance at 330 nm for hydrophilic chromatography.  
Lipophilic compounds Polar caffeic acid derivatives 
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Table 2.1. Concentration and percentage of known amides and caffeic acid derivatives in Echinacea preparations 
    
E. 
angustifolia       E. pallid       E. purpurea   
  
µg/mg 
extracta 
% 
metabolitesb µg/d/mousec   
µg/mg 
extract 
% 
metabolites µg/d/mouse   
µg/mg 
extract 
% 
metabolites µg/d/mouse 
amide 1  1.620 1.50 5.447      6.708 7.68 22.550 
amide 2  1.161 1.08 3.904  6.443 21.83 21.660  12.471 14.27 41.921 
amide 3  3.319 3.08 11.158  1.626 5.51 5.466  12.532 14.34 42.127 
amide 4  0.488 0.45 1.639  1.403 4.75 4.715  6.184 7.08 20.789 
amide 5  2.531 2.35 8.507  0.704 2.38 2.367  2.483 2.84 8.347 
amide 7  0.000 0.00 0.000  0.000 0.00 0.000  3.619 4.14 12.167 
amide 8  55.425 51.47 186.319  0.000 0.00 0.000  21.573 24.69 72.521 
amide 9  7.685 7.14 25.835  6.885 23.32 23.146  12.477 14.28 41.942 
amide 10  5.334 4.95 17.931  0.431 1.46 1.449  0.905 1.04 3.042 
amide 11  13.306 12.36 44.730  0.713 2.42 2.398  0.782 0.90 2.630 
amide 12  4.055 3.77 13.631  0.000 0.00 0.000  0.000 0.00 0.000 
amide 13  3.834 3.56 12.888  0.000 0.00 0.000  0.000 0.00 0.000 
amide 14  3.011 2.80 10.121  0.000 0.00 0.000  0.000 0.00 0.000 
Total amides 101.769 94.499 342.110  18.206 61.673 61.200  79.734 91.256 268.036 
 
           
caftaric acid 0.000 0.00 0.000  0.543 1.84 1.824  1.184 1.36 3.980 
chlorogenic acid 0.473 0.44 1.590  1.357 4.60 4.563  0.000 0.00 0.000 
cynarin  1.929 1.79 6.483  0.000 0.00 0.000  0.000 0.00 0.000 
echinacoside  3.523 3.27 11.843  8.350 28.29 28.069  0.000 0.00 0.000 
cichoric acid 0.000 0.00 0.000  1.064 3.60 3.577  6.456 7.39 21.702 
5.924 5.50 19.916  11.314 38.33 38.033  7.640 8.74 25.682 Total caffeic acid 
derivatives            
 
           
Total metabolites 107.694 100 362.025   29.520 100 99.234   87.374 100 293.719 
. Average of duplicate determinations.  
b. % metabolites = (concentration of individual metabolite / concentration of total metabolites) × 100. 
c. Intake of individual metabolite for each mouse on each day of oral Echinacea administration. 
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Fig. 2.2. Effect of Echinacea preparations on the percentages of splenic (A) CD49+ subset 
and (B) CD19+ subset.  Male BALB/c mice were orally administered one of three Echinacea 
preparations 130mg/kg daily for consecutive 7 days. The vehicle control mice received equally 
volumetric vehicle of 5% ethanol. Spleen cells were isolated to analyze the expression of the 
CD49 (NK cell subset) and CD19 (B-cell subset) markers by flow cytometry as described in 
experimental methods. Results were presented as the mean ±standard error of two independent 
experiments (N=6). *Indicates a significant group difference from the vehicle control at p< 
0.05. 
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Fig. 2.3. Effect of Echinacea preparations on NK cytotoxity after covarying for the 
percentage of CD49+ splenocytes in each animal. NK cell cytotoxicity was measured as 
described in experimental methods and expressed as percentage cytolysis of target cells. 
Results were presented as the mean ±standard error of two independent experiments (N=6).   
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Fig. 2.4. Effect of Echinacea preparations on splenic plaque forming cell (PFC) response 
after covariance for the percentage of CD19+ splenocytes in each animal.  PFC response 
was assayed as described in experimental methods and expressed as PFC per 106 splenocytes. 
Results were presented as the mean ±standard error of two independent experiments (N=6). 
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Fig. 2.5. Effect of Echinacea preparations on (A) splenic lymphocyte proliferation and (B) 
blood lymphocyte proliferation. Lymphocyte proliferation assay was conducted as described 
in experimental methods and was expressed as cpm (3H-incorporation) ×103. Results were 
presented as the mean ±standard error of two independent experiments (N=6). The value in the 
parenthesis means the concentration of mitogen (µg/ml). * Indicates a significant difference 
from the vehicle control at p<0.05. 
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   E. angustifolia,        E. pallida,       E. purpurea,       vehicle,       no gavage 
Fig. 2.6. Effect of Echinacea preparations on TH2 cytokine production by mouse 
splenocytes stimulated in vitro without or with mitogen. Spleen cells were incubated 
without or with Con A at 10 µg/ml for 72 h. Cytokine levels were determined as described in 
experimental methods. Results were presented as the mean ± standard error of two independent 
experiments (N=6).  * Indicates a significant difference from the vehicle control at p<0.05. # 
Indicates a significant difference of combination of corresponding Echinacea treatment groups 
with the vehicle control 
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Fig. 2.7. Effect of Echinacea preparations on TH1 cytokine production by mouse 
splenocytes stimulated in vitro without or with mitogen. Spleen cells were incubated 
without or with Con A at 10 µg/ml for 48h. Cytokine levels were determined as described in 
experimental methods. Results were presented as the mean ± standard error of two independent 
experiments (N=6). * Indicates a significant difference from the vehicle control at p<0.05. # 
Indicates a significant difference of combination of corresponding Echinacea treatment groups 
with the vehicle control 
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  E. angustifolia,        E. pallida,       E. purpurea,       vehicle,      no gavage 
Fig. 2.8. Effect of Echinacea preparations on macrophage cytokine production in vitro 
without or with mitogen. Spleen cells were incubated without or with LPS at 10 µg/ml for 24 
at 37°C in a 7% CO2 incubator. Cytokine levels were determined as described in experimental 
methods. Results were presented as the mean ± standard error of two independent experiments 
(N=6). * Indicates a significant difference from the vehicle control at p<0.05. # Indicates a 
significant difference of combination of corresponding Echinacea treatment groups with the 
vehicle control.   
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CHAPTER 3. ALCOHOL EXTRACTS OF ECHINACEA INHIBIT 
PRODUCTION OF NITRIC OXIDE AND TUMOUR NECROSIS 
FACTOR-ALPHA BY MACROPHAGES IN VITRO 
 
A paper published in Food and Agricultural Immunology1 
 
Zili Zhai2,3, Devon M. Haney2,4, Lankun Wu5, Avery K. Solco6, Patricia A. Murphy6, Eve S. 
Wurtele5, Marian L. Kohut7, Joan E. Cunnick2,3,4 
 
Abstract 
        Echinacea has been suggested to have anti-inflammatory activity in vivo. Nitric oxide 
(NO), tumour necrosis factor-alpha (TNF-α), and interleukin-1beta are important mediators in 
the inflammatory response. The effects of alcohol extracts of E. angustifolia (EA), E. pallida 
(EPA) and E. purpurea (EP) on production of these inflammatory mediators in both LPS-
stimulated RAW 264.7 macrophages in vitro and murine peritoneal exudate cells (PECs) in 
vivo were investigated. As macrophages produce these inflammatory mediators in response to 
pathogenic infection, parallel cultures of macrophages were studied for phagocytosis and 
intracellular killing of Salmonella enterica. EPA and EP in vitro inhibited NO production and 
TNF-α release in a dose-dependent manner. RAW 264.7 cells treated with EA or EP showed 
decreased killing over 24 hours although EA enhanced bacterial phagocytosis. Upon bacterial 
infection, RAW 264.7 cells produce high levels of NO; however, an Echinacea-mediated  
1
 Reprinted with permission of Food and Agricultural Immunology, 2007,18(3-4):221-236.  
2 Department of Animal Science, Iowa State University 
3 Neuroscience Interdepartmental Graduate Program, Iowa State University 
4 Interdepartmental Microbiology Program, Iowa State University  
5 Department of Genetics, Development and Cell Biology, Iowa State University  
6 Department of Food Science and Human Nutrition, Iowa State University  
7 Department of Health and Human Performance, Iowa State University 
67 
 
 
decrease in NO production was observed. Echinacea alcohol extracts administered orally at 
130 mg kg-1 d-1× 7d had a weak effect on NO production and phagocytosis by LPS-stimulated 
PECs. The results indicated that all Echinacea species significantly decreased inflammatory 
mediators in vitro, however, only EA and EP reduced bacterial killing. Oral administration of 
Echinacea alcohol extracts did not adversely affect the development and anti-bacterial function 
of inflammatory PECs in vivo, however, NO production was decreased during bacterial 
infection of PECs. 
Introduction 
        The genus Echinacea is a popular natural immunostimulant. Reports indicate that 
Echinacea increases phagocytosis by neutrophils and macrophages, and stimulates these 
inflammatory cells to produce proinflammatory cytokines and free radicals (Burger et al. 1997; 
Goel et al. 2002; Steinmuller et al. 1993; Stimpel et al. 1984), which are responsible for the 
antimicrobial activity. Contrary to these reports, Echinacea is also used as an anti-
inflammatory agent. The anti-inflammatory effects have been demonstrated using murine 
inflammatory models such as carrageenan-induced paw oedema and abraded skin (Raso et al. 
2002; Speroni et al. 2002; Tubaro et al. 1987). These seemingly contradictory, but 
interdependent biological activities of Echinacea products are, to a very large extent, related to 
their immunomodulating properties and may be due to the variability in composition of the 
herb products utilized in each study (Percival 2000). Several active components have been 
identified in Echinacea, including lipophilic alkamides, polar caffeic acid derivatives (mainly 
echinacoside and cichoric acid) and high molecular weight polysaccharides (Barnes et al. 
2005). In the current herbal market, Echinacea products are a mixture of many varieties and 
may be blended with other herbs in various forms, making it hard to clarify which components 
play a predominant role in the immunomodulatory activity. The interaction between the 
components of Echinacea crude preparations is also unclear. The effects of Echinacea products 
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might also depend on the host condition. Echinacea may enhance immune function in the body 
with a weakened immune system (Currier & Miller 2000; Bodinet et al. 2002), but suppress it 
when an inflammatory response predominates. Our previous animal study found that 
Echinacea treatment restored mild stress-induced immune changes to normal levels (Zhai et al. 
2007).  
        The inflammatory response in vivo involves infiltration of macrophages that function 
through secretion of inflammatory mediators, i.e. tumour necrosis factor-alpha (TNF-α), 
interleukin-1beta (IL-1β) and nitric oxide (NO) (Park & Barbul 2004). The inflammatory 
cytokines TNF-α and IL-1β enhance phagocytosis by macrophages and trigger the release of 
NO (Nussler & Billiar 1993). NO, a signal of macrophage activation, is central to macrophage 
cytostatic and cytotoxic activity against various bacteria and tumour cells (Burgner et al. 1999; 
MacMicking et al. 1997). However, when produced in excessive quantities, NO is detrimental 
to both pathogenic agents and the host’s own tissues (Brune et al. 1997; Chang et al. 2000). 
Therefore, production of NO and other inflammatory mediators is tightly regulated by a set of 
complex anti-inflammatory mechanisms which involve IL-4 and IL-10 (Salmon-Her et al. 
2000; Sato et al. 1999). Our previous ex vivo observations show that orally administered 
alcohol extracts of Echinacea increased the production of IL-4 and IL-10, but inhibited TNF-α 
and IL-1β secretion by mitogen-stimulated splenocytes (Zhai et al. 2007). Other research 
groups show that the alkamides from Echinacea downregulate NO production in activated 
macrophages in vitro (Chen et al. 2005) and decrease TNF-α release in LPS-stimulated human 
whole blood cells ex vivo (Woelkart et al. 2006). These studies suggest that alcohol extracts of 
Echinacea as well as its alkamide fraction possess anti-inflammatory activity. 
        In this study, the effects of alcohol extracts of the three commonly used Echinacea 
species, E. angustifolia (EA), E. pallida (EPA), and E. purpurea (EP) were further examined 
both in vivo and in vitro by determining the production of inflammatory mediators, NO, TNF-α 
and IL-1β in activated macrophages. Parallel cultures of ex vivo macrophages and the 
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macrophage cell line RAW 264.7 cells were studied for phagocytosis and intracellular killing 
of Salmonella in order to understand if Echinacea alcohol extracts compromise the 
antibacterial function of macrophages through inhibition of inflammatory mediators.  
Materials and Methods 
Preparation of alcohol extracts    
        The plants EA, EPA and EP were harvested in the USDA North Central Regional Plant 
Introduction Station (Ames, IA) with identification numbers PI 631285, PI 631293, and PI 
631307, respectively. Alcohol extracts from the dried roots were prepared as previously 
described (Zhai et al. 2007) followed by evaporation until dry. These dry residues were 
subsequently dissolved in ethanol and phosphate buffed saline (PBS) to desired concentrations 
for in vitro assays or dissolved in ethanol and Nanopure water for animal studies. Those 
extracts used for in vitro assays were further filter-sterilized using a 0.45 µm microfilter 
(Costar, Corning, NY). Aliquots of alcohol extracts were stored at -80°C (for in vitro assays) or 
-20°C (for animal studies) and freshly thawed for each experiment. The endotoxin levels were 
evaluated in aliquots using the Limulus Amebocyte Lysate Test (BioWhittaker, Inc., 
Walkersville, MD) according to the manufacturer's specifications for a microplate assay and 
were detected to be below the limit of detection (0.1 EU ml−1). Phytochemical analysis was 
performed to detect alkamides and caffeic acid derivatives in aliquots using high performance 
liquid chromatography (HPLC) as described previously (Wu et al. 2004).  
Animals   
        Animal care and experimental procedures were approved by the Iowa State University 
Committee on Animal Care. Male BALB/c mice at 8 weeks of age were obtained through Iowa 
State University Laboratory Animal Resources from Harlan Laboratories (Indianapolis, IN) 
and allowed to acclimatise to the new environment for 2 weeks. The mice were housed 
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three/cage and provided free access to food and water under a reverse 12 h light/dark regimen 
(lights off at 9:00 AM).   
Echinacea administration in vivo   
        The mice were randomly assigned to five groups. Groups 1-3 were gavaged with one of 
the three alcohol extracts. Group 4 was gavaged with an equal volume of 5% ethanol as vehicle 
control. Group 5 served as a no gavage control. The vehicle control and the no gavage control 
were established to control for the effects of the vehicle as well as handling stress. The extracts 
were orally administered to the animals at 130 mg kg−1 body weight once daily for 7 
consecutive days. This dosage and regimen was chosen based on an extrapolation of the 
maximum dose recommended for humans and calculated as previously described (Zhai et al. 
2007). Three days prior to euthanasia, all mice were injected intraperitoneally with 3% 
proteose peptone (Difco Laboratories, Detroit, MI) to induce an inflammatory cell response. 
The animal experiment was repeated three times. 
Peritoneal exudate cell collection   
        Twelve to fifteen hours after the last gavage, the mice were euthanized by CO2 
asphyxiation, and peritoneal exudate cells (PECs) were immediately collected by peritoneal 
lavage with ice-cold EDTA (0.1%; w/v) in Hank’s balanced salt solution (Fortier & Falk 
1994). For each group, PECs were pooled and washed twice with RPMI 1640 medium 
supplemented with 2 mM glutamine, 25 mM Hepes, 50 µg ml−1 gentamicin and 10% heated-
inactivated foetal bovine serum (complete medium). 
Macrophage cell line   
        The murine peritoneal macrophage cell line RAW 264.7 cells were acquired from 
American Type Culture Collection (ATCC, Rockville, MD) and passaged in complete medium 
with heated-inactivated iron-fortified bovine calf serum (JRH Biosciences, Lenexa, KS) at 
37°C in a 7% CO2 incubator. Cells between passage 5 and 20 were used in this study. 
71 
 
 
Cell viability assay 
        Mitochondrial reduction of MTS, a tetrazolium compound, to a coloured formazan was 
determined as an indicator of cell viability. RAW 264.7 cells and PECs were seeded at 4×104 
cells per well in 96-well tissue culture plates with or without 1µg ml−1 lipopolysaccharide 
(LPS, E. coli 055:B5, L6529; Sigma, St. Louis, MO). For cultures of RAW 264.7 cells, one of 
alcohol extracts was added at 0-500 µg ml−1 at the same time the cells were plated in the 
absence or presence of LPS. After overnight incubation, MTS (Promega, Madison, WI) was 
added and cultures then successively incubated for 3 (PECs) or 1 (RAW 264.7 cells) h. The 
extent of formazan formation was determined photometrically at absorbance 490 nm using a 
Bio Kinetics Reader (Bio-Tek Instruments, Winooski, VT). The absorbance of cell-free 
complete medium with or without vehicle or Echinacea alcohol extracts was used as a blank 
and subtracted from the value of the corresponding treatment groups.  
Growth and freezing of Salmonella 
        Salmonella enterica subspecies enterica serovar Typhimurium were obtained from Dr. H. 
Harris (Iowa State University) and grown overnight at 37°C in Luria-Bertani (LB) broth with 
shaking to a density of 109 cells ml−1. The Salmonella were washed once in PBS and frozen at -
80°C in LB broth containing 16% sterile glycerol. A freshly thawed aliquot of Salmonella was 
used for each experiment.  
Gentamicin protection assays 
        Engulfment and killing of Salmonella were performed using both RAW 264.7 cells and 
PECs. The protocol for each cell type was identical with the exception that Echinacea 
alcohol extracts were added to cultures of RAW 264.7 cells. PECs were collected from mice 
which had been gavaged with one of the alcohol extracts in vivo. RAW 264.7 cells and PECs 
were seeded at a concentration of 4 × 105 cells per well (1 ml) in 24-well plates and 
incubated overnight. After harvest of culture supernates for NO and cytokine assays, 
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described below, cells were washed three times in gentamicin-free complete medium. 
Salmonella were then added to the adherent RAW 264.7 cells and PECs at a multiplicity of 
infection (MOI) of 100 bacteria per cell. Following 2 h of infection, cells were washed in 
warm complete medium containing 50 µg ml−1 of gentamicin and maintained in gentamicin-
containing complete medium for the remainder of the experiment to kill all extracellular 
bacteria. At 0, 4 and 24 h post infection, one set of parallel cell cultures were washed with 
sterile PBS to remove gentamicin and then lysed in distilled water to release the intracellular 
bacteria. Intracellular bacteria were enumerated by serial dilution and plate count on LB agar. 
Lysate dilutions on LB agar were incubated overnight at 37°C and counts were expressed as 
colony forming units (CFU) ml−1. CFU at the 0 h time point reflects the amount of 
phagocytosis by the cultured RAW 264.7 cells and PECs, while the reduction in CFU at 4 
and 24 h time points reflects the killing of intracellular bacteria by the cells. As Echinacea 
treatment induced some changes in eukaryotic cell growth (see Fig 3.1), the intracellular 
bacteria quantitation was adjusted based on the parallel MTS assay to normalize each 
treatment group to the same cell count before bacterial infection by using the formula: 
number of intracellular bacteria = number of viable bacteria counted × (control cells MTS 
OD) / (treated cells MTS OD).  
Nitrite assay 
        NO in the presence of oxygen is rapidly converted to nitrite. Supernates collected from 
RAW 264.7 cells and PECs cultured with and without LPS or with Salmonella (as described 
above) were tested for nitrite based on the Griess reaction (Chou et al. 1997). The absorbance 
at 550 nm was measured using a microplate reader. The cell-free culture medium alone 
containing a trace amount of nitrite was subtracted from each value obtained with cells. The 
NO levels were calculated based upon the absorbance of sodium nitrite (0.39-100 µM) as a 
standard. The NO levels in supernates from RAW 264.7 cells post Salmonella infection were 
adjusted based on the MTS data to normalize for differences in cell number.   
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        In the absence of LPS, very low amounts of NO (< 0.5 µM) were measured in culture 
supernates from RAW 264.7 cells incubated in vitro for 24 h. Thus, we report only NO 
production of cultures from LPS stimulated cells. 
Cytokine assays 
        Supernates from RAW 264.7 cells and PECs incubated with LPS for 24 h (as described 
above) were assayed for TNF- α (RAW 264.7 cells) or IL-1β and IL-10 (PECs) by enzyme-
linked immunosorbent assay (ELISA). In the absence of LPS in vitro, very low (or lower 
than limit of detection) amounts of the cytokines of interest were measured in culture 
supernates of both RAW 264.7 cells and PECs. In the presence of LPS, RAW 264.7 cells 
secrete high levels of TNF-α and PECs secrete high levels of IL-1β and IL-10. ELISAs for 
these cytokines were conducted according to the manufacturer’s protocols (BD Biosciences, 
San Diego, CA). The cytokine levels were calculated by using purified recombinant mouse 
cytokines as a standard.    
Statistical analysis 
        Statistix software (version 8.0, Analytical Software, Tallahasee, FL) was used for the 
statistical analysis. Differences between the vehicle and other groups were tested by two-way 
analysis of variance (group × experiment). A value p<0.05 was considered significant.     
Results 
Phytochemical analysis 
        Echinacea alcohol extracts contain several chemical components. Lipophilic alkamides 
and hydrophilic caffeic acid derivatives are two groups of the most studied metabolites. The 
concentrations of phytochemicals identified and quantified using HPLC are listed in Table 3.1. 
Alkamides were the major phytochemicals detected, especially in EA and EP alcohol extracts. 
Note that amides 7 and 8 appear in the present EPA extracts though they were undetectable in 
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our previously prepared alcohol extracts (Zhai et al. 2007). Among the caffeic acid derivatives, 
echinacoside was found in higher quantities in both EA and EPA extracts while cichoric acid 
was the main form in EP extract.  
In vitro experiments 
        Before measurement of the production of inflammatory mediators by RAW 264.7 cells, 
we first evaluated the cytotoxicity of Echinacea alcohol extracts by using the MTS-based 
assay. Echinacea alcohol extracts displayed different patterns of effects in the presence as 
opposed to the absence of LPS (Fig 3.1). In the absence of LPS, all three alcohol extracts at 
200 and 500 µg ml−1 significantly increased cell number when these two groups were jointly 
compared to the vehicle control, but in the presence of LPS, EPA and EP at 500 µg ml−1 
significantly decreased cell number when compared to cells treated with vehicle (0.25% 
ethanol) (p’ s ≤0.006). Treating RAW 264.7 cells with the vehicle had modest effects on cell 
number. The vehicle, in comparison to the baseline control, decreased cell number in the 
absence of LPS, but increased cell number when LPS was present.  
        To assess the effect of Echinacea alcohol extracts on NO production, RAW 264.7 cells 
were exposed to LPS plus alcohol extracts for 24 h. The alcohol extracts reduced NO 
production in a dose-dependent manner (Fig 3.2A). In comparison to the vehicle control, 
EPA at 100 µg ml−1 significantly decreased the production of NO (p = 0.009). When the 
herbal concentration was raised to 200 µg ml−1, NO production was significantly inhibited by 
all three alcohol extracts (p values ≤ 0.042). None of the three alcohol extracts at the 
concentrations tested interfered with the reaction between nitrite and the Griess reagent (data 
not shown). 
        RAW 264.7 cells activated by LPS secrete high levels of TNF-α (reaching up to 9000 
pg ml−1). The effect of Echinacea alcohol extracts on the TNF-α levels was evaluated in the 
same culture supernates analyzed for the NO levels. All three extracts had a similar 
inhibitory effect on TNF-α secretion as on NO production (Fig 3.2B). When compared to the 
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vehicle control, both EPA and EP at a concentration of 100 µg ml−1 significantly decreased 
TNF-α secretion (p < 0.02 and p < 0.0001, respectively). EA, as well as EPA and EP at the 
highest concentration tested of 200 µg ml−1 also inhibited TNF-α secretion (p’s < 0.04). 
        After incubation with Echinacea alcohol extracts overnight, RAW 264.7 cells were 
assessed for phagocytosis (CFU at 0 h) and bacterial killing (reduction in CFU at 4 and 24 h) 
after addition of Salmonella. Fig 3.3 shows the survival of bacteria in RAW 264.7 cells 
pretreated with one of the three alcohol extracts in the absence of LPS. Incubation of RAW 
264.7 cells with EA at 100 - 200 µg ml−1 enhanced the subsequent phagocytosis (p’s < 0.04), 
but inhibited bacterial killing at 4 (p’s < 0.026) and 24 h (p’s < 0.026) post-infection. EPA 
displayed no significant effects on bacterial phagocytosis, but increased bacterial killing over 
24 h incubation (p = 0.002 at 200 µg ml−1). EP had no effect on bacterial phagocytosis, but 
decreased later bacterial killing. EP at 100 - 200 µg ml−1 significantly inhibited bacterial 
killing 4 h post-infection (p’s < 0.037). At 24 h post-infection, EP at 10 µg ml−1 also showed 
an inhibitory effect on bacterial killing (p = 0.011).  
        NO production was also evaluated in the culture of RAW 264.7 cells following 
exposure to Salmonella (Fig 3.4). RAW 264.7 cells pretreated with Echinacea alcohol 
extracts showed a dose-related trend of decreased NO production 24 h after exposure to 
bacteria. When compared to the vehicle, EA and EPA at 200 µg ml−1 significantly inhibited 
NO production when assayed at 24 h post-infection (p = 0.036 and p = 0.018, respectively). 
At 4 h post-infection, EP at 100 µg ml−1 significantly decreased NO production (p = 0.030), 
but the decrease in NO was not significant at the 24 hour time point for EP. 
Ex vivo experiments 
        Parallel studies were performed using proteose peptone-elicited PECs. After mice were 
gavaged with Echinacea alcohol extracts for 7 consecutive days, PECs were harvested and 
incubated overnight in the absence or presence of LPS. There were no significant differences in 
cell number as determined by the MTS assay (Fig 3.5A) and NO production (Fig 3.5B) 
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between the vehicle control and any of the Echinacea treatment groups. Also, no significant 
differences in secretion of cytokines IL-1β and IL-10 in culture supernates of PECs in the 
presence of LPS were associated with oral administration of the extracts as compared to the 
vehicle control (Fig 3.5C). For all these assays of PECs (cell viability, NO production and 
cytokines), no significant difference was observed between the two control groups (the no 
gavage control and the vehicle control). 
        After incubation of PECs overnight without LPS stimulation, cells were further assessed 
for phagocytosis and bacterial killing as well as NO production at 0, 4 and 24 h post-
infection. In comparison to the no gavage control, the vehicle control displayed significantly 
decreased phagocytosis (p < 0.02) (Fig 3.6A). However, one of the three extracts, EPA, 
showed a marginal increase in bacterial phagocytosis over the vehicle control (p = 0.052). 
With increasing time after infection, there were no significant differences in bacterial killing 
between the vehicle control and any of other groups. Measurement of NO production post-
infection showed that mice gavaged with the vehicle displayed increased potential in NO 
production and a significant increase in the vehicle control was found at 4 h  after infection 
as compared to the no gavage mice (p < 0.05) (Fig 3.6B). Conversely, three Echinacea 
treatments showed to some extent decreased NO production when compared to the vehicle 
control and EP exhibited a significant decrease in NO production compared to the vehicle 
control (p < 0.03) at 4 h, but not 24 h post-infection. 
Discussion 
        This study demonstrates that Echinacea alcohol extracts in vitro inhibit LPS-induced 
generation of NO and TNF-α in macrophages. Although NO and TNF-α are needed for 
clearing and containing bacterial infection, excessive NO and TNF-α are implicated in a 
pathological role in inflammatory responses. Such an inhibitory property may endow 
Echinacea alcohol extracts as an effective anti-inflammatory remedy. In the present study we 
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found evidence that Echinacea can decrease inflammatory mediators in vitro, but that the 
effect in vivo was observed only in comparison with the vehicle control group which 
exhibited an excessive production of NO during Salmonella infection. Interestingly enough 
the excessive NO production and suppressed NO production did not correlate with any 
biological effects of bacterial killing in the PECs. 
        Echinacea alcohol extracts consist of both hydrophilic and lipophilic fractions. There is 
evidence to believe that polar caffeic acid derivatives have anti-inflammatory activities 
(Speroni et al. 2002). There are several types of caffeic acid derivatives in Echinacea (Table 
1). Echinacoside was predominately present in EPA and EA, whereas cichoric acid was the 
principal caffeic acid derivative of EP. In recent years much attention has been paid to the 
antioxidant activities and free radical scavenging abilities of Echinacea-derived caffeic acid 
derivatives (Dalby-Brown et al. 2005; Facino et al. 1995; Hu & Kitts 2000; Pellati et al. 
2004). The alkamide mixture of Echinacea alone shows weak or no antioxidant activity, 
however, the alkamides have been found to significantly increase the antioxidant activity of 
the caffeic acid derivatives, possibly due to the lipophilic nature of the alkamides (Dalby-
Brown et al. 2005). Moreover, individual alkamides and mixtures of alkamides have been 
reported to have anti-inflammatory effect by inhibiting NO production in LPS-stimulated 
macrophages in vitro (Chen et al. 2005). The observed inhibition of inflammatory mediators 
by Echinacea alcohol extracts in vitro in the present study might be due to the additive or 
synergistic action of hydrophilic fractions (caffeic acid derivatives) and lipophilic fractions 
(alkamides). 
        The NO and TNF-α inhibitory potential of the three alcohol extracts in vitro is generally 
EPA>EP>EA. The basis of this difference in the modulation of NO and TNF-α production 
may rest on the distinct amounts and types of phytochemicals between the three herbal 
preparations. HPLC data showed that EPA and EP had higher levels of echinacoside or 
cichoric acid, respectively, and they share high levels of some individual alkamides, such as 
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alkamide 2 which occurs in relatively small amount in EA. These herbal components may be 
quantitatively important as modulators of NO and TNF-α production. Further studies are 
needed to address the respective role of individual phytochemicals and their interaction in the 
modulation of inflammatory mediators. 
        NO generated by LPS-activated macrophages is a strong inducer of cell damage and 
apoptosis (Brune et al. 1997; Chang et al. 2000). The downregulation of NO production by 
Echinacea alcohol extracts possibly protects macrophages from NO damage. Since 
production of TNF-α and NO by macrophages are precisely controlled by several ubiquitous 
transcription factors including NF-κB (Baeuerle & Baltimore 1996), Echinacea-mediated 
reduction of both inflammatory mediators likely results from the perturbance of a common 
upstream signalling pathway.  
        Interestingly, Sharma et al. (2006) recently reported that an alcohol tincture from EP 
roots increased the nuclear expression of multiple pro-inflammatory transcription factors 
(e.g. NF-κB and STATs) in nonactivated human bronchial epithelial cell line BEAS-2B, but 
inhibited the expression of these transcription factors when the cells were infected with 
rhinovirus, providing strong mechanistic evidence to explain the observed phenomena in this 
study; that is, Echinacea alcohol extracts have different influences on the nonactivated and 
activated macrophages and the effects of Echinacea on the inflammatory mediators are 
associated with the modulation of transcription factor expression. 
        The opposite effects of Echinacea alcohol extracts on the nonactivated and activated 
macrophages were also seen in cell numbers with the use of the MTS assay (Fig 3.1). In 
comparison to the vehicle, Echinacea resulted in decreased cell number in the presence of 
LPS. While macrophages are in a resting state, Echinacea stimulated to some extent an 
increase in cell number. Echinacea alcohol extracts might stimulate the nonactivated 
macrophages (e.g. increase cell number and/or function), but reduce macrophage 
proliferation when they are activated. 
79 
 
 
        Macrophages constitute one of the first lines of host defence against microbial infections 
based on their abilities to produce NO and reactive oxygen species. NO is believed to 
represent an important effector molecule in the killing of a variety of pathogens, including 
Salmonella (Alam et al. 2002; Babu et al. 2006; Burgner et al. 1999; MacMicking et al. 
1997). Since Echinacea preparations, mainly from fresh-pressed juice or the high molecular 
weight polysaccharide fraction, have been shown to upregulate production and secretion of 
proinflammatory cytokines and oxygen radicals, consistent with an immune activated 
antimicrobial effect (Burger et al. 1997; Steinmuller et al. 1993; Stimpel et al. 1984), it is 
interesting to know the possible consequence upon inhibition of NO production by 
Echinacea alcohol extracts. We attempted to investigate and correlate the phagocytic activity 
and bacterial killing of macrophages with NO production following exposure to Echinacea 
alcohol extracts. Although EA enhanced phagocytic activity, treatment with EA or EP clearly 
showed an inhibitory effect on intracellular bacterial killing. This inhibition may be a 
secondary effect of the downregulation of NO production. Macrophages infected with 
bacteria produce high levels of NO that can be blocked by alcohol extracts of Echinacea, 
especially at high concentrations. Nonetheless, EPA at 200 µg ml−1 simultaneously increased 
the potential of bacterial killing but inhibited NO production by macrophages. A reasonable 
explanation is that macrophages may depend on multiple mediators (i.e. reactive oxygen 
intermediates (Cherayil & Antos 2001)), not just NO, to provide them with Salmonella-
killing activity. 
        RAW 264.7 cells closely resemble the murine peritoneal macrophages in their response 
to inflammatory stimuli and pathogenic microbes. We expected that Echinacea alcohol 
extracts could exert a similar, although not identical, effect on PECs as they did on the 
macrophage-like RAW 264.7 cells. Unfortunately, a weak in vivo effect on inflammatory 
PECs was seen. The only notable change in PECs was an EP-mediated reduction in NO 
production at the 4 h time point after Salmonella engulfment. Interestingly, the reduction in 
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NO production did not result in a significant decrease in bacterial killing. The in vivo effect 
in this regard might be largely influenced by several factors, such as the metabolism of the 
phytochemicals, the activation state of PECs and the complex in vivo environment (e.g. 
constitutive expression of cytokines, growth factors and hormones (Pruett et al. 2005)). 
Although inflammatory agents, such as proteose peptone and thioglycollate, are commonly 
applied to induce an inflammatory response resulting in an influx of strongly activated 
macrophages into the peritoneum and thus an increased peritoneal macrophage yield, it is 
unclear as to how and what extent these inflammatory agents affect the functional state of 
macrophages (Fortier & Falk 1994). On the other hand, lack of an inhibitory effect of orally 
administered Echinacea alcohol extracts on bacterial phagocytosis and killing by PECs may 
indicate that Echinacea will not adversely affect these important innate immune functions. 
        To summarize, Echinacea alcohol extracts have a potential anti-inflammatory activity, 
but this effect was mainly observed in vitro, especially at relatively high concentrations of 
the extracts. Increased knowledge of the biological properties and the mode of action of the 
physiologically relevant concentrations of Echinacea alcohol extracts are necessary.  
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Table 3.1. The levels of amides and caffeic acid derivatives in Echinacea alcohol extracts 
        
  In vitro study       In vivo study   
Phytochemicals E. angustifolia E. pallid E. purpurea   E. angustifolia E. pallida E. purpurea 
Total alkamides 17.05 10.44 26.07  74.84 12.62 55.01 
   amide 1  0.42 0.00 2.57  1.35 0.00 4.90 
   amide 2  0.26 3.72 4.72  0.84 4.50 9.11 
   amide 3  0.64 0.89 4.25  2.68 1.12 8.80 
   amide 4  0.08 0.77 2.06  0.33 1.00 4.40 
   amide 5  0.43 0.38 0.83  1.90 0.49 1.70 
   amide 7 0.00 0.23 1.11  0.00 0.34 2.49 
   amide 8  9.35 3.40 6.62  40.88 3.76 14.48 
   amide 9  1.26 0.46 3.47  5.86 0.65 7.64 
   amide 10 0.72 0.22 0.25  3.49 0.31 0.64 
   amide 11  1.77 0.38 0.20  8.28 0.46 0.83 
   amide 12 0.91 0.00 0.00  3.71 0.00 0.00 
   amide 13 0.68 0.00 0.00  2.92 0.00 0.00 
   amide 14 0.54 0.00 0.00  2.58 0.00 0.00 
        
Total caffeic acid derivatives 7.80 15.93 5.23  10.02 18.28 6.72 
   caftaric acid 0.00 0.58 0.65  0.00 0.70 1.06 
   chlorogenic acid 0.90 2.13 0.00  0.95 2.22 0.00 
   cichoric acid 0.00 0.61 4.58   0.00 0.89 5.66 
   cynarin  2.96 0.00 0.00  3.02 0.00 0.00 
   echinacoside  3.94 12.61 0.00  6.05 14.46 0.00 
* Units are µg metabolite mg−1 dried extract. 
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Fig. 3.1. Viability of RAW 264.7 cells exposed to Echinacea alcohol extracts. EA. E. 
angustifolia; EPA. E. pallida; EP. E. purpurea. Cells were treated with the extracts in the 
presence (B) or absence (A) of LPS (1 µg ml−1). Cell viability was determined by the MTS 
assay. Data are expressed as mean ± standard error of the mean of 3 independent experiments 
in duplicates. Absorbance of baseline LPS treated cells (no vehicle and no alcohol extracts) 
was expressed as 100%. * p<0.05 for the individual group vs the corresponding vehicle 
control. 
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Fig. 3.2. Effect of Echinacea alcohol extracts on NO production and TNF-α secretion in 
LPS-activated RAW 264.7 cells. EA. E. angustifolia; EPA. E. pallida; EP. E. purpurea. Cells 
were incubated in the presence of LPS (1 µg ml−1) and alcohol extracts for 24 h. The culture 
supernates were harvested for nitrite accumulation (A) and TNF-α (B) assays. Data are 
expressed as mean ± standard error of the mean of 3 independent experiments in duplicates. 
Values of LPS treated cells cultured with vehicle were referred to as 100%. * p<0.05 for the 
individual group vs the corresponding vehicle control. 
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Fig. 3.3. Survival of 
Salmonella within RAW 
264.7 cells pretreated with 
indicated concentrations of 
Echinacea alcohol extracts. 
EA. E. angustifolia; EPA. E. 
pallida; EP. E. purpurea. Cells 
were infected at an MOI of 
100:1 for 2 h. At set time 
points, internalized bacteria 
were assessed by gentamicin 
protection assay. Data are 
expressed as mean ± standard 
error of the mean of 3 
independent experiments in 
duplicates. * p<0.05 for the 
individual group vs the vehicle 
control at the same time point.  
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Fig. 3.4. NO production by 
RAW 264.7 cells infected 
with Salmonella at an MOI 
of 100:1 for 2h. EA. E. 
angustifolia; EPA. E. 
pallida; EP. E. purpurea. 
Before infection, cells were 
treated with indicated 
concentrations of Echinacea 
alcohol extracts overnight. 
At set time points after 
exposure to bacteria, NO 
production was measured by 
the Griess reaction. Data are 
expressed as mean ± 
standard error of the mean of 
3 independent experiments 
in duplicates.  
* p<0.05 for the individual 
group vs the vehicle control 
at the same time point. 
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Fig. 3.5. Effect of 
Echinacea alcohol extracts 
in vivo on cell viability of 
PECs as well as NO and 
cytokine release by PECs. 
EA. E. angustifolia; EPA. E. 
pallida; EP. E. purpurea. 
Upon completion of 
Echinacea administration at 
130 mg kg-1 d-1× 7d, PECs 
were harvested and 
incubated in the absence or 
presence of LPS (1 µg ml−1) 
for 24 h. The culture 
supernates were harvested 
for nitrite accumulation and 
cytokine assays. Cells were 
assessed for viability by the 
MTS assay. Only cytokine 
data with LPS stimulation 
are shown. Data are 
expressed as mean ± 
standard error of the mean of 
3 independent experiments 
in duplicates.  
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Fig. 3.6. Survival of Salmonella within PECs (A) and NO production by PECs (B) 
harvested from mice treated with Echinacea alcohol extracts. EA. E. angustifolia; EPA. E. 
pallida; EP. E. purpurea. PECs were infected at an MOI of 100:1 for 2 h. At set time points, 
internalized bacteria were assessed by gentamicin protection assay and nitrite accumulation in 
the culture assayed by the Griess reaction. Data are expressed as mean ± standard error of the 
mean of 3 independent experiments in duplicates. * p<0.05 and # p<0.1 for the individual 
group vs the vehicle control at the same time point.  
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CHAPTER 4. ECHINACEA INCREASES ARGINASE ACTIVITY AND 
HAS ANTI-INFLAMMATORY PROPERTIES IN RAW 264.7 
MACROPHAGE CELLS INDICATIVE OF ALTERNATIVE 
MACROPHAGE ACTIVATION 
 
Zili Zhai1,2, Lankun Wu3, Avery K. Solco4, Patricia A. Murphy4, Eve S. Wurtele3,  
Marian L. Kohut5, Joan E. Cunnick1,2,6 
 
Abstract 
        The genus Echinacea is currently a popular immunomodulator. Recent reports indicated 
that Echinacea products inhibit nitric oxide (NO) production in activated macrophages. Since 
decreased NO production is related to the anti-inflammatory nature of the herb, we further 
determined the inhibitory effects of alcohol extracts and individual fractions of alcohol extracts 
of Echinacea on NO production, and explored the mechanism underlying the pharmacological 
activity. The results showed that alcohol extracts of three medicinal Echinacea species, E. 
angustifolia, E. pallida and E. purpurea, significantly inhibited NO production by 
lipopolysaccharide (LPS)-activated macrophage cell line RAW 264.7 cells, among them E. 
pallida was the most active. The Echinacea-mediated decrease in NO production was unlikely 
due to a direct scavenging of NO because it lacked an ability to directly inhibit NO released 
from an NO donor, sodium nitroprusside. An immunoblotting assay demonstrated that alcohol 
extract of E. pallida inhibited inducible nitric oxide synthase (iNOS) protein expression in LPS 
treated macrophages. The enzymes iNOS and arginase metabolize a common substrate, L-
arginine, but produce distinct biological effects. While iNOS is involved in inflammatory 
response and host defense, arginase participates actively in anti-inflammatory activation. 
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Arginase activity of RAW 264.7 cells stimulated with 8-bromo-cAMP was determined and 
found to be significantly increased by alcohol extracts of all three Echinacea species. Among 
five fractions prepared from alcohol extracts, the polar fraction containing caffeic acid 
derivatives was capable of enhancing arginase activity, while the lipophilic fraction containing 
alkamides exhibited a potential of inhibiting NO production and iNOS expression. These 
results suggest that the anti-inflammatory activity of Echinacea might be due to multiple active 
metabolites, which work together to switch macrophage activation from classical activation 
towards alternative activation.     
Introduction 
        Botanical supplements are currently popular in the United States due to their multiple 
purported health benefits yet low side effects. The genus Echinacea, one of the top-selling 
botanical supplements, in fact, has been widely used for centuries in North America and later 
in Europe for many therapeutic purposes. There are nine known species of Echinacea, three 
of them, E. angustifolia (EA), E. pallida (EPA) and E. purpurea (EP), are of similar and 
important medicinal values in the modulation of the immune system (Borchers et al., 2000). 
Three Echinacea species are rich in bioactive metabolites in which lipophilic alkamides, 
water-soluble phenolic compounds (mainly caffeic acid derivatives) and polysaccharides are 
the most recognized for their immunomodulatory properties (Barnes et al., 2005). Although 
historically polysaccharides were considered critical for stimulation of the nonspecific 
immune responses (Borchers et al., 2000; Percival, 2000), recent research interest focuses on 
two other groups of phytochemicals, namely, alkamides and caffeic acid derivatives. Caffeic 
acid derivatives are good antioxidants in cell-free free radical generation systems (Hu et al., 
2000; Pellati et al., 2004; Dalby-Brown et al., 2005) and echinacoside, the main caffeic acid 
derivative in EA and EPA, has been functionally linked to anti-inflammatory and wound 
healing properties of Echinacea when applied locally (Speroni et al., 2002; Rousseau et al., 
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2006). Pharmacokinetic studies of natural or synthesized caffeic acid derivatives (e.g. caftaric 
acid, chlorogenic acid and echinacoside) showed that they are quickly absorbed in the rat 
stomach, but rapidly eliminated from the blood circulation (Jia et al., 2006; Lafay et al., 
2006; Vanzo etal., 2007). Matthias et al. (2004) suggested a low bioavailability for caffeic 
acid derivatives of Echinacea based on the observations that they permeate poorly through 
the Caco-2 monolayers, a model for the intestinal epithelial barrier. These data indicate that 
there might be a limited pharmacological role for caffeic acid derivatives when consumed 
orally. In this regard, lipophilc alkamides might play a more important role as they are 
considered to be orally bioavailable (Matthias et al., 2005; Woelkart et al., 2005).  
        There is evidence to substantiate that Echinacea-derived alkamides have 
immunomodulatory and anti-inflammatory activity (for review see Woelkart et al., 2007). 
The alkamides inhibit production of proinflammatory tumor necrosis factor-alpha (TNF-α) 
and nitric oxide (NO) in activated murine macrophage cell line RAW 264.7 cells (Chen et al., 
2005; Matthias et al., 2007). Similarly, alkamide-containing alcohol extracts had similar 
inhibitory activities with low cytotoxicity in vitro (Zhai et al., 2007a). When alcohol extracts 
of Echinacea were administered orally to mice, a significantly decreased production of TNF-
α and interleukin (IL)-1β  by activated splenocytes was seen (Zhai et al., 2007b). Although 
Echinacea extracts containing alkamides exhibit suppressive effects on the tested endpoints 
of inflammatory response, the underlying cellular mechanism is unclear. 
        TNF-α and NO are two important components of the inflammatory response produced 
by macrophages, and their production involves the NF-κB signal pathway (Yamamoto and 
Gaynor, 2001). When macrophages are in a resting state, the transcription factor NF-κB is 
stabilized in the cytosol by binding to its inhibitory protein IκB-α. Upon induction by certain 
inflammatory stimuli, e.g., bacterial lipopolysaccharide (LPS), IκB-α is rapidly 
phosphorylated and degraded by the 26S proteosome (Katsuyama et al., 2001). As a result, 
free NF-κB translocates into the nucleus where it regulates the expression of a wide variety 
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of genes involved in inflammatory responses, e.g., the cytokines TNF-α and IL-1β, and the 
enzymes inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (McKay and 
Cidlowski, 1999). The enzyme iNOS catalyzes the conversion of amino acid L-arginine to 
NO, which is cytotoxic and cytostatic (Meurs et al., 2003). Although NO as an active free 
radical and inflammatory mediator is part of the host defense, excessive production of NO 
and its reactive nitrogen intermediates is involved in the pathogenesis of many chronic 
diseases, such as inflammatory bowel disease, arthritis, atherosclerosis and tumors (Chan et 
al., 2000; Yamamoto and Gaynor, 2001). Selective inhibition of the iNOS pathway is an 
important strategy for control of many chronic inflammatory diseases (Chan et al., 2000). 
        L-arginine metabolism can be redirected toward the synthesis of L-ornithine catalyzed 
by the enzyme arginase. The subsequent products from L-ornithine, such as polyamines and 
L-proline, are involved in cell growth, collagen synthesis and wound healing (Meurs et al., 
2003). Thus, arginase and iNOS are the two enzymes that catalyze a common substrate but 
produce divergent biological effects. They are generally recognized to be functionally 
competitive because the stimulation of one enzyme will negatively regulate the other one due 
to the limited availability of the same substrate (Wang et al., 1995; Gotoh and Mori, 1999). 
These two cross-regulated metabolic processes may reflect opposite functional states of 
macrophages. It is well known that macrophages can be either classically activated or 
alternatively activated, and are therefore termed as inflammatory or anti-inflammatory cells 
(Munder et al., 1998; Porcheray et al., 2005). A given macrophage may switch from one 
activated state to another upon a specific signal (Porcheray et al., 2005). Inflammatory 
mediators and cytokines induce classical activation involving iNOS expression and, on the 
contrary, anti-inflammatory cytokines induce alternative activation with upregulated arginase 
activity (Modolell et al., 1995; Munder et al., 1998; Yamamoto et al., 1998). Animal studies 
showed that alcohol extracts of Echinacea increase production of IL-4 and IL-10, but 
decrease production of TNF-α and IL-1β in activated spleen cells (Zhai et al., 2007b), 
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suggesting that Echinacea may modulate macrophage function to be anti-inflammatory via  a 
decreased proinflammatory/anti-inflammatory cytokine ratio. This finding led us to 
hypothesize that Echinacea can perturb the iNOS/arginase balance in macrophages in favor 
of increasing arginase activity for alternative anti-inflammatory activation. 
        In this study, we examined the effects of Echinacea extracts and their fractions on the 
production of NO in activated macrophage cell line as well as the cellular mode of action 
underlying the biological activity. We found that alcohol extracts of Echinacea had opposite 
effects on NO production and arginase activity, and these differential effects were induced by 
different fractions (or chemical constituents), which could work coordinately to drive 
macrophages to alternative activation.   
Materials and Methods 
 Preparation of alcohol extracts  
        Dried powdered roots of EA, EPA and EP harvested in 2003 were provided by Iowa State 
University Botanical Supplements Research Center; and by the USDA North Central Regional 
Plant Introduction Station in Ames, Iowa, with accession numbers PI 631285, PI 631293, and 
PI 631307, respectively. Alcohol extracts from the root powders of these plants were prepared 
as previously described (Zhai et al., 2007b) with 95% aqueous ethanol using Soxhlet apparatus 
for at least 6 h for exhaustive extraction. The extracts were evaporated to dryness using a rotary 
evaporator set at 30ºC. The residues were redissolved in a 50/50 mixture of ethanol and sterile 
phosphate buffered saline (PBS) and then diluted to 20 mg/ml in PBS containing 5% ethanol. 
Aliquots of the dilutions were stored at -80°C for up to 2.5 years during which no obvious 
herbal efficacy was reduced.   
 Fractionation of alcohol extracts 
        For fractionation, the dried powdered roots of the plants harvested in 2005 (EA) or 2006 
(EPA and EP) were used to prepare new alcohol extracts using the Soxhlet extraction. The dry 
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residues were redissolved in 75% ethanol to obtain ≤ 0.6 g/ml. Five milliliters were injected 
into a semi-preparative high performance liquid chromatography (HPLC). The starting 
conditions of the semi-preparative HPLC was 90% Pump A, which was 0.1% acetic acid, and 
10% Pump B, which was acetonitrile at a flow rate of 3 ml/min. Eluent collected from time 0 to 
31 when Pump B increased from 10% - 30% was fraction 1; eluent collected from time 33 to 
42 when Pump B increased from 30% - 40% was fraction 2; eluent collected from time 43-83 
when Pump B increased from 40% to 80% was fraction 3; eluent collected from time 84-94 
when Pump B increased from 80% to 100% was fraction 4; and eluent collected from time 95-
115 when Pump B was running at 100% was fraction 5. The gap of 1-2 minutes between 
fractions indicated the time of stopping the flow of the mobile phase for the change of the 
collection flasks. The fractions were then evaporated to remove the mobile phase and 
lyophilized when needed. After redissolution and dilution to 4 mg/ml in PBS containing 25% 
ethanol, aliquots were kept at -80°C and used within one year.  
 Phytochemical analysis 
        The phytochemical analysis was performed to detect bioactive metabolites of alkamides 
and caffeic acid derivatives in the crude alcohol extracts with the use of HPLC as described 
previously (Wu et al., 2004). We did not identify ketones as no internal standards for ketones 
were used. However, in these alcohol extracts ketones are expected to be present as lipophilic 
compounds and usually concomitantly appear in alkamide fractions of EPA.  
        Fractions were identified as described by Liu and Murphy (2007). All of the following 
parts are from Beckman Coulter (Fullerton, CA, USA): System Gold 126 Pump module; 
System Gold 508 autosampler; System Gold 168 detector (photodiode array); and 32 Karat 
Software version 5.0. The columns used were YMC-PACK ODS-AM 250 mm length × 4.6 
mm I.D. s-5 µm, 12 nm, reversed-phase C18 columns. 
        The mobile phase used for the analytical HPLC method were, for Pump A, 0.1% acetic 
acid; while for Pump B, acetonitrile. The flow rate was 1 ml/min. The injection volume was 10 
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µl. UV scan was collected in the range of 190-600 nm. Alkamides were viewed at 260 nm, 
while caffeic acid derivatives were viewed at 330 nm. 
        Peak identification was based on relative retention time, similarity of UV spectra, internal 
standards, spiking and chromatogram fingerprinting (Wu et al., 2004; Liu and Murphy, 2007).  
Individual standards were run to check for relative retention times and UV spectra. EP sample 
with identified peaks was also run to obtain the finger print of the chromatogram, the relative 
retention times of the alkamides and caffeic acid derivatives, and to obtain the UV spectra of 
identified compounds.   
 Determination of endotoxin in herbal preparations  
        All glassware used in the extraction and fractionation procedure was baked at 185°C 
overnight prior to use in order to minimize endotoxin contamination. Endotoxin-free Nanopure 
water was used for preparation and dilution of crude alcohol extracts and fractions. The 
endotoxin levels were evaluated in aliquots of the herbal preparations using the Limulus 
Amebocyte Lysate Test (Cambrex Bio Science Walkersville, Inc., Walkersville, MD, USA) 
according to the manufacturer's specifications for a microplate assay, and were found to be 
below the limit of detection (< 0.1 EU/ml).  
 Macrophage cell line   
        The murine peritoneal macrophage cell line RAW 264.7 cells were obtained from 
American Type Culture Collection (ATCC, Rockville, MD, USA) and grown in RPMI 1640 
medium (GIBCO, Invitrogen Corporation, Grand island, NY, USA) supplemented with 2 mM 
glutamine, 25 mM Hepes, 50 µg/ml gentamicin and 10% heated-inactivated iron-fortified 
bovine calf serum (JRH Biosciences, Lenexa, KS, USA) at 37°C in a 7% CO2 incubator. Cells 
between passage 5 and 20 (Kiemer et al., 2002) were used in this study. 
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 NO and TNF-α assays 
        RAW 264.7 cells were seeded in flat bottom 96-well tissue culture plates (Corning Inc., 
Corning, NY, USA) at a density of 8×104 cells per well in the presence or absence of various 
concentrations of Echinacea preparations (as indicated in each graph) and /or LPS (E. coli 
055:B5; Sigma, St. Louis, MO, USA). Final concentration of ethanol used as a solvent of 
lipophilic metabolites in each well was 0.25% (v/v). Ethanol (0.25%) control wells were 
tested in parallel. After 23 h incubation, culture supernates were collected for NO and TNF-α 
assays, and the attached cells were evaluated for cell viability (see below).   
        In a second set of experiments, Echinacea extracts (100 µg/ml) were either added 
simultaneously with LPS (1 µg/ml) or up to 6 h after LPS addition (Kiemer et al., 2002). 
Culture supernates from cells activated with LPS for 22 h were collected for NO assay. 
        Nitrite, a stable NO metabolite, was determined by the method of Griess reaction (Park 
et al., 2005). A trace amount of nitrite present in cell-free culture medium was subtracted 
from each value obtained with cells. Sodium nitrite (0.39-100 µM) was used as a standard. It 
was confirmed that Echinacea extracts at 200 µg/ml did not interact with nitrite and interfere 
with its detection (data not shown).  
        TNF-α was assayed by BD OptEIA ELISA set (BD Biosciences, San Diego, CA, USA). 
The cytokine levels were calculated by using a purified recombinant mouse cytokine as a 
standard.   
 Scavenging of NO production from NO donor 
        Sodium nitroprusside (SNP), an NO donor, in aqueous solution at physiological pH 
spontaneously liberates NO, which rapidly interacts with oxygen to produce nitrite 
(Sreejayan et al., 1997; Chan et al., 2000; Kiemer et al., 2002). In order to determine if 
Echinacea metabolites directly interact with NO, SNP (final concentration 2.5 mM; Sigma) 
was mixed with the Griess reagent (a mixture of equal volumes of 10% (w/v) sulfanilamide 
in 5% (v/v) phosphoric acid and 0.1% (w/v) naphthylenediamine) in the presence of 0.25% 
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ethanol or various concentrations of alcohol extracts, and then incubated at room temperature 
for a set of time points. NO released from SNP in this reaction system was immediately 
captured by Griess reagent via nitrite, which was sequentially monitored on a plate reader 
(Bio-Tek Instruments, Winooski, VT, USA). A series of sodium nitrite standard 
concentrations instead of SNP was set up and measured at the same time. The reading of the 
standard curve remained stable throughout the observational period. 
 Determination of arginase activity 
        Arginase activity was determined according to a microplate method (Corraliza et al., 
1994; Munder et al., 1998) with slight changes. Cells were seeded at 4×105 cells/ml in 96-
well tissue culture plates in the presence or absence of LPS (1 µg/ml), 8-bromo-cAMP (0.25 
mM; Sigma) and/or Echinacea preparations. After 23-24 h incubation, supernates were 
collected for NO assay, the cells rinsed with PBS, and then lysed with a CelLytic M lysis 
solution (Sigma). Following centrifugation at 2500 g for 5 min at 4°C, 50 µl of the lysate was 
mixed with 40 µl of 25 mM Tris-HCl (pH 7.4) and 10 µl of 10 mM MnCl2. The arginase was 
activated by heating for 10 min at 56°C. Aginine hydrolysis to urea was conducted by 
addition of 100 µl of 0.5 M L-arginine (Sigma), pH 9.7, with incubation at 37°C for 60 min. 
The reaction was stopped with 800 µl of H2SO4 (96%)/H3PO4 (85%)/H2O (1/3/7, v/v/v). The 
urea concentration was measured at 550 nm after addition of 40 µl of 9% (w/v) α-
isonitrosopropiophenone (Sigma) dissolved in 100% ethanol and heating at 95°C for 90 min. 
A standard curve was performed with 2-fold dilutions of urea (0.03-4 mM) followed by 
mixing with the stop reagent and heating. One unit of arginase activity is defined as the 
amount of enzyme that catalyzes the formation of 1 µmol urea per min at 37°C. Protein 
concentrations in cell lysate were determined using a micro BCA (Bicinchoninic Acid) 
protein assay (Pierce Labs, Rockford, IL, USA). 
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 Western blotting analysis 
        Cells were seeded in 24-well plates at a density of 5×105 cells per well in the presence 
or absence of LPS (1 µg/ml) and various Echinacea preparations. After 24 h incubation, cells 
were rinsed with ice-cold PBS and then lysed with the CelLytic M lysis solution containing 
1% (v/v) protease inhibitor cocktail (Sigma). Cell debris was removed by 
microcentrifugation (12,000 g×15 min), and the resultant supernates were kept at -80°C till 
use. The thawed cell lysates were mixed with 4× NuPAGE SDS sample loading buffer 
(Invitrogen). Equal amounts of cellular protein (25 µg/lane) were separated on 10% Tris-HCl 
ready gel (Bio-Rad Laboratories, Hercules, CA, USA), followed by electrotransfer onto a 
PVDF plus membrane. The immunoblot was performed by incubation with a 1:500 dilution 
of rabbit polyclonal anti-iNOS (sc-8310, Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) in 5% non-fat milk in PBS/0.1% Tween-20 (PBST) overnight at 4°C. Blots were 
rinsed with PBST, followed by incubation with a 1:2500 dilution of horseradish peroxidase-
conjugated donkey anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology Inc.) for 1 
h at room temperature. Blots were washed again, and the bands were visualized using an 
amplified Opti-4CN Substrate kit (Bio-Rad Laboratories). The bands were photographed and 
quantified with Kodak Image Station 440 CF and Kodak 1D image analysis software 
(Eastman Kodak Company, Rochester, NY, USA). To assess the changes of iNOS expression 
and to normalize protein loading, membranes run in parallel were incubated with a 1:5000 
dilution of mouse monoclonal antibody against β-actin (Santa Cruz Biotechnology Inc.).      
Cell viability assay 
        Mitochondrial reduction of MTS, a tetrazolium compound, to a colored formazan was 
used as an indicator of cell viability (Cory et al., 1991). Briefly, after removing of 100 µl of 
culture supernates (i.e. for NO and TNF-α assays),  15 µl of MTS (CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay, Promega Corporation, Madison, WI, USA) was added to the 
remaining 100 µl of culture medium incubation continued for 1 h. The extent of formazan 
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formation was determined photometrically at absorbance 490 nm on a plate reader. The 
absorbance of cell-free culture medium with or without vehicle or Echinacea preparations was 
used as a blank (self-control) and subtracted from the value of the corresponding treatment 
groups.  
 Statistical analysis 
        Statistix software (version 8.0, Analytical Software, Tallahasee, FL, USA) was used for 
the statistical analysis. Differences between the vehicle and other groups were tested by two-
way analysis of variance (group × experiment). A value P<0.05 was considered significant.     
Results 
 Phytochemical analysis 
        Table 4.1 lists the amounts of total alkamides and several important caffeic acid 
derivatives in crude alcohol extracts of three Echinacea species. 
        The chemical constituents in the fractions are shown in Table 4.2. Fraction 1 was rich in 
polar caffeic acid derivatives. Fraction 3 contained lipophilic constituents including alkamides 
(in all three species) and ketones (in EPA). Other hydrophobic compounds were found in 
fractions 4 and 5. For fractions 3-5, the later fractions contained compounds which are more 
hydrophobic than the earlier ones.  
 Inhibition of TNF-α production by alcohol extracts 
        As TNF-α production was regulated by Echinacea in vivo (Zhai et al., 2007b), we 
measured this cytokine in Echinacea-treated RAW 264.7 cells. In the absence of LPS, very low 
amounts (or lower than limit of detection, 15 pg/ml) of TNF-α were measured in the supernates 
from RAW 264.7 cells incubated with or without alcohol extracts of Echinacea overnight. In 
the presence of LPS, the cells secrete high levels of TNF-α. Vehicle (0.25% ethanol) alone had 
no effect on the cytokine production, however, all three alcohol extracts at a concentration of 
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100 µg/ml significantly inhibited TNF-α production (P values <0.001, Fig 4.1A). The 
inhibitory effects of Echinacea extracts in the presence of 0.1 µg/ml LPS were dose-dependent 
as indicated by a significant linear effect of dose (P values < 0.05) (Fig 4.1B). Alcohol extracts 
of Echinacea at the test concentration range of 10-200 µg/ml had little effect on cell viability 
based on the MTS assay (Fig 4.1B), indicating that the inhibitory effect of Echinacea extracts 
on TNF-α is unlikely due to cytotoxicity. 
 Inhibition of NO production by alcohol extracts 
        In the absence of LPS, less than 0.5 µM of NO was detectable in culture medium of RAW 
264.7 cells incubated in vitro for 23 h. These low levels of NO are the product of constitutive 
NOS rather than iNOS. In the presence of increasing concentrations of LPS, cells produce NO, 
which reached a maximum with LPS at 1 µg/ml (Fig 4.2A). Exposure to vehicle had no effect 
on NO production, however, the three Echinacea extracts at 100 µg/ml reduced NO 
production. The inhibitory effect of Echinacea extracts on NO production was dose-dependent 
as indicated by a significant linear effect of dose (P values < 0.008) (Fig 4.2B). At 100 µg/ml, 
the inhibitory potential of three species extracts in the presence of 1 µg/ml LPS is generally 
EPA > EP > EA. All three extracts at tested concentrations had no effect on cell viability (Fig 
4.2B). 
 Direct scavenging of NO generated by alcohol extracts 
        NO production was estimated by measuring nitrite using the Griess reaction system. NO 
derived from SNP increased in a linear time-dependent manner (Fig 4.3A). Vehicle alone had 
no any effect on the NO production, but alcohol extracts of EA and EPA at a final 
concentration of 50 µg/ml significantly inhibited nitrite accumulation beginning 120 min after 
initiating of the reaction (Fig 4.3A) (P values <0.018 at 120-min time points). However, the 
inhibitory rates of NO production by these two extracts throughout the 3-h observation period 
were small (<15%), and were not concentration-dependent (Fig 4.3B). EP extracts at lower 
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concentrations of 5-25 µg/ml, but not at higher concentrations (50-200 µg/ml), significantly 
reduced nitrite accumulation (P values <0.015).  
 Inhibition of iNOS induction by alcohol extracts 
        Effects of alcohol extracts on iNOS induction were measured by an indirect method 
described by Kiemer et al. (2002). Once macrophages are activated, iNOS gene transcription is 
initiated about 1 h after activation, whereas its protein expression occurs some 3-4 h later. If the 
Echinacea-mediated decrease in NO production is through interference with the transcriptional 
induction process, earlier treatment (i.e. 0.5 h after LPS stimulation) with Echinacea extracts 
should have a more profound effect on NO production than adding the extracts later. Therefore, 
in these experiments, alcohol extracts (100 µg/ml) were either added simultaneously with LPS 
(1 µg/ml) or up to 6 h after addition of LPS. The results  showed that after LPS activation, the 
earlier addition of alcohol extracts resulted in more inhibition of NO production (Fig 4.4), 
indicating that Echinacea inhibits the transcriptional induction of iNOS. Of three alcohol 
extracts, EPA extract was the most active, in agreement with its strongest inhibitory potential 
of TNF-α and NO production. 
 Opposite regulation of NO production and arginase activity by alcohol extracts 
        Raw 264.7 cells were incubated with alcohol extracts in the presence or absence of LPS to 
stimulate iNOS or 8-bromo-cAMP to induce arginase activity (Morris et al., 1998). The 
induction of arginase activity by 8-bromo-cAMP was further enhanced by the addition of LPS, 
which itself is a weak stimulant of arginase. In the presence of LPS alone, alcohol extracts of 
EP and EPA at 100 µg/ml significantly inhibited NO production (P values <0.05) (Fig 4.5A), 
but their influence on arginase activity did not reach statistical significance. Note that 8-bromo-
cAMP alone did not induce NO production, but decreased the NO production when added with 
LPS to RAW 264.7 cells. Moreover, all three alcohol extracts induced additional suppression 
of NO production in conjunction with 8-bromo-cAMP. In the presence of 8-bromo-cAMP, the 
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three Echinacea extracts at 100 µg/ml significantly increased arginase activity up to 2-fold (P 
values <0.001) (Fig 4.5B). The enhancing effect of Echinacea extracts on arginase activity was 
also seen when both 8-bromo-cAMP and LPS were present in the culture medium (Fig 4.5B). 
When the concentrations of Echinacea extracts were reduced to 10 µg/ml, an enhancing effect 
was still seen when cells re exposed to Echinacea extracts (Fig 4.5C). The test dose range (10-
200 µg/ml) of Echinacea extracts had no effect on cell viability (Fig 4.5C).    
 Differential regulation of NO production and arginase activity by fractions 
        In order to understand if the same fractions that inhibited NO production are responsible 
for increased arginase activity, five fractions of alcohol extracts were prepared (Table 4.2). 
Generally, the HPLC fractions of the three Echinacea extracts exhibited very similar patterns 
of effects on NO production and arginase actvity. Note that the opposite effects of Echinacea 
extracts on NO production and arginase activity resulted from different fractions. For all three 
species of Echinacea, fraction 3 containing abundant alkamides had robust inhibition of NO 
production. For EA, NO was also suppressed by fraction 4 with greater suppression by fraction 
5, and for EP, there is some NO suppression by all fractions with the greatest suppression by 
fractions 2, 3, and 5 (Fig 4.6A). On the other hand, the polar fractions (fractions 1) induced 
increased arginase activity (Fig 4.6B). However for EPA, the greatest enhancement of arginase 
activity was seen with fraction 4 which contains unidentified hydrophobic compounds. The 
HPLC fractions of alcohol extracts showed no cytotoxicity as indicated by the MTS assay (data 
not shown). 
 Inhibition of iNOS protein expression 
        Decreased NO production might be relative to decreased iNOS protein expression as 
indirectly indicated in Fig 4.4. To that end, we carried out Western blot analysis of lysates of 
cells exposed to alcohol extracts of three Echinacea species at 100 µg/ml or their fractions at 
25 µg/ml for 24 h in the presence of LPS. For EA, iNOS expression was significantly inhibited 
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by fractions 3, 4 and 5 (P values <0.05). For EPA, the unfractionated alcohol extract and its 
fraction 3 had a robust inhibiting activity (P values <0.05). The unfractionated alcohol extract 
of EP and its fractions all showed, to some extent, an inhibiting effect, but they did not reach 
statistical significance except for fraction 5 (P = 0.046).      
Discussion 
        NO and TNF-α are two key mediators in host defence and inflammatory response. They 
positively regulate each other (Yamamoto and Gaynor, 2001; Wu et al., 2003) and therefore 
amplify inflammatory signals. However, improper upregulation of these inflammatory players 
are implicated in a pathological role in inflammatory processes (Yamamoto and Gaynor, 2001; 
Kiemer et al., 2002). Our results demonstrated the suppressive effects of Echinacea extracts 
and certain individual fractions on production of NO and TNF-α by an activated macrophage 
cell line, in accordance with previous in vitro observations (Chen et al., 2005; Matthias et al., 
2007; Zhai et al., 2007a). In order to understand the cellular mechanism as well as the 
biological implication underlying the herbal anti-inflammatory activity, we carried out 
additional experiments. We focused our interest on the mechanistic basis for decreased NO 
production because NO is an important effector molecule in the classical activation of 
macrophages (MacMicking et al., 1997; Munder et al., 1998).   
        Macrophages metabolize arginine to produce either NO through iNOS or ornithine 
through arginase. These two metabolic processes have important yet divergent roles in the 
cellular function. NO functions primarily with cytotoxic and cytostatic activity while the 
products of arginase pathway promote cell proliferation (Meurs et al., 2003). The 
predominance of one pathway over the other may rest on the presence of desirable inducers 
in the microenvironment. Macrophages express two arginase isoforms with distinct 
subcellular localizations: cytosolic type I and mitochondrial type II (Louis et al., 1999). LPS 
co-induces iNOS and arginase II, but the arginase II expression lags behind iNOS expression 
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(Wang et al., 1995; Morris et al., 1998; Gotoh and Mori, 1999). The delayed expression of 
arginase II helps control NO production, and prevent NO-induced cell apoptosis (Munder et 
al., 1998; Gotoh and Mori, 1999). We hypothesized that Echinacea-mediated decrease in NO 
production insinuates an increased activity of arginase in activated macrophages. As 
expected, Echinacea extracts oppositely regulate NO production and arginase activity even 
though the determinations of these two parameters were performed with different inducers 
(LPS or 8-bromo-cAMP). This differential regulation of two cross-regulated metabolic 
processes by Echinacea species may have important implications in the anti-inflammatory 
activity. 
         We predicted that one fraction responsible for decreased NO production would also be 
a strong stimulant of arginase. Surprisingly, this speculation was not supported by our 
observations that the opposite regulatory effects on NO production and arginase activity were 
due to different fractions. Lipophilic fraction 3 was found to be the most effective in 
suppressing NO production while the polar fraction containing caffeic acid derivatives was 
an inducer of arginase activity, though the polar metabolites from EPA only showed an 
increasing trend in arginase activity. It is not surprising that the lipophilic fractions mediated 
a decrease in NO production, since an anti-inflammatory effect of alkamides has been 
reported previously (Chen et al., 2005; Matthias et al., 2007). Rather, it is noteworthy that 
caffeic acid derivatives (fraction 1) from EA and EPA have no effects on NO production 
considering that they are well demonstrated antioxidants (Hu et al., 2000; Pellati et al., 2004; 
Dalby-Brown et al., 2005). Some natural antioxidants (e.g., flavonoids, resveratrol and 
curcumin) have been found to have strong inhibitory effects on iNOS expression and NO 
production in activated macrophages (Surh et al., 2001; Yamamoto and Gaynor, 2001).   
       Although caffeic acid derivatives have been determined to penetrate poorly across Caco-
2 monolayers (Matthias et al., 2004), we suggest that in vitro they enter into cells to 
accumulate high enough concentrations and consequently affect arginase activity. Cyclic 
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AMP-stimulated arginase expression is through a complicated signal pathway involving 
intracellular activation of protein kinase A, tyrosine kinase phosphorylation, and p38 
mitogen-activated protein kinase activation (Chang et al., 2000), and it has been proposed 
that Th2 cytokine-induced increase in arginase activity is cAMP-dependent (Corraliza et al., 
1997; Wei et al., 2000). Although we can not answer based on the present data if caffeic acid 
derivatives directly mediate the activation of protein kinase A pathway, it is possible that in 
vivo they affect the signal pathway by upregulating Th2 cytokines, such as IL-4 and IL-10. 
Echinacea-mediated increase in Th2 cytokines after oral administration has been reported by 
us previously (Zhai et al., 2007b). 
        The lipophilic fraction of EPA includes two classes of phytochemicals, alkamides and 
ketones. While alkamides are widely investigated, ketones are almost completely neglected. 
Ketones are, in fact, the main lipophilic constituents in EPA roots, and one of ketones, ketone 
23, is recognized as the diagnostic marker for hydrophobic metabolites (Kraus et al., 2005). 
The biological activity of ketones from EPA is little known. It has been suggested that ketones 
have antifungal activity (Binns et al., 2000). Obviously, like other bioactive metabolites of 
Echinacea (Awang, 1999), the antifungal activity of ketones might be through modulation of 
immune cell function rather than through a direct fungal killing. For lipophilic fraction 3 of 
EPA, it is possible that in addition to alkamides, ketones play in part role in the regulation of 
NO production. 
        In an aerobic environment, NO reacts rapidly with oxygen to form nitrogen dioxide, a gas 
capable of inducing cell damage (Meurs et al., 2003). Since it has been suggested that the polar 
caffeic acid derivatives of Echinacea possess the antioxidant and radical scavenging nature (Hu 
et al., 2000; Pellati et al., 2004; Dalby-Brown et al., 2005), which could be enhanced by 
lipophilic alkamides (Dalby-Brown et al., 2005), we investigated whether Echinacea extracts 
(a mixture of caffeic acid derivatives and alkamides) could scavenge or interact with NO and 
nitrogen dioxide species directly. Addition of high concentration of alcohol extracts (200 
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µg/ml) to a series of standard solutions of sodium nitrite (0.39-100 µM) did not interfere with 
the nitrite detection by Griess reaction, indicating that Echinacea does not interact with nitrite 
ions or nitrogen dioxide species directly. Moreover, we demonstrated that Echinacea extracts 
are a weak scavenger of NO because they could not strongly inhibit nitrite accumulation by 
competing with oxygen to react with NO generated from SNP. Additional studies showed that 
Echinacea extracts could not effectively protect RAW 264.7 cells from SNP-induced cell 
damage or cytotoxicity via the release of high levels of NO as determined by tritiated 
thymidine incorporation (data not shown). Based on these collected data, we could conclude 
that Echinacea-mediated decrease in NO production by macrophages is mainly via the 
modulation of the production yield of NO, but not direct scavenging of NO. 
        Our results demonstrated that Echinacea present at the onset of LPS-induced iNOS 
expression resulted in a stronger inhibitory effect on NO production, suggesting that 
Echinacea could block the LPS-initiated upstream signaling pathway. Sharma et al. (2006) 
recently screened the activation of transcription factors in rhinovirus-infected human 
bronchial epithelial cell line with a protein/DNA array analysis, and found an alcohol tincture 
of EP roots significantly inhibited the nuclear expression of multiple pro-inflammatory 
transcription factors including NF-κB and STATs. It has also been demonstrated that in 
stimulated macrophages, certain individual alkamides could inhibit NF-κB activity (Matthias 
et al., 2007). Down-regulation of NF-κB expression will lead to decreased iNOS expression 
and NO production. Our results suggested that the Echinacea-mediated decrease in NO 
production was generally associated with decreased protein expression of iNOS as indicated 
by Western blotting assay. The control protein β-actin was not affected under the same 
conditions suggesting that Echinacea-mediated inhibition of iNOS expression did not result 
simply from a broad decrease in protein expression. Note that several Echinacea preparations 
showed relatively weak inhibition of iNOS protein expression when compared with their 
effects on NO production, this may suggest other mechanisms in the context of decreased 
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NO production, i.e. a direct inhibition of iNOS enzyme activity. In fact, NO production 
correlates with iNOS activity and is commonly used as an indirect indicator of iNOS activity 
(which can be directly assayed by measuring the production of L-citrulline from L-arginine) 
(Wang et al., 1995; Munder et al., 1998). In addition, decreased NO production might be in 
part due to a switch of macrophage function to alternative activation, leading to less 
availability of the substrate for the iNOS pathway.  
        Like Echinacea, some other natural occurring chemicals (e.g., flavonoids, resveratrol, 
and curcumin) have both immunomodulatory and anti-inflammatory activity including 
inhibition of NO production and iNOS enzyme expression (Surh et al., 2001; Yamamoto and 
Gaynor, 2001). Although we can not extrapolate the action mechanism of Echinacea based 
on these different structural natural metabolites, there may be a certain common nature that 
determines a similar biological activity. It has been suggested that NF-κB activation could be 
regulated by the intracellular redox state (van den Berg et al., 2001). There is evidence to 
support that the above mentioned natural chemicals, flavonoids, resveratrol and curcumin, 
strongly suppress NF-κB activation by way of blocking upstream signaling, i.e. inhibition of 
phosphorylation of IκB-α (van den Berg et al., 2001; Surh et al., 2001; Lin, 2007). It is likely 
that Echinacea-derived caffeic acid derivatives as potential antioxidants could regulate the 
NF-κB activation. However, direct evidence is needed to support this speculation because 
alkamide fractions, but not caffeic acid fractions exerted robust inhibition of NO production 
by macrophage cell line.  
        Taken together, Echinacea affects macrophage immune function at multiple levels, 
resulting in inhibition of NO production and increased arginase activity. Observations on 
fractions of alcohol extracts of Echinacea indicate that Echinacea-mediated decrease in NO 
production is due to bioactive alkamides. Such in vitro effects may be directly applicable to 
in vivo administration as alkamides are bioavailable. Moreover, the anti-inflammatory 
activity of Echinacea might be dependent on a synergistic action of both alkamides and 
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caffeic acid derivatives, which act together to drive macrophages to alternative activation. 
These noteworthy findings will help define the mechanisms behind the success of traditional 
use of Echinacea in phytotherapy for inflammatory diseases.              
Acknowledgements 
        This publication or project was made possible by the National Institute of 
Environmental Health Sciences (P01ES012020), the Office of Dietary Supplements, and the 
National Center for Complementary and Alternative Medicine (9 P50 AT004155-06), at the 
National Institutes of Health, and was performed as part of the Center for Research on 
Dietary Botanical Supplements at Iowa State University and the University of Iowa. Its 
contents are solely the responsibility of the authors and do not necessarily represent the 
official views of NIEHS, ODS, NCCAM or the NIH. We thank Dr. Manuel Modolell (Max-
Planck-Institut für Immunbiologie, Germany), Dr. Nair Sreejayan (University of Wyoming), 
and Dr. Jodi Mckay (Iowa State University) for technical help.  
References 
Awang, D.V.C., 1999. Immune stimulants and antiviral botanicals: Echinacea and ginseng. In: 
J. Janick (Ed.), Perspectives on new crops and new uses, ASHS Press, Alexandria, VA, 
pp. 450–456. 
Barnes, J., Anderson, L.A., Gibbons, S., Phillipson, J.D., 2005. Echinacea species (Echinacea 
angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) 
Moench): a review of their chemistry, pharmacology and clinical properties. The Journal 
of Pharmacy and Pharmacology 57, 929-954. 
van den Berg, R., Haenen, G.R., van den Berg, H., Bast, A., 2001. Transcription factor NF-
kappaB as a potential biomarker for oxidative stress. British Journal of Nutrition 86, 
S121-S127. 
Binns, S.E., Purgina, B., Bergeron, C., Smith, M.L., Ball, L., Baum, B.R., Arnason, J.T., 2000. 
Light-mediated antifungal activity of Echinacea extracts. Planta Medica 66, 241-244.   
112 
 
Borchers, A.T., Keen, C.L., Stern, J.S., Gershwin, M.E., 2000. Inflammation and Native 
American medicine: the role of botanicals. American Journal of Clinical Nutrition 72, 
339-347. 
Chan, M.M., Mattiacci, J.A., Hwang, H.S., Shah, A., Fong, D., 2000. Synergy between ethanol 
and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric 
oxide synthase pathway. Biochemical Pharmacology 60, 1539-1548. 
Chang, C.I., Zoghi, B., Liao, J.C., Kuo, L., 2000. The involvement of tyrosine kinases, cyclic 
AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated 
arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide 
production. The Journal of Immunology 165, 2134-2141. 
Chen, Y., Fu, T., Tao, T., Yang, J., Chang, Y., Wang, M., Kim, L., Qu, L., Cassady, J., Scalzo, 
R., Wang, X., 2005. Macrophage activating effects of new alkamides from the roots of 
Echinacea species. Journal of Natural Products 68, 773-776. 
Corraliza, I.M., Campo, M.L., Soler, G., Modolell, M., 1994. Determination of arginase 
activity in macrophages: a micromethod. Journal of Immunological Methods 174, 231-
235. 
Corraliza, I.M., Modolell, M., Ferber, E., Soler, G., 1997. Involvement of protein kinase A in 
the induction of arginase in murine bone marrow-derived macrophages. Biochimica et 
Biophysica Acta 1334, 123-128. 
Cory, A.H., Owen, T.C., Barltrop, J.A., Cory, J.G., 1991. Use of an aqueous soluble 
tetrazolium/formazan assay for cell growth assays in culture. Cancer Communications 3, 
207-212.  
Dalby-Brown, L., Barsett, H., Landbo, A.K., Meyer, A.S., Molgaard, P., 2005. Synergistic 
antioxidative effects of alkamides, caffeic acid derivatives, and polysaccharide fractions 
from Echinacea purpurea on in vitro oxidation of human low-density lipoproteins. 
Journal of Agricultural and Food Chemistry 53, 9413-9423. 
Gotoh, T., Mori, M., 1999. Arginase II downregulates nitric oxide (NO) production and 
prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. The 
Journal of Cell Biology 144, 427-434. 
113 
 
Hu, C., Kitts, D.D., 2000. Studies on the antioxidant activity of Echinacea root extract. Journal 
of Agricultural and Food Chemistry 48, 1466-1472. 
Jia, C., Shi, H., Wu, X., Li, Y., Chen, J., Tu, P., 2006. Determination of echinacoside in rat 
serum by reversed-phase high-performance liquid chromatography with ultraviolet 
detection and its application to pharmacokinetics and bioavailability. Journal of 
Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 844, 
308-313. 
Katsuyama, K., Hirata, Y., 2001. A pyrrolidinone derivative inhibits cytokine-induced iNOS 
expression and NF-kappaB activation by preventing phosphorylation and degradation of 
IkappaB-alpha. Journal of Biochemistry 129, 585-591. 
Kiemer, A.K., Muller, C., Vollmar, A.M., 2002. Inhibition of LPS-induced nitric oxide and 
TNF-α by α-lipoic acid in rat Kupffer cells and in RAW 264.7 cells. Immunology and 
Cell Biology 80, 550-557. 
Kraus, G.A., Bae, J., Schuster, J., 2005. The first synthesis of a diynone from Echinacea 
pallida. Synthesis 2005, 3502-3504. 
Lafay, S., Gil-Izquierdo, A., Manach, C., Morand, C., Besson, C., Scalbert, A., 2006. 
Chlorogenic acid is absorbed in its intact form in the stomach of rats. The Journal of 
Nutrition 136, 1192-1197. 
Lin, J.K., 2007. Molecular targets of curcumin. Advances in Experimental Medicine and 
Biology 595, 227-243. 
Liu, Y., Murphy, P.A., 2007. Alkamide stability in Echinacea purpurea extracts with and 
without phenolic acids in dry films and in solution. Journal of Agricultural and Food 
Chemistry 55, 120-126.  
Louis, C.A., Mody, V., Henry, W.L. Jr., Reichner, J.S., Albina, J.E., 1999. Regulation of 
arginase isoforms I and II by IL-4 in cultured murine peritoneal macrophages. American 
Journal of Physiology. Regulatory, Integrative and Comparative Physiology 276, R237-
R242. 
MacMicking, J., Xie, Q.W., Nathan, C., 1997. Nitric oxide and macrophage function. Annual 
Review of Immunology 15, 323-350. 
114 
 
Mckay, L.I., Cidlowski, J.A., 1999. Molecular control of immune/inflammatory responses: 
interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. 
Endocrine Reviews 20, 435-459. 
Matthias, A., Addison, R.S., Penman, K.G., Dickinson, R.G., Bone, K.M., Lehmann, R.P., 
2005. Echinacea alkamide disposition and pharmacokinetics in humans after tablet 
ingestion. Life Sciences 77, 2018-2029. 
Matthias, A., Banbury, L., Stevenson, L.M., Bone, K.M., Leach, D.N., Lehmann, R.P., 2007. 
Alkylamides from Echinacea modulate induced immune responses in macrophages. 
Immunological Investigations 36, 117-130. 
Matthias, A., Blanchfield, J.T., Penman, K.G., Toth, I., Lang, C.S., De Voss, J.J., Lehmann, 
R.P., 2004. Permeability studies of alkylamides and caffeic acid conjugates from 
Echinacea using a Caco-2 cell monolayer model. Journal of Clinical Pharmacy and 
Therapeutics 29, 7-13. 
Meurs, H., Maarsingh, H., Zaagsma, J., 2003. Arginase and asthma: novel insights into nitric 
oxide homeostasis and airway hyperresponsiveness. Trends in Pharmacological Sciences 
24, 450-455. 
Modolell, M., Corraliza, I.M., Link, F., Soler, G., Eichmann, K., 1995. Reciprocal regulation of 
the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by 
TH1 and TH2 cytokines. European Journal of Immunology 25, 1101-1104. 
Morris, S.M. Jr., Kepka-Lenhart, D., Chen, L.C., 1998. Differential regulation of arginases and 
inducible nitric oxide synthase in murine macrophage cells. The American Journal of 
Physiology 275, E740-E747. 
Munder, M., Eichmann, K., Modolell, M., 1998. Alternative metabolic states in murine 
macrophages reflected by the nitric oxide synthase/arginase balance: competitive 
regulation by CD4+ T cells correlates with Th1/Th2 phenotype. Journal of Immunology 
160, 5347-5354. 
Park, E., Kum, S., Wang, C., Park, S.Y., Kim, B.S., Schuller-Levis, G., 2005. Anti-
inflammatory activity of herbal medicines: inhibition of nitric oxide production and tumor 
necrosis factor-alpha secretion in an activated macrophage-like cell line. The American 
Journal of Chinese Medicine 33, 415-424. 
115 
 
Pellati, F., Benvenuti, S., Magro, L., Melegari, M., Soragni, F., 2004. Analysis of phenolic 
compounds and radical scavenging activity of Echinacea spp. Journal of Pharmaceutical 
and Biomedical Analysis 35, 289-301. 
Percival, S.S., 2000. Use of Echinacea in medicine. Biochemical Pharmacology 60, 155-158. 
Porcheray, F., Viaud, S., Rimaniol, A.C., Léone, C., Samah, B., Dereuddre-Bosquet, N., 
Dormont, D., Gras, G., 2005. Macrophage activation switching: an asset for the resolution 
of inflammation. Clinical and Experimental Immunology 142, 481-489. 
Rousseau, B., Tateya, I., Lim, X., Munoz-del-Rio, A., Bless, D.M., 2006. Investigation of anti-
hyaluronidase treatment on vocal fold wound healing. Journal of Voice 20, 443-451. 
Sharma, M., Arnason, J.T., Hudson, J.B., 2006. Echinacea extracts modulate the production of 
multiple transcription factors in uninfected cells and rhinovirus-infected cells. Phytotherapy 
Research 20, 1074-1079. 
Speroni, E., Govoni, P., Guizzardi, S., Renzulli, C., Guerra, M.C., 2002. Anti-inflammatory 
and cicatrizing activity of Echinacea pallida Nutt. root extract. Journal of 
Ethnopharmacology 79, 265-272. 
Sreejayan, Rao, M.N., 1997. Nitric oxide scavenging by curcuminoids. The Journal of 
Pharmacy and Pharmacology 49, 105-107. 
Surh, Y.J., Chun, K.S., Cha, H.H., Han, S.S., Keum, Y.S., Park, K.K., Lee, S.S., 2001. 
Molecular mechanisms underlying chemopreventive activities of anti-inflammatory 
phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa 
B activation. Mutation Research 480-481, 243-268. 
Vanzo, A., Cecotti, R., Vrhovsek, U., Torres, A.M., Mattivi, F., Passamonti, S., 2007. The 
fate of trans-caftaric acid administered into the rat stomach. Journal of Agricultural and 
Food Chemistry 55, 1604-1611. 
Wang, W.W., Jenkinson, C.P., Griscavage, J.M., Kern, R.M., Arabolos, N.S., Byrns, R.E., 
Cederbaum, S.D., Ignarro, L.J., 1995. Co-induction of arginase and nitric oxide synthase 
in murine macrophages activated by lipopolysaccharide. Biochemical and Biophysical 
Research Communications 210, 1009-1016. 
116 
 
Wei, L.H., Morris, S.M., Jr., Cederbaum, S.D., Mori, M., Ignarro, L.J., 2000. Induction of 
arginase II in human Caco-2 tumor cells by cyclic AMP. Archives of Biochemistry and 
Biophysics 374, 255-260. 
Woelkart, K., Bauer, R., 2007. The role of alkamides as an active principle of Echinacea. 
Planta Medica 73, 615-623.  
Woelkart, K., Koidl, C., Grisold, A., Gangemi, J.D., Turner, R.B., Marth, E., Bauer, R., 2005. 
Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea 
angustifolia in humans. Journal of Clinical Pharmacology 45, 683-689. 
Wu, C.H., Chen, T.L., Chen, T.G., Ho, W.P., Chiu, W.T., Chen, R.M., 2003. Nitric oxide 
modulates pro- and anti-inflammatory cytokines in lipopolysaccharide-activated 
macrophages. The Journal of Trauma 55, 540-545. 
Wu, L., Bae, J., Kraus, G., Wurtele, E.S., 2004. Diacetylenic isobutylamides of Echinacea: 
synthesis and natural distribution. Phytochemistry 65, 2477-2484. 
Yamamoto, T., Sawada, Y., Katayama, I., Nishioka, K., 1998. Increased production of nitric 
oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients 
with systemic sclerosis. British Journal of Rheumatology 37, 1123-1125.  
Yamamoto, Y., Gaynor, R.B., 2001. Therapeutic potential of inhibition of the NF-kappaB 
pathway in the treatment of inflammation and cancer. The Journal of Clinical Investigation 
107, 135-142. 
Zhai, Z., Haney, D., Wu, L., Solco, A., Murphy, P.A., Wurtele, E.S., Kohut, M.L., Cunnick, 
J.E., 2007. Alcohol extracts of Echinacea inhibit production of nitric oxide and tumor 
necrosis factor-alpha by macrophages in vitro. Food and Agricultural Immunology 18, 221-
236. 
Zhai, Z., Liu, Y., Wu, L., Senchina, D.S., Wurtele, E.S., Murphy, P.A., Kohut, M.L., Cunnick, 
J.E., 2007. Enhancement of innate and adaptive immune functions by multiple Echinacea 
species. Journal of Medicinal Food 10, 423-434. 
 
 
 
 
117 
 
 
 
 
 
 
 
Table 4.1. Concentration of known metabolites in alcohol extracts 
 
 
 Species  
Metabolites E. angustifolia E. pallid E. purpurea 
Amides  1.71* 1.04 2.61 
Caftaric acid  ND 0.06 0.06 
Chlorogenic acid 0.09 0.21 ND 
Cichloric acid ND** 0.06 0.46 
Echinacoside 0.39 1.26 ND 
* % of dried extract 
** ND = not detectable 
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Table 4.2. Echinacea fractions and their chemical constituents 
 
 
 Species  
Fractions E. angustifolia E. pallid E. purpurea 
1 Caffeic acid derivatives Caffeic acid derivatives Caffeic acid derivatives 
2 Unknown Unknown Unknown 
3 Alkamides Alkamides and ketones Alkamides 
4 Alkamide 11 and other very hydrophobic compounds 
Very Hydrophobic 
compounds Very hydrophobic compounds 
5 Most hydrophobic 
compounds 
Most hydrophobic 
compounds 
Most hydrophobic 
compounds 
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Fig. 4.1. Alcohol extracts of Echinacea inhibit production of TNF-α by LPS-stimulated 
macrophages.  RAW 264.7 cells were incubated in vitro for 23 h in the presence of indicated 
Echinacea extracts 100 µg/ml plus different concentrations of LPS (A), or incubated with 
different concentrations of Echinacea extracts (0-200 µg/ml) in the presence of 0.1µg/ml LPS 
(B). Culture supernates were assayed for TNF-α by ELISA (A and B (solid lines)). The 
attached cells were evaluated for cell viability by MTS assay (B (dashed lines)). The data are 
expressed as mean ± standard error of the mean of 3 independent experiments performed in 
triplicate. *P<0.001 vs the vehicle control at the same concentration of LPS.   
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Fig. 4.2. Alcohol extracts of Echinacea inhibit production of NO by LPS-stimulated 
macrophages.  Cells were incubated in vitro for 23 h in the presence of Echinacea extracts 
100 µg/ml plus different concentrations of LPS (A), or incubated overnight with different 
concentrations of indicated Echinacea extracts (0-200 µg/ml) in the presence of 1 µg/ml LPS 
(B). After removing supernates for NO assay (A and B (solid lines)), cell viability was 
evaluated by addition of MTS (B (dashed lines)). The data are expressed as mean ± standard 
error of the mean of 3 independent experiments performed in triplicate. 
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Fig. 4.3. Scavenging of NO derived from SNP by alcohol extracts of Echinacea. A. SNP 
was mixed with Griess reagent in the presence of vehicle (0.25% ethanol) or 50 µg/ml of 
Echinacea extracts and incubated for 6 h. Nitrite accumulation was monitored at 550nm at 
various time points and calculated based on the absorbance of sodium nitrite standards 
manipulated in the same way with Griess reagent. B. SNP was mixed with Griess reagents 
containing various concentrations of Echinacea extracts and then incubated for 150 min. The 
data are expressed as mean ± standard error of the mean of 3 independent experiments 
performed in triplicate. 
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Fig. 4.4. Time course of inhibition of NO production by alcohol extracts of Echinacea. Echinacea 
extracts (100 µg/ml) were either added simultaneously with LPS (1 µg/ml) (0 h) or up to 6 h 
after addition of LPS. The nitrite accumulation by RAW 264.7 cells was determined 22 h after 
LPS stimulation by the Griess reaction. The data are expressed as mean ± standard error of the 
mean of 4 experiments performed in triplicate. *P<0.05 and **P<0.001 vs 0.25% ethanol in 
the presence of LPS (control). +P<0.05 and ++P<0.001 vs respective group in the presence of 
LPS at time point 0 h.              
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Fig. 4.5. Regulation of NO 
production and arginase activity of 
activated RAW 264.7cells by 
alcohol extracts of Echinacea. Cells 
were incubated in the presence or 
absence of indicated concentrations 
of Echinacea extracts, LPS (1 µg/ml) 
and /or 8-bromo-cAMP (abbreviated 
cAMP, 0.25 mM) for 23-24 h, then 
supernates were collected for NO 
assay (A). The cell lysates were 
assayed for arginase activity (B and 
C (solid lines)) as described in 
Materials and Methods. Cell viability 
was determined by MTS assay (C 
(dashed lines)). Data are mean ± 
standard error of the mean of 4-5 
experiments performed in triplicate 
(for NO and cell viability) or 
duplicate (arginase). *P<0.05 and 
**P<0.001 vs 0.25% ethanol as 
control in respective treatment group. 
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Fig. 4.6. Regulation of NO production and arginase activity of activated RAW 264.7 cells 
by fractions of alcohol extracts of Echinacea. NO production was determined in supernates 
of cells exposed to LPS (1 µg/ml) plus individual fraction (25 µg/ml) for 24 h (A).  Arginase 
activity was assayed in cells treated with LPS (1 µg/ml), 8-bromo-cAMP (0.25 mM) and 
individual fraction (25 µg/ml) for 24 h (B). Data are expressed as mean ± standard error of the 
mean of 4-5 experiments performed in triplicate (NO) or duplicate (arginase). *P<0.05 and 
**P<0.001 vs 0.25% ethanol as vehicle as in respective treatment group. 
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Fig. 4.7. Regulation of iNOS 
expession by alcohol extracts and 
fractions of Echinacea. Cells were 
incubated with or without LPS (1 
µg/ml) plus Echinacea extract (100 
µg/ml) or individual fraction (25 µg/ml) 
for 24 h. The iNOS expression was 
analyzed by Western blotting and 
digitally quantitated using image 
analysis software. The data represent 
the mean of three independent 
experiments with different cell 
preparations. Representative bands are 
shown. The net intensity of iNOS bands 
was compared to that of corresponding 
β-actin with the same treatment, and the 
ratio was expressed as a percent of the 
ratio for the vehicle- and LPS-treated 
cells. A. EA; B. EPA; C. EP. *P<0.05 
vs vehicle plus LPS.   
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CHAPTER 5. ALCOHOL EXTRACT OF ECHINACEA PALLIDA 
REVERSES STRESS-DELAYED WOUND HEALING IN MICE  
 
Zili Zhai1,2, Devon M. Haney1, Lankun Wu3, Avery K. Solco4, Patricia A. Murphy4,  
Eve S. Wurtele3, Marian L. Kohut5, Joan E. Cunnick1,2,6, 
 
Abstract 
        Open skin wounds heal gradually beginning with an inflammatory response. Factors that 
affect this immune event may lead to a variable course of wound recovery. Restraint stress 
has been well documented to delay wound closure, partially via glucocorticoid (GC)-
mediated immunosuppression. Echinacea, a popular herbal immunomodulator, is purported 
to be beneficial for wound healing due to its ability to modulate inflammatory cell function. 
To test the hypothesis, an alcohol extract of E. pallida was administrated orally to male 
SKH-1 mice at 130 mg/kg per day for 3 days prior to, and 4 days post wounding with a 3.5 
mm biopsy punch on the dorsum. At the same time, mice were exposed to 3 cycles of daily 
12-h restraint stress prior to, and 4 cycles post wounding. Wound healing was recorded daily 
by photography. The results showed that Echinacea accelerated wound closure in the 
stressed mice, but had no apparent wound healing effect for the non-stressed mice when 
compared to their respective controls. To test if the positive healing effect is through 
modulation of GC release, plasma corticosterone concentrations were measured in 
unwounded mice that had experienced 4 consecutive cycles of daily restraint stress and were 
simultaneously treated with the herbal extract for 4 doses, one dose per day. The results 
showed that Echinacea induced an increase, rather than a decrease in the plasma  
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corticosterone concentrations when compared to the vehicle control. That data suggest that 
the improved effect of Echinacea in stressed mice is not mediated through modulation of GC 
signaling.   
1. Introduction 
        The wound repair process is adaptive and progressive; inflammation, cell proliferation 
and tissue regeneration are three orderly but temporally overlaid stages (Hubner et al., 1996; 
Park and Barbul, 2004). The inflammatory response that mounts immediately after physical 
injury holds the key to the efficacy of the subsequent stages in wound healing. Inflammation 
is a double-edged sword; it has important physiological significance in the normal healing 
process, but excessive inflammation is detrimental to wound repair (Midwood et al., 2004). 
Homeostatic regulation of the early inflammatory event is beneficial for faster wound 
healing.  
        The genus Echinacea, one of the currently popular herbal medicines, is a promising 
anti-inflammatory agent. Historically, three Echinacea species, E. angustifolia (EA), E. 
pallida (EPA) and E. purpurea (EP), have been empirically used in phytotherapy for wound 
healing, pain relief and alleviation of cold symptoms (Borchers et al., 2000). Recently 
laboratory studies indicated that alkamides or alkamide-rich alcohol extracts of Echinacea 
inhibit production of inflammatory mediators, i.e. nitric oxide (NO) and prostaglandin E2 in 
lipopolysaccharide (LPS)-activated mouse macrophage cell line in vitro (Lalone et al., 2007; 
Zhai et al., 2007a). These inhibitory effects may be partially related to blockade of 
transcriptional factor NF-κB (Stevenson et al., 2005; Matthias et al., 2007) whose activation 
is mainly responsible for the inflammatory response and production of inflammatory 
mediators.  
        Macrophages are important players in the inflammatory response and at the early stage 
of wound healing. They can undergo classical activation by LPS and tumor necrosis factor-
128 
 
alpha (TNF-α) to activate inducible nitric oxide synthase (iNOS) and produce NO that causes 
inflammation, or undergo alternative activation by interleukin (IL)-4 and IL-10 to activate 
arginase leading to production of L-ornithine (Modolell et al., 1995), an important precursor 
for cell growth and collagen synthesis in wound recovery (Meurs et al., 2003). We recently 
investigated the differential effects of Echinacea on these two competitive metabolic 
pathways; alcohol extracts of Echinacea reduced TNF-α production, but increased IL-4 and 
IL-10 production in an in vivo gavage model (Zhai et al., 2007b). Moreover, Echinacea 
inhibited NO production, but stimulated arginase activity in activated macrophage cell line 
(Zhai et al., unpublished). These data further indicate that Echinacea presents a clear anti-
inflammatory activity that may promote wound tissue recovery.  
        Nevertheless, there is not sufficient evidence to support in vivo wound healing efficacy 
of Echinacea. Alcohol extracts of Echinacea are typically composed of two classes of natural 
chemicals, lipophilic alkamides and water-soluble caffeic acid derivatives. Caffeic acid 
derivatives are effective antioxidants in free radical generation systems (Dalby-Brown et al., 
2005), and have an antihyaluronidase activity (Facino et al., 1993). This later enzyme 
inhibiting nature has been functionally linked to the healing effect of topical application of a 
standardized Echinacea on vocal fold wounds in a pig animal model (Rousseau et al., 2006). 
Hyaluronidase catalyzes the hydrolysis of cellular hyaluronan. A suppression of 
hyaluronidase will allow accumulation of enough hyaluronan in the extracellular matrix for 
scarless wound repair (Rousseau et al., 2006). In an excision wound model in rats, it was 
seen that in comparison to the untreated wounds, wound tissues treated topically with EPA 
extract or its constituent echinacoside, a caffeic acid derivative, for 72 h showed a positive 
healing process characterized by less inflammatory response and higher hyaluronan contents 
(Speroni et al., 2002). However, until now no information about the wound healing 
properties of alkamides from Echinacea has been reported, nor a favorable wound healing 
effect of Echinacea via oral administration.  
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        Another advantage not to be ignored in treating wounds with Echinacea may reside in 
the herb’s multiple immunomodulatory properties. Echinacea is known for strengthening the 
immune system against pathogenic infections partially through the activation of neutrophils 
and macrophages to produce inflammatory mediators (Awang, 1999; Goel et al., 2002). The 
actual action of Echinacea, either inflammatory or anti-inflammatory, is largely determined 
by the host immune cell functional state (Zhai et al., 2007a). Echinacea seems to have an 
ability to help the body’s immune system maintain homeostasis and work more efficiently. 
Although chronic inflammation can disrupt normal wound repair, acute inflammation 
occurring at the very early stages of an open wound healing process has a critical 
physiological implication, i.e. removal of cellular debris and pathogens from wound tissue 
(Kondo and Ohshima, 1996; Weller, 2003; Midwood et al., 2004). Any extrinsic factors that 
disturb this physiological inflammatory process might adversely affect wound healing. One 
of the notable examples is a stressor. In a murine model of cutaneous punch biopsy wound 
healing, a decreased inflammatory response induced by repeated restraint stress resulting in 
increased corticosterone has been well demonstrated to slow wound healing (Padgett et al., 
1998; Rojas et al., 2002). It is likely that the dual biological activities (immunomodulation 
and alternative macrophage activation) of Echinacea are beneficial to wound healing even 
under an unfavorable condition like chronic stressor, however, direct evidence is needed. 
        Precisely because of the immunomodulatory, arginase enhancing and anti-inflammatory 
properties of Echinacea, we preliminarily evaluated for the first time the wound healing 
effect of oral administration of EPA extract on the punch biopsy wound healing process in 
mice exposed to repeated restraint stress and non-retrained controls. We chose EPA as the 
Echinacea treatment as it decreased NO production to the greatest degree and enhanced 
arginase activity equivalently to other medicinally used Echinacea species, EA and EP (Zhai 
et al., unpublished).  
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2. Materials and Methods 
2.1. Preparation of EPA extract    
        The plant EPA was harvested in 2006 in the USDA North Central Regional Plant 
Introduction Station (Ames, IA) with identification number PI 631293. Alcohol extract from 
the dried roots was prepared by Soxhlet extraction followed by evaporation to dryness (Zhai et 
al., 2007b). The dry residue was subsequently dissolved and diluted to 16 mg/ml in 5% 
ethanol. Aliquots of this dilution were stored at -20°C and thawed for gavage with each aliquot 
used once. The phytochemicals in the dilution were analyzed using high performance liquid 
chromatography (HPLC) as described previously (Wu et al., 2004; Lalone et al., 2007). N-
isobutylundeca-2-ene-8,10-diynamide and 3,5-dimethoxy-4-hydroxy-cinnamic acid were used 
as internal standards for quantification of lipophilic compounds and water soluble compounds, 
respectively. To exclude bacterial or endotoxin contamination, the endotoxin levels were 
evaluated in aliquots using the Limulus Amebocyte Lysate Test (BioWhittaker, Inc., 
Walkersville, MD, USA) according to the manufacturer's specifications for a microplate assay, 
and were found to be below the limit of detection (< 0.1 EU/ml). 
2.2. Animals   
        Male SKH-1 mice at 5 weeks of age were obtained from Charles River Laboratories, Inc. 
(Wilmington, MA, USA), and allowed to acclimate to the new environment for 2 weeks. This 
outbred strain of mice was used to evaluate wound healing, because they are hairless which 
permits better viewing of the wounds (Padgett et al., 1998), yet immune competent. The mice 
were housed 2-4/cage under a reverse 12-h light/dark regimen with lights off at 8:30 AM. 
Unless indicated, the mice had access to water and Harlan Teklad standard rodent chow 
(#2018; 18% protein rodent diet) ad lib. All experimental manipulations were approved by the 
Iowa State University Committee on Animal Care. 
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2.3. Animal study 1: Wound healing effect of EPA 
        This study consisted of two independent experiments (experiment 1 and 2) with an 
identical study design (total n = 6-7 mice/group). 
2.3.1. Restraint stress treatment 
        Mice were stressed in a manner described previously (Padgett et al., 1998). After the mice 
were randomly assigned to groups, the restraint stressed groups of mice were placed 
individually into 50-ml conical centrifuge tubes drilled with holes of 0.4 cm diameter for air 
flow, heat exchange, and some urine and fecal drainage. The restraint was administrated for 12 
h per day (one cycle) during the light phase, with a total of seven cycles applied: three cycles 
prior to and four cycles post wounding. The first stress cycle after wounding began 30-32 h 
after wounding. When the stressed mice were subjected to the restraint process, the non-
stressed animals were simultaneously food and water deprived (FWD), but remained in their 
home cages. To determine the potential effect of FWD on wound healing, an extra group was 
tested with continued free access to food and water (Food ad lib) throughout the experimental 
procedure.  
2.3.2. Echinacea administration  
        An alcohol extract of EPA was orally administered by gavage to the animals at 130 mg/kg 
body weight once daily for a total of seven doses; three doses were given immediately after 
each stress cycle prior to wounding, and four doses were given before each stress cycle post 
wounding. This dosage and regimen was generally selected based on an extrapolation of the 
dose recommended for humans and calculated as previously described (Zhai et al., 2007b).  
2.3.3. Wound biopsy 
        Mice were anesthetized with an intraperitoneal injection of a mixture of 20 mg/ml 
rompum and 100 mg/ml ketamine (provided by laboratory Animal Resources of Iowa State 
University) at a dose of 8.8 µl/g body weight. After the dorsal area was disinfected with 70% 
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ethanol, a sterile 3.5 mm biopsy punch (Miltex, Inc., York, PA, USA) was used to make two 
full-thickness wounds on the back (Padgett et al., 1998). In order to prevent dehydration and 
hypothermia, the mice were subsequently injected intraperitoneally with 1 ml of sterile 0.9% 
saline solution and placed under a warm lamp until they recovered consciousness. 
2.3.4. Wound healing evaluation 
        Wounds were photographed immediately after wounding and then photographed daily 
until the end of the experiments. In order to obtain higher quality pictures, beginning from the 
day after wounding, the mice were temporarily anesthetized using isoflourane (Abbott 
Laboratories, North Chicago, IL, USA) inhalation. Each individual wound and a standard dot 
placed beside the wound were analyzed by measuring the horizontal and vertical length using 
Canvas X software (ACD Systems of America, Miami, FL, USA). The area of an ellipse (π × 
vertical length × horizontal length divided by 4) was used to estimate the wound size and the 
corresponding standard dot size. Beginning 7 days after wounding, healing was also assessed 
by the absence of an enzymatic reaction during application of 3% hydrogen peroxide (Padgett 
et al., 1998). Temporary use of this hydrogen peroxide solution has no negative influence on 
wound healing (Drosou et al., 2003). 
2.4. Animal study 2: Immune and corticosterone modulation of EPA 
        This study extended study 1 and reused the animals from animal study 1. To rule out the 
potential effect of wounding history on the observational parameters, the animals were given 
30-45 days to recover after experimental manipulation in study 1. Animals from experiment 1 
were sampled for corticosterone assay and corticosterone was found to return to the baseline 
levels. The data reported here were collected from the mice used in experiment 2 of study 1. 
This study 2 includes 7 groups, 3-4 mice per group. Group treatments were randomly 
reassigned to Echinacea and restraint treatments without wounding. Mice were stressed as 
described above but with a total of four consecutive stress cycles, and were gavaged with 
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Echinacea extract at 130 mg/kg body weight once daily before each stress cycle. Body weight 
was recorded daily during the experimental procedure.  
2.4.1. Sample collection 
        Two hours after the last stress cycle, the stressed mice along with the non-restraint 
stressed mice were euthanized by CO2 asphyxiation. Body weight and spleen weight were 
recorded. Blood was collected by heart puncture using a heparinized syringe and then 
centrifuged at 12,000 g for 10 min. Plasma was collected and frozen at -80°C until assays. The 
spleens were dissociated into a single cell suspension, and the splenocytes were enumerated 
using a Hemavet 850 Hematology Analyzer (Drew Scientific, Inc., Oxford, CT, USA) and 
diluted to 5×106 cells/ml in RPMI 1640 medium (Gibco, Invitrogen Corporation, Carlsbad, 
CA, USA) supplemented with 2 mM glutamine, 25 mM Hepes buffer, 50 µg/ml gentamicin 
and 10% heated-inactivated fetal bovine serum.  
2.4.2. Corticosterone sensitivity assay 
        Corticosterone suppresses splenocyte proliferation in vitro (Avitsur et al., 2001). To test 
the sensitivity of splenocytes to inhibition by corticostreone, cell viability was evaluated by 
MTS assay. Cells were seeded at 5×105 cells per well in 96-well tissue culture plates with or 
without 1 µg/ml of LPS (E. coli 055:B5, L6529; Sigma, St. Louis, MO, USA) and 0.1-1 µM 
corticosterone (Sigma) diluted in ethanol with a final concentration of 0.1% (v/v) in cell 
culture. Following 45 h of incubation, 15 µl of a tetrazolium compound MTS (CellTiter 96 
Aqueous One Solution Cell Proliferation Assay, Promega Corporation, Madison, WI, USA) 
was added to 100 µl of cultures with continued incubation for 3 h. The extent of formazan 
formation from MTS was determined photometrically at absorbance 490 nm using a plate 
reader (Bio-Tek Instruments, Winooski, VT, USA).   
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2.4.3. Plasma corticosterone assay 
        Corticosterone was determined using an enzyme immunoassay kit (Assay Designs, Inc., 
Ann Arbor, MI, USA) according to the manufacturer’s protocol. Before assay, plasma samples 
were appropriately diluted with the assay buffer included with the kit so that samples could be 
read directly from the standard curve.       
2.4.4. Plasma cytokine assay   
        Plasma IL-6 was determined by an OptEIA ELISA mouse kit (BD Biosciences, San 
Diego, CA, USA) according to the manufacturer’s protocol with the exception that the plate 
was read at 655 nm after addition of the substrate solution for 30 min. 
2.5. Statistical analysis 
        Statistix software (version 8.0, Analytical Software, Tallahasee, FL, USA) was used for 
the statistical analysis. For analysis of study 1, differences between the treatment groups 
were tested by two-way analysis of variance (stress × gavage type) with subsequent a priori 
contrasts. For analysis of study 2, differences between treatment groups were tested by one-
way analysis of variance with subsequent a priori contrasts. A value of P < 0.05 was 
considered significant.     
3. Results 
3.1. Phytochemical analysis 
        The HPLC profiles of EPA extract are shown in Fig. 5.1 and the amounts of 
phytochemicals identified and quantified are shown in Table 5.1. The alcohol extract of EPA 
contains two basic groups of natural chemicals, lipophilic alkamides and ketones and water-
soluble caffeic acid derivatives. Alkamide 2 and 8 are the main forms of alkamides, while 
Echinacoside is the main caffeic acid derivative, followed by cichoric acid. One novel aspect 
of the EPA extract is that it contains ketones (mainly ketone 20).  
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3.2. Study 1. Wound healing effect of EPA 
3.2.1. Effect of stress and EPA on body weight gain 
        Restraint stress can cause many physical and psychological changes. Decreased body 
weight gain and increased plasma conticosterone levels are two typical indicators of chronic 
stress (Munhoz et al., 2006). The restraint stress paradigm used in this study resulted in a 
remarkable loss of body weight relative to the non-restraint stressed animals whose body 
weight increased gradually (Fig. 5.2). Upon discontinuation of stress exposure, the body 
weight of the stressed mice returned rapidly, but was still lower than that of the non-stressed 
groups in body weight gain at the end of the experiments (P < 0.001). EPA, (FWD+EPA) 
and (RST+EPA), has no effect on body weight gain when compared to its respective controls 
in the non-stressed and the stressed mice [(FWD + vehicle) or (RST + vehicle) respectively]. 
3.2.2. Effect of stress and EPA on wound closure  
        Fig. 5.3 shows daily changes in wound area compared to the original wound size. The 
results of the two-way ANOVA of wound size differences between the treatment groups for 
each day are shown below Fig. 5.3. Among the non-stressed animal groups (Fig. 5.3A), there 
was no difference in wound closure between the Food ad lib and FWD control groups. Thus, 
these no gavage, no restraint groups were combined during further analysis. Wound healing 
in the FWD + vehicle group was significantly delayed compared to the combined Food ad lib 
and FWD control groups on days 1-2 and 5-6 post biopsy (P values ≤ 0.031). Interestingly, 
the FWD + EPA group was not different from the combined Food ad lib and FWD control 
groups except for day 6 (P = 0.026. Indicating that gavage was stressful and that EPA 
administration could partially compensate for delay in wound healing.  
         Fig. 5.3B displays the data for wound closure for the RST stressed mice along with the 
FWD control. The RST and the (RST + vehicle) stress groups were not significantly different 
from each other on any day of the analysis. Thus, these two stressed groups were combined 
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in during further analysis. The combined stress groups (RST and the RST + vehicle) are 
significantly delayed in wound healing from day 1 through day 12 compared to the Food ad 
lib and FWD control groups (the Food ad lib group is not shown on this graph in order to 
simplify the graph) (P values < 0.05). More interestingly, the wound closure for the RST + 
EPA group was equivalent to the Food ad lib and FWD controls for days 1-5 post wounding 
and significantly different from the RST and RST + vehicle groups on these days (P values < 
0.05). On day 6 post biospy the positive effect of EPA is no longer seen and the RST + EPA 
group demonstrated wound healing that is significantly behind than the Food ad lib and FWD 
controls (P = 0.01), and not significantly different from the RST and RST + vehicle groups.  
3.2.3. Effect of stress and EPA on healing time 
        Wound healing was also assessed by determining the total time to complete wound 
healing (Fig. 5.4). Complete healing is indicated by a lack of enzymatic reaction of hydrogen 
peroxide applied on the wound. Compared to the Food ad lib and FWD groups only the RST 
and RST + vehicle treatments demonstrated a significant delay in complete re-epithelization 
(P values < 0.001). The time to complete wound healing for the FWD + EPA and RST + 
EPA groups was not significantly different from the Food ad lib and FWD control groups. 
The RST + EPA group shortened healing time compared to the RST and RST + vehicle 
groups (P < 0.001).  
3.3. Study 2. Immune and corticosterone modulation of EPA   
3.3.1. Effect of stress and EPA on spleen/body weight ratio 
        Restraint stress induced a gradually decreased body weight gain when compared to the 
non-stressed mice (data not shown). In order to determine if stress reduces spleen mass, 
spleen/body weight ratio was calculated. Restraint stress showed a trend to reduce 
spleen/body weight ratio, but there was no significant difference between the stressed and the 
non-stressed mice. EPA did not significantly affect the spleen/body weight ratio (Fig. 5.5A).   
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3.3.2. Effect of stress and EPA on corticosterone sensitivity 
        The effect of oral EPA on cell viability of splenocytes cultured ex vivo was assessed 
using an MTS assay. Cell number was increased in the presence of LPS, but there were no 
differences among the seven groups. Addition of corticosterone decreased LPS-stimulated 
cell proliferation. To better evaluate the corticosterone sensitivity of splenocytes, a 
“corticosterone resistance” index (Avitsur et al., 2001) was calculated, which represents the 
percentage of cell viability of each treatment group treated with LPS plus corticosterone 
compared to that of the same group treated with LPS alone. Splenocytes of the stressed mice 
lose the sensitivity to inhibition by corticosterone, when compared to the non-stressed mice 
(Fig. 5.5B). When compared to the RST + vehicle group, the RST +EPA group showed 
increased MTS incorporation and corticosterone resistance, indicating the RST + EPA group 
might have higher corticosterone levels in vivo. 
3.3.3. Effect of stress and EPA on plasma corticosterone and IL-6 
        As expected, restraint stress significantly increased plasma corticosterone (the RST 
group vs the FWD group, P = 0.007) (Fig. 5.5C). For the stressed mice, gavage with vehicle 
(RST + vehicle), but not EPA (RST + EPA) significantly decreased the stress-induced 
corticosterone levels (P = 0.013). 
        Restraint stress was also found to increase plasma IL-6 levels (the RST group vs the 
FWD group, P = 0.002) (Fig. 5.5D). The RST + vehicle group, rather than the RST + EPA 
group significantly decreased the IL-6 levels when compared to the RST control (P = 0.031). 
4. Discussion 
        Wound healing is a multifactorial process that involves neutrophils, macrophages, 
fibroblasts and wound remodeling (Diegelmann and Evans, 2004; Park and Barbul, 2004). 
Neutrophils and macrophages are two important immune cell types responsible for the 
inflammatory stage of wound healing that takes place from the time of injury to about 5-6 
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days after injury. Although the inflammatory response reflects host immune defense, it must 
be tightly regulated in order for the later healing stages to be initiated. Since our previous 
studies showed that alcohol extracts of Echinacea species inhibited NO and TNF-α 
production by LPS-stimulated macrophage cell line in vitro and suppressed TNF-α and IL-1β 
production by LPS-activated splenocytes ex vivo (Zhai et al., 2007a, 2007b), we 
hypothesized that early treatment with Echinacea can improve wound healing through the 
modulation of macrophage function. We expected a one-week treatment course with EPA 
extract would help the immune system including macrophages function more efficiently for 
enhanced and complete wound repair.  
        Stress was introduced in this wound healing model in order to test the multiple 
modulating effects of Echinacea on wound healing in a different host internal milieu. The 
restraint stress used in this study is considered a chronic stress. Unlike acute stress which 
may stimulate the immune system and help the body fight diseases, chronic stress is mostly 
immunosuppressive in the periphery and detrimental to the body (i.e. worsen existing 
diseases) (Padgett and Glaser, 2003; Munhoz et al., 2006). It is well documented in a 
cutaneous wound healing model that chronic restraint stress significantly impaired wound 
healing (Padgett et al., 1998; Rojas et al., 2002; Sheridan et al., 2004; Head et al., 2006). This 
study confirmed the previous observations as the combined RST and RST + vehicle groups 
showed slower wound closure and longer healing time in comparison to the non-stressed 
control groups. Interestingly, stress-induced negative effects on wound healing could be 
prevented by EPA extract in the early phases of wound healing, the initial 5-6 days when 
neutrophil and macrophage function are most important.   
        There was no improvement of wound healing in the non-stressed mice given EPA 
(FWD + EPA). Interestingly, this group did not exhibit differences in rates of wound closure 
as found with the FWD + vehicle group. The alcohol extract of EPA contains high levels of 
echinacoside (Table 1) which has been shown to benefit wound healing with its 
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antihyaluronidase activity in animal models when topically applied (Speroni et al., 2002; 
Rousseau et al., 2006). However, the improved healing effect may not be the result of oral 
administration of echinacoside because pharmacokinetic data do not support absorption of 
caffeic acid derivatives in the gastrointestinal tract (Matthias et al., 2004, 2005a, 2005b). In 
this regard, alkamides are relatively orally bioavailable (Matthias et al., 2004, 2005a, 2005b; 
Woelkart et al., 2005a). In vitro, alkamides have been demonstrated to strongly inhibit LPS-
induced end points (i.e. NO and TNF-α) of macrophage cell line and human whole blood 
(Woelkart and Bauer, 2007). It was, therefore, speculated that the alkamides should behave 
in a similar manner in vitro and in vivo. However, it is unclear as to what extent these in vitro 
effects can readily translate into in vivo with oral administration. The in vitro effects may not 
be a mirror of in vivo effectiveness. We previously compared the effects of Echinacea 
extracts on LPS-activated macrophage cell line in vitro and on LPS-activated mouse 
peritoneal macrophages derived from mice orally gavaged with EPA, and found that 
Echinacea showed a potential anti-inflammatory effect in vitro, but not in vivo (Zhai et al., 
2007a).   
        Chronic restraint stress caused decreased body weight and increased plasma 
glucocorticoid (GC) levels. They both appear to be relative to stress-induced activation of 
corticotrophin-releasing factor receptors (Harris et al., 2002), which is involved in the 
modulation of circulating GC levels and food intake. Higher levels of GCs released by 
hypothalamic-pituitary-adrenal (HPA) axis have been directly correlated with stress-impaired 
wound healing. Upon binding of GCs to their cytosolic receptors, the newly formed ligand-
receptor complexes strongly inhibit inflammatory NF-κB function through both direct and 
indirect pathways (Leung and Bloom, 2003). The subsequent weakened inflammatory 
response decreases cellular recruitment and proliferation at the wound site and therefore 
slows wound healing (Rojas et al., 2002; Sheridan et al., 2004).  
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        It remains unclear how EPA reverses restraint stress-delayed wound healing. Since 
restraint stress displays an anti-inflammatory nature through GC-dependent mechanism 
(Head et al., 2006), we proposed that Echinacea might have anti-GC activity resulting in 
enhancement of the immune system. Immunostimulatory effects of Echinacea have been 
reported. Goel et al. (2002) found oral administration of alkamides mixed with caffeic acid 
derivatives and polysaccharides stimulated alveolar macrophages and spleen cells to produce 
inflammatory mediators in healthy rats. We found in healthy mice alcohol extracts of 
Echinacea increased lymphocyte function (i.e. NK cell cytotoxicity and T-cell cytokine 
release), but inhibited TNF-α and IL-1β production by spleen cells (Zhai et al., 2007b). 
Nevertheless, all these effects were seen in a healthy non-stressed host, but not in disease 
models. It should be noted that both caffeic acid derivatives and polysaccharides are poorly 
absorbed or uncertain (Bone, 1997; Matthias et al., 2004, 2005a, 2005b). Therefore, the 
beneficial healing effect of EPA extract is possibly attributed to alkamides. In recent years, 
alkamides are suggested to be involved in activation of the endocannabinoid system (Gertsch 
et al., 2004; Woelkart et al., 2005b). This system is composed of endogenous ligands and two 
cannabinoid (CB) receptors, CB1 and CB2. CB1 receptors are predominantly, but not 
exclusively found in the brain, while CB2 receptors occur mainly in the immune system 
(Klein et al., 2003). Due to its distribution and function in the immune system, CB2 receptors 
have received specific attention in the study of the action mechanism of alkamides. There is 
evidence to indicate that the in vitro immunomodulatory effects of alkamides can be largely 
ascribed to their binding to CB2 receptors (Woelkart and Bauer, 2007). However, the in vivo 
relevance of the CB2 receptor-involved molecular mechanism is still not clear.       
    Given that stress-delayed wound healing is associated with elevated plasma GCs, we 
hypothesized that Echinacea can modulate GC release or suppresses activation of the HPA 
axis, thus reducing GC-induced negative effects. This hypothesis is supported by the findings 
that the endocannabinoid system modulates the HPA axis function (Rademacher and Hillard, 
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2007). Activation of CB1 receptors inhibits restraint stress-induced HPA axis activation, 
whereas blockade of CB1 receptors increases the plasma GC levels (Patel et al., 2004). 
Alkamides from Echinacea have shown some affinity to the CB1 receptors though the 
binding is much weaker compared to the CB2 receptors in vitro (Raduner et al., 2006). 
Alkamides are highly lipophilic and, therefore, may readily pass through the blood-brain 
barrier and the plasma membrane of many types of cells in the central nervous system, where 
they bind to and activate CB1 receptors. We determined both plasma corticosterone levels 
and splenocyte sensitivity to inhibition by corticosterone. Our speculation was not supported 
as the alcohol extract of EPA showed no inhibitory effects on the HPA axis activation. On 
the contrary, the stressed mice treated with EPA showed higher levels of plasma 
corticosterone and increased splenocyte resistance to corticosterone inhibition when 
compared to the RST + vehicle control. Because elevated plasma IL-6 is also an indicator of 
stress (Nukina et al., 2001), we measured plasma IL-6 and found the RST + EPA group 
showed a non-significant increase in the IL-6 level compared to the RST + vehicle group. 
Surprisingly, the stressed mice gavaged with vehicle exhibited decreased plasma IL-6 and 
corticosterone levels. Gavage with the small volume of 5% ethanol may induce some 
immune responses, however, its role in modulation of IL-6 is unknown.  
    Since blockade of GC receptors with an antagonist RU486 could only partially reverse 
stress-delayed wound healing (Padgett et al., 1998), suggesting that in addition to activation 
of the HPA axis to release GCs, stress may impair wound healing through other mechanisms, 
i.e. activation of the sympathetic-adrenal mendullary (SAM) axis (Padgett and Glaser, 2003). 
Stress stimulates the SAM axis to produce catecholamines, which has immune modulating 
activity through adrenergic receptors expressed on immunocytes, including lymphocytes and 
macrophages (Padgett and Glaser, 2003). It was demonstrated that phentolamine, an α-
adrenergic receptor antagonist, to some extent improves stress-impaired wound healing 
(Eijkelkamp et al., 2007). The effect of Echinacea on the SAM axis needs to be investigated.         
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    In addition to alkamides and caffeic acid derivatives, ketones are also found in alcohol 
extract of EPA. Like alkamides, ketones are lipophilic and easily absorbed by the intestines 
(Chicca et al., 2008). Because of their usually concomitant appearance, the interaction 
between ketones and alkamides is unknown. Ketones have been suggested to have antifungal 
activity (Binns et al., 2000) and direct cytotoxicity on cancer cells (Pellati et al., 2006; 
Chicca et al., 2008). The biological activities of ketones need to be further identified.   
        Taken together, we preliminarily evaluated the modulating effect of EPA extract in a 
cutaneous wound healing model, and found that this herbal preparation exhibited a beneficial 
healing effect when the animals were exposed to a chronic restraint stressor. However, the 
mechanism underlying this result as well as the immunological, biochemical and 
physiological modulation closely related to the wound healing remain completely unknown. 
The positive effect of oral administration of Echinacea may be attributable to its readily 
bioavailable alkamides. Because EP and EA contain higher amounts of alkamides than EPA, 
it is necessary to investigate the healing effect of EP and EA in this wound healing model. 
On the other hand, topical application of Echinacea might be a choice of administration 
routes. This can avoid the bioavailability problem, and also concentrate high levels of 
bioactive compounds at the wound site. 
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Fig. 5.1. HPLC chromatograms of alcohol extract of EPA: (A) lipophilic alkamides and 
ketones detected with UV absorbance at 210 nm (upper line) and 260 nm (lower line), and (B) 
water soluble caffeic acid derivatives detected with UV absorbance at 330 nm. HPLC analysis 
was performed as described previously by Wu et al. (2004) and Lalone et al. (2007).   
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Table 5.1. The amounts of alkamides, ketones and caffeic acid 
derivatives in EPA preparation as determined using HPLC 
Group Metabolite  Concentration*  
Alkamide amide 2  1.01 
 amide 3  0.58 
 amide 5  0.45 
 amide 8  2.35 
 amide 9  0.94 
   
Ketone ketone 20 1.34 
 ketone 21 0.17 
   
Caffeic acid derivative caftaric acid 0.61 
 chlorogenic acid 0.67 
 cichoric acid 1.07 
  echinacoside  7.78 
* Values are µg metabolite/mg dried extract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 
 
 
 
Fig. 5.2. Effects of RST and EPA on body weight loss. A sterile 3.5 mm punch biopsy was 
used to make two identical wounds on the dorsum on day 0. The stressed animals were 
administrated three cycles of 12-h interval restraint (RST) stress prior to wounding and 4 
cycles post wounding. The non-stressed mice were deprived of water and food (FWD) when 
the stressed mice were under restraint cycles except the food ad lib group, which had free 
access to food and water throughout the experimental procedure. The mice were orally gavaged 
three doses of alcohol extract of EPA at 130 mg/kg prior to and four doses post wounding, one 
dose per day. Body weight was recorded on days as indicated and then was adjusted by the 
weight at the start of the experiment to reflect change in body weight. Data represent the mean 
± SE of each treatment group (n= 6-7 mice/group).  
 
 
 
 
 
 
 
 
151 
 
 
 
 
 
 
The P values of the ANOVA analysis of wound size 
  Days post wounding 
ANOVA contrasts d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 
Food  ad lib  vs  FWD                   
[Food ad lib + FWD] vs (FWD + vehicle)  0.009 0.031   0.005 0.009     
[Food ad lib + FWD] vs (FWD + EPA)       0.026     
RST vs  (RST + vehicle)           
[Food ad lib + FWD]  vs  [RST + (RST + vehicle)] 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.001 0.009 0.037 
[Food ad lib + FWD] vs (RST + EPA)      0.010 0.012    
(RST + EPA) vs [RST + (RST + vehicle)] 0.000 0.001 0.000 0.014 0.015      
 
 
Fig. 5.3. Effects of RST and EPA on wound closure of (A) the non-restraint stressed 
groups and (B) the stressed groups with the non-stressed FWD group. The animals were 
treated with RST and EPA as described in Fig. 5.1. Wounds were photographed immediately 
after wounding and then daily until healing. Individual wound size was calculated as a ratio in 
comparison to a standard-sized dot placed next to the wound and then expressed as the 
percentage of the original size. Data represent the mean ± SE of each treatment group (n= 6-7 
mice/group).      
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Fig. 5.4. Effects of RST and EPA on healing time. Healing was assessed daily by application 
of 3% hydrogen peroxide beginning 7 days after wounding and defined as the absence of 
enzymatic reaction. Data represents the mean ± SE of each treatment group (n=6-7 
mice/group). The healing time of each individual animal is the average of its two wounds.  
*P < 0.001 vs the Food ad lib and FWD groups; # P < 0.001 vs the RST + EPA group. 
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Fig. 5.5. Effects of RST and EPA on (A) spleen/body weight ratio, (B) viability of 
splenocytes treated with LPS (1 µg/ml) and corticosterone, and plasma concentrations of 
(C) corticosterone and (D) IL-6. Animals were administrated four consecutive 12-h interval 
restraint stress cycles (during light phase) and at the same time treated with an alcohol extract 
of EPA at 130 mg/kg body weight once daily for 4 doses. Two hours after the last stress cycle, 
animals were euthanized and body weight and spleen weight were recorded. Corticosterone 
resistance, plasma corticosterone and IL-6 were measured as described in the Material and 
methods. Dashed line in B indicates cell viability of splenocytes of each treatment group 
stimulated with LPS alone and referred to 100%. Data represent mean ± standard error of the 
mean of 3-4 mice. *P < 0.05; ** P < 0.001. 
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CHAPTER 6.  GENERAL CONCLUSIONS 
General Discussion 
        Chapter 2-5 are original papers in which we demonstrated the immunomodulatory, anti-
inflammatory and wound healing properties of Echinacea alcohol extracts in in vitro or in vivo 
gavage models. We chose the preparation form of alcohol extracts because they consist of two 
main classes of active metabolites – alkamides and caffeic acid derivatives. Alkamides are 
identified to be bioavailable (Jager et al, 2002; Matthias et al, 2005a; Woelkart et al, 2005a). 
        Three medicinally used Echinacea species were investigated in parallel in chapters 2-4, 
thus providing the possibility to compare their efficacy at the same dose (at crude extract level). 
Generally, the three species harbor similar biological activities. However, they demonstrated 
quantitative but not qualitative differences in immunomodulatory potentials, which are relevant 
to their distinct chemical profiles. 
        Echinacea possesses an ability to modulate both innate immunity and adaptive immunity. 
This was demonstrated in a healthy animal model in which alcohol extracts were gavaged for 7 
consecutive days (chapter 2). Alcohol extracts of Echinacea significantly enhanced both B-cell 
antibody production and T-cell cytokine production. These enhancing effects were more robust 
when compared to the placebo group, but not the no-gavage group, suggesting that Echinacea 
has a potential to maintain host immune homeostasis. As a dietary supplement, such an 
immunomodualtory nature may be of more health significance than just a unidirectional 
immunomodulation. 
        In vitro, alcohol extracts of Echinacea exhibited anti-inflammatory properties by 
inhibiting production of inflammatory mediators, NO and TNF-α by macrophage cell line 
RAW 264.7 cells (chapter 3). Echinacea-mediated decrease in NO production was not due to a 
direct scavenging of NO given that caffeic acid derivatives are good antioxidants and free 
radical scavengers (Hu et al, 2000; Pellati et al, 2004; Dalby-Brown et al, 2005). We suggested 
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that decreased NO production is at least partially relevant to inhibition of iNOS enzyme 
expression as determined by Western blot (chapter 4). 
        NO is generated from L-arginine which can also be metabolized to produce L-ornithine 
via arginase. These two competitive metabolic processes preferentially occur in different types 
of activated macrophages. Macrophages undergo classical activation by TNF-α and IL-1β to 
activate iNOS and produce NO that involves an inflammatory response. Macrophages can also 
undergo alternative activation by IL-4 and IL-10 to activate arginase and produce L-ornithine 
which is a precursor of tissue regeneration. We proposed that Echinacea alcohol extracts can 
switch macrophages to alternative activation. They increase production of IL-4 and IL-10 in 
animal model (chapter 2), while inhibit TNF-α production in RAW 264.7 cell model (chapter 
3). Moreover, alcohol extracts of Echinacea enhance arginase activity in RAW 264.7 cells 
(chapter 4). 
        Alkamides and caffeic acid derivatives are two active principles with clearly different 
biological natures. The alkamide fraction inhibits NO production and iNOS enzyme expression 
while caffeic acid and its derivatives increase arginase activities (chapter 4). For arginine 
metabolism, alkamides and caffeic acid derivatives work in coordination to direct macrophages 
to produce L-ornithine.       
        NO and TNF-α are two of main effector molecules of macrophages in pathogenic 
infection. We were interested in knowing if the Echinacea-mediated decrease in NO and TNF-
α production could compromise macrophage antimicrobial activities. We found three alcohol 
extracts had mixed effects on phagocytosis and bacterial killing by macrophages in vitro. 
Especially, EPA had the strongest effect on NO production, but simultaneously increased the 
potential of bacterial killing (chapter 3), suggesting that Echinacea may not adversely affect 
their important immune functions of macrophages. 
        However, the in vitro anti-inflammatory activities of Echinacea were only partially 
substantiated by evaluating PECs for NO production before and after bacterial infection. The 
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only statistically significant change in PECs was an EP-mediated decrease of NO production 
upon infection (chapter 3). Furthermore, the immunomodualtory activities of EPA alcohol 
extract was evaluated in a skin wound healing model by monitoring the progressive changes in 
wound size and healing time (chapter 5). No difference was found between the herb and the 
vehicle group (for no restraint stressed animals). The in vivo effect in this regard might be 
easily influenced by multiple factors, such as bioavailability of active phytochemicals, 
interplay of different immune cell types and even the physiological complex in actual 
organism. The in vitro effects may not be a mirror of in vivo effectiveness. 
        Interestingly, when the external factor of chronic restraint stress was introduced into the 
wound healing model, the healing-enhancing effect of EPA alcohol extract was significant. 
Chronic restraint stress was immunosuppressive via up-regulation of corticosterone release. 
The wound healing effect of EPA might not be associated with modulation of corticosterone 
level but through other unknown mechanisms. 
          Taken together, this dissertation provides new evidence, though limited, that the herb 
Echinacea has immunomodulatory properties. This research work will help understand 
mechanistically the traditional use of Echinacea in phytotherapy for upper respiratory tract 
infections and inflammatory diseases. 
Recommendations for Future Research 
        As a preliminary basis and applied study of the biological activities of the popular herbal 
medicine Echinacea, this dissertation provides the first step towards a more systematic and in-
depth exploration of the herb. 
        Based on our experimental data, we do not know exactly how Echinacea modulates the 
immune system for a better health, but we propose that Echinacea is immunologically active 
on both innate immune cells and adaptive immune cells. B lymphocytes and T lymphocytes 
comprise adaptive immunity branch and also involve in host response against infection. It is 
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necessary to determine whether the in vivo influence of Echinacea on these cell types is due to 
a direct enhancing effect or is secondary to activation of other cell types, such as macrophages 
and neutrophils. Moreover, it is worthy of exploring how Echinacea works on these different 
types of immune cells. If they share a common action mechanism, what it is? 
         In vitro Echinacea inhibits LPS-induced endpoint products (i.e. NO and TNF-α) in RAW 
264.7 macrophages. Although in vitro analytical results sometimes can not be translated into in 
vivo effects due to bypassing of ingestion and absorption, in vitro studies are relatively easily 
manipulated and can be considered as a supplementary means towards understanding of in vivo 
assays. In this regard, immune cell lines, like RAW 264.7 cells, might be used to understand 
the immunological basis for Echinacea at a molecular level because LPS-mediated signal 
pathways are relatively clear. At present, the effects of Echinacea on the upstream signaling 
molecules that activate and regulate NF-κB is completely unknown. 
        We also observed the wound healing effect of EPA, however, we were unable to identify 
any potential effects of EPA on the biochemical, physiological and immunological events that 
occur in wound tissues. Wound tissues might be a good material used for investigation of the 
biological properties of Echinacea by use of various techniques such as immunostaining and 
histological assays. In addition, our preliminary results suggested the healing effect of EPA in 
the stressed mice might be not associated with regulation of glucocorticoid release. This needs 
to be further confirmed. In addition to the glucocorticoid signal, restraint stress might 
negatively influence early wound healing through other pathways, i.e. α-adrenergic receptors 
(Eijkelkamp et al, 2007). Stress can induce elevated levels of norepinephrine and epinephrine, 
which activate α- and β-adrenergic receptors (Cunnick et al, 1990; Padgett & Glaser 2003). 
The effect of Echinacea on the norepinehrine and epinephrine signaling pathways needs to be 
determined. 
        We did not obtain a positive effect of EPA in the nonrestraint stressed mice. Two 
experimental issues should be considered in the future studies. On the one hand, EP instead of 
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EPA or both EP and EPA could be (comparably) used since EP contains higher levels of 
alkamides which can survive in the gastrointestinal environment. On the other hand, topical 
application of the herb might be a choice of administration routes. This can not only avoid the 
bioavailability problem, but also concentrate high levels of bioactive natural compounds at the 
wound site, therefore, resulting in the maximum efficacy.       
        Echinacea is currently used as botanical supplement, in other words, it is being used as 
mixtures, crude preparations or plants. To our current knowledge, the crude preparations are 
more efficacious and even safer as opposed to fractions or individual chemicals (Bodinet et al, 
2002; Currier et al, 2003; Randolph et al, 2003). Therefore, it is of significance for health 
practice to study the market used herbal forms and the interactive action of individual 
compounds within crude preparation. However, the structure-activity relationship of Echinacea 
active principles including alkamides, ketones and caffeic acid derivatives is worthy of special 
exploration in the future because this may lead to clearly understanding of the interaction 
between individual components, and also help develop new drugs.  
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